Pleural Mesothelioma Treatment Without Surgery: A Personalised Ayurvedic Support Plan

Pleural mesothelioma treatment without surgery should be understood as a personalised, integrative supportive-care strategy rather than a replacement for oncology treatment. When surgery is not medically possible, care may still include chemotherapy, immunotherapy, pleural-fluid procedures, symptom control, nutritional rehabilitation, muscle preservation, palliative care and carefully supervised Ayurvedic support.

Being told that pleural mesothelioma is inoperable or unresectable can make patients and families feel that no meaningful treatment remains. However, surgery is only one component of mesothelioma management. When an operation cannot remove the disease safely, or when its expected benefit does not outweigh the risks, the treatment objective may shift toward disease control, relief of breathlessness, management of pleural effusion, preservation of body strength and maintenance of quality of life.

Ayurvedic care may support selected concerns such as appetite, digestive tolerance, bowel regularity, sleep, fatigue, nutritional intake and functional recovery. It should not delay chemotherapy, immunotherapy, thoracentesis, pleurodesis, indwelling pleural-catheter care, oxygen, antibiotics, anticoagulation or emergency treatment.

Ayurvedic Treatment for Pleural Mesothelioma Without Surgery: At a Glance

When Surgery Is Not Possible, Treatment Does Not Necessarily Stop

Being told that surgery is not possible can be one of the most distressing moments for a person living with pleural mesothelioma. Patients and families often hear the words “inoperable” or “unresectable” and assume that no meaningful treatment remains. In many cases, however, this is not correct.

Surgery is only one component of pleural mesothelioma care. When an operation cannot remove the disease safely, when the tumour has extended beyond a surgically manageable area, or when the physical burden of surgery is greater than its expected benefit, the treatment strategy changes. The focus may shift toward controlling the cancer, reducing breathlessness, managing pleural fluid, preserving body weight and muscle, supporting treatment tolerance and maintaining the greatest possible degree of independence [1–3].

Eligible patients with unresectable pleural mesothelioma may still receive chemotherapy, immunotherapy or a combination selected by their oncology team. The choice depends on the tumour subtype, previous treatment, general strength, organ function, associated illnesses and local treatment availability [1–6].

When fluid collects around the lung and causes chest pressure, cough or breathlessness, medical procedures may also be required. These may include therapeutic drainage, pleurodesis or placement of an indwelling pleural catheter. The appropriate procedure depends on how quickly the fluid returns, whether the lung can expand after drainage and the patient’s overall condition [7–10].

The central message is important: when surgery is not possible, care does not necessarily end. The objectives and methods of treatment must instead be reconsidered and personalised.

What Does It Mean When Pleural Mesothelioma Is Considered Inoperable?

Pleural mesothelioma grows along the lining surrounding the lung. Unlike a single, clearly defined tumour, it may spread across a large pleural surface and extend into nearby tissues. Surgery may not be recommended when the disease involves areas that cannot be removed safely, when it has spread outside a manageable surgical field, or when adequate macroscopic removal is unlikely to be achieved.

The decision may also be influenced by lymph-node involvement, histological subtype, the speed of progression and the expected biological behaviour of the tumour [1–4].

In some cases, the tumour may appear technically removable, but the patient may not be physically able to tolerate a major thoracic operation. Reduced lung capacity, heart disease, impaired kidney or liver function, frailty, severe weight loss, skeletal-muscle depletion, infection or poor performance status can make surgery excessively risky.

Age may form part of the assessment, but age alone should not determine whether surgery is possible. The decision should consider the patient’s total health, cardiopulmonary reserve, nutritional condition, expected recovery and personal treatment goals [1–3].

For some patients, surgery is not recommended because the potential benefit does not justify the risk of complications, prolonged hospitalisation, delayed recovery or loss of independence. Contemporary evidence has reinforced the need for careful selection rather than assuming that a more extensive operation is always beneficial [4].

A second opinion from an experienced mesothelioma centre may be reasonable when the original decision was not made by a specialist thoracic multidisciplinary team. The purpose of a second opinion is to confirm the diagnosis, stage and treatment strategy. It should not be used to create the impression that every unresectable tumour can eventually be made operable.

Disease-Control Intent and Functional-Recovery Intent

When surgery is excluded, treatment usually develops around two closely connected objectives: disease control and functional recovery.

Disease-control treatment is directed toward the mesothelioma itself. Its purpose may be to reduce measurable tumour burden, delay progression, maintain stable disease or extend survival. These outcomes are evaluated through specialist imaging, clinical assessment and recognised response criteria.

Chemotherapy and immunotherapy have demonstrated meaningful benefits in selected patients with unresectable pleural mesothelioma. However, no treatment can guarantee the same result for every person [1–6].

Functional-recovery treatment has a different objective. It focuses on helping the patient breathe more comfortably, eat adequately, preserve muscle, sleep better, remain mobile, tolerate cancer treatment and maintain independence.

A person may experience a meaningful improvement in appetite, mobility, sleep or symptom control even when a scan does not show tumour shrinkage. These improvements should not be dismissed because they do not represent radiological response.

Palliative and supportive care may be introduced alongside active anticancer treatment. It does not mean that treatment has been stopped or that the medical team has given up. Its purpose is to reduce symptom burden, protect quality of life and support the patient and family throughout the illness [11–14].

In this article, the word “recovery” refers to the recovery or preservation of function, nutrition, strength, resilience and quality of life. It should not be interpreted as a claim that Ayurvedic treatment has been clinically proven to cure pleural mesothelioma.

Why Personalised Treatment Is More Important Than a Generic Cancer Formula

Two people with the same diagnosis may require completely different supportive strategies.

One patient may have recurrent pleural effusion and severe breathlessness but relatively stable body weight. Another may have little fluid accumulation but marked muscle loss, poor appetite, constipation and weakness after systemic treatment. A third may be receiving immunotherapy and require close monitoring for immune-related complications. Another may be too frail for further tumour-directed treatment and may prioritise comfort, sleep and the ability to remain at home.

For this reason, treatment should not begin with a standard list of so-called anticancer herbs. It should begin with a structured review of the diagnosis, pathology, stage, current oncology plan, respiratory condition, pleural-fluid history, laboratory investigations, nutritional status, performance status and complete medicine list.

The Ayurvedic assessment should be added only after this biomedical foundation has been established. The clinician may then assess Prakriti, Vikriti, Agni, Koshta, Bala, Satmya, sleep, bowel habits, appetite, food tolerance, dominant symptoms and the degree of tissue depletion.

This combined assessment helps identify whether the immediate priority is medical stabilisation, digestive support, relief of specific symptoms, nutritional rebuilding, functional rehabilitation or avoidance of treatments that may further weaken the patient.

Personalisation is particularly important when pleural fluid exists alongside dehydration, low albumin, severe muscle loss and poor intake. It would be unsafe to interpret every fluid-related symptom simply as excessive Kapha and automatically prescribe strong Langhana, Rukshana or purificatory treatment.

The presence of fluid does not remove the need to protect hydration, circulation, kidney function, nutrition and overall Bala.

The Realistic Role of Ayurveda

Ayurveda may be considered as a complementary component of a coordinated treatment plan when its purpose is clearly defined and when it does not delay oncology, pleural procedures or emergency care.

Depending on the individual patient, supportive objectives may include improving digestive tolerance, supporting appetite, maintaining bowel regularity, reducing sleep disturbance, addressing selected treatment-related discomforts, organising an appropriate daily routine and helping the patient maintain nutritional intake and functional strength.

Ayurvedic care may also help personalise the timing, texture, quantity and digestibility of food. Rest, activity, sleep routines and symptom-sensitive supportive measures may be adjusted according to the patient’s present strength and treatment phase.

These interventions may be meaningful when they are carefully selected, monitored and integrated with the patient’s medical treatment.

Ayurveda should not be presented as a replacement for chemotherapy, immunotherapy, pleural drainage, pleurodesis, catheter care, antibiotics, oxygen, anticoagulation or emergency treatment.

There is presently no reliable clinical evidence that Ayurveda alone can cure pleural mesothelioma, permanently eliminate malignant pleural fluid, make every unresectable tumour operable or guarantee longer survival.

Complementary care means care used alongside standard medical treatment, not instead of it [23].

A responsible treatment plan should identify specific supportive goals before treatment begins. These goals should then be measured through symptoms, nutritional status, functional ability, laboratory results and oncology follow-up rather than assumed to have improved.

Stabilisation Must Be the First Priority

A patient with severe breathlessness, rapidly increasing pleural fluid, fever, chest pain, low oxygen levels, dehydration, persistent vomiting, confusion or signs of infection requires urgent medical evaluation.

An online consultation or Ayurvedic appointment should never delay hospital assessment in these circumstances.

When symptomatic pleural fluid is present, the pleural or oncology team must determine whether drainage, pleurodesis, an indwelling pleural catheter or another medical intervention is required [7–10].

Ayurvedic medicines should not be tried as a way of postponing drainage when the lung is being compressed or the patient’s breathing is deteriorating.

The stabilisation phase should also include an assessment of hydration, electrolytes, blood counts, kidney function, liver function, albumin, infection risk, pain, constipation, nausea, sleep and oral intake.

Only after immediate medical risks have been assessed should a longer-term Ayurvedic plan be considered.

Strong Panchakarma, prolonged fasting, forceful breathing techniques, aggressive purgation, unverified diuretic herbs and the simultaneous use of multiple supplements should be avoided in an unstable, breathless, dehydrated, cachectic or actively treated patient.

The first responsibility is to prevent avoidable deterioration.

Every Herb and Supplement Must Be Reviewed for Interactions

The word “natural” does not guarantee safety during cancer treatment.

Herbs and supplements may influence drug absorption, liver enzymes, transport proteins, bleeding risk, immune activity and kidney clearance. They may alter the effectiveness or toxicity of chemotherapy, immunotherapy, anticoagulants, pain medicines, antibiotics and other prescribed treatments [24].

Before any Ayurvedic medicine is prescribed, the clinician should know the exact names, doses and schedules of all current treatments.

Recent complete blood count, kidney-function tests, liver-function tests and electrolyte values should be reviewed. The patient should also disclose every powder, tablet, capsule, tea, supplement and home remedy already being used.

Starting several formulations at the same time makes it difficult to determine which product produced benefit, intolerance or laboratory changes.

A safer method is to introduce only what is clinically justified, document the purpose of each intervention, define the required monitoring and establish clear criteria for reducing, holding or stopping treatment.

What the First Clinical Review Should Establish

The first review should confirm whether the diagnosis is supported by histopathology and immunohistochemistry. It should identify the mesothelioma subtype, disease extent, reason surgery was considered inappropriate and the current recommendation from the oncology team.

The clinician should establish whether pleural fluid is stable, increasing or repeatedly recurring. The presence of a pleural catheter, previous drainage, oxygen use and recent hospital admissions should also be documented.

The patient’s present breathlessness, chest pain, cough, appetite, weight changes, muscle loss, mobility, sleep, bowel function and treatment tolerance should be reviewed in detail.

The assessment should also examine whether the patient can manage daily activities independently or increasingly requires caregiver assistance.

Laboratory investigations and all prescribed and non-prescribed medicines should be reviewed before a treatment decision is made.

The result should not be a generic prescription based only on the diagnosis. It should be a written plan explaining what must continue, what may safely be added, what should be avoided, which outcomes will be monitored and which symptoms require escalation to the oncology team or hospital.

This process improves safety, creates realistic expectations and allows supportive care to be evaluated objectively.

What Patients and Families Should Understand Before Starting

Pleural mesothelioma without a surgical option remains a serious medical condition. However, the absence of surgery does not remove the value of carefully planned treatment.

A responsible strategy may combine oncology-led disease control, appropriate pleural procedures, symptom management, nutritional rehabilitation, muscle preservation, palliative support and carefully selected Ayurvedic interventions within a coordinated framework [1–3, 7–8, 14].

Some patients may experience improved appetite, better sleep, more regular bowel function, reduced symptom distress or greater ability to participate in daily activity.

Some may tolerate oncology treatment more successfully. Others may achieve stable disease through their medical cancer treatment while receiving supportive care for nutrition and function.

These outcomes can be monitored, but they should never be promised before treatment begins.

A trustworthy clinical service should not claim that every patient can be cured. It should explain what is medically established, what remains uncertain, which symptoms require urgent care and which supportive outcomes may reasonably be pursued.

Patients who wish to explore an integrative approach should begin with a review of their biopsy report, immunohistochemistry, latest scans, oncology treatment summary, pleural-fluid records, recent laboratory investigations and complete medicine list.

Severe or suddenly worsening breathlessness, chest pain, coughing blood, fainting, confusion or bluish lips requires emergency medical care rather than a routine consultation.

Request a Personalised Pleural Mesothelioma Case Review

A personalised case review may help patients and families understand what supportive options remain when surgery has not been recommended.

The purpose of the review is to organise the available medical information, identify immediate risks, clarify realistic treatment objectives and determine whether supervised Ayurvedic care can be added safely alongside oncology and pleural treatment.

The review should take place before purchasing, preparing or starting any Ayurvedic formulation.

Pleural mesothelioma treatment cannot be responsibly standardised from the diagnosis alone. The patient’s present symptoms, strength, nutritional condition, organ function, oncology medicines, pleural status and Ayurvedic assessment all influence the treatment strategy.

This information is educational and does not replace evaluation by an oncologist, thoracic specialist, pulmonologist, palliative-care physician or emergency department.

Ayurvedic Samprapti: Understanding the Patient’s Current Disease Pattern

Pleural mesothelioma is a modern pathological diagnosis established through imaging, histopathology and immunohistochemistry. It should not be equated directly with a single disease described in the classical Ayurvedic texts. There is no classical condition that can be claimed to correspond exactly to pleural mesothelioma.

Ayurvedic Samprapti should therefore be used to understand how the diagnosed disease is expressing itself in the individual patient. It helps the clinician assess the relationship between Dosha, Dushya, Agni, Srotas, Bala, Ama, obstruction, tissue depletion and the patient’s present symptoms. It does not replace the biomedical diagnosis, tumour staging or oncology assessment.

This distinction is essential. The biopsy identifies the cancer. Imaging shows its extent. The oncology team determines disease stage, treatment options and resectability. Ayurvedic examination adds another clinical layer by assessing how the illness, pleural fluid, constitutional factors and previous treatments are affecting the patient’s digestion, respiration, nutrition, strength, sleep, bowel function and functional capacity.

The principal classical foundations for this assessment include Srotovimaniya Adhyaya in Charaka Samhita, Vimanasthana, Chapter 5; Rogabhishagjitiya Vimana in Charaka Samhita, Vimanasthana, Chapter 8; and Hikka-Shwasa Chikitsa in Charaka Samhita, Chikitsasthana, Chapter 17 [30, 32, 33].

Samprapti Must Be Constructed for the Individual Patient

A diagnosis of pleural mesothelioma alone is not sufficient to determine an Ayurvedic treatment plan. Two patients with the same histopathological diagnosis may have markedly different Ayurvedic presentations.

One patient may have recurrent pleural effusion, heaviness in the chest, productive cough, reduced appetite and a feeling of obstruction during breathing. Another may have severe dry cough, sharp pleuritic pain, anxiety, insomnia, constipation and progressive tissue depletion. A third may have fever, inflammation, burning sensations, bleeding tendency or treatment-related mucosal irritation. Another may present predominantly with profound weakness, loss of muscle, poor food tolerance and declining Ojas.

The Ayurvedic clinician must therefore construct the Samprapti from the patient’s current presentation rather than applying a fixed Vata–Kapha label to every case.

The assessment should identify which Dosha is dominant, which Dosha is obstructed, which Dhatus are affected, which Srotas are involved, whether Ama is genuinely present, whether the patient is in a state of excess or depletion and whether treatment should begin with stabilisation, gentle correction, nourishment or symptom-specific support.

Probable Dosha Involvement

Vata and Kapha may be clinically prominent in many patients with pleural disease, but their involvement should be interpreted carefully.

Kapha-related features may include heaviness in the chest, excessive secretions, reduced appetite, sluggish digestion, a sensation of obstruction and fluid accumulation. However, malignant pleural effusion should not be simplistically described as Kapha that can be removed through drying herbs or Langhana. Pleural fluid is a structural and oncological complication that may require drainage, pleurodesis or an indwelling pleural catheter.

Vata involvement may become prominent because of pain, difficult respiration, dry cough, anxiety, sleep disturbance, constipation, tissue depletion and the progressive loss of strength. Repeated hospitalisation, invasive procedures, chemotherapy, reduced food intake and prolonged illness may further aggravate Vata.

The classical description of Shwasa in Charaka Samhita, Chikitsasthana, Chapter 17, discusses the interaction of Vata and Kapha within the Pranavaha pathways [33]. This provides a useful framework for understanding obstruction and disturbed respiratory movement. It should not, however, be used to claim that pleural mesothelioma is identical to a classical form of Shwasa.

Pitta and Rakta involvement may require consideration when the patient has inflammatory symptoms, fever, burning sensations, haemoptysis, mucosal irritation, treatment-related inflammation or disturbed liver function. These manifestations must first be medically evaluated because they may indicate infection, bleeding, drug toxicity or disease progression.

The Dosha assessment must therefore remain dynamic. It may change during chemotherapy, immunotherapy, pleural drainage, infection, nutritional decline or disease progression.

Pranavaha Srotas and the Disturbance of Respiratory Function

Pranavaha Srotas is central to the Ayurvedic understanding of the patient’s respiratory distress. In pleural mesothelioma, breathing difficulty may arise from several biomedical causes, including pleural fluid, restriction of lung expansion, pain, tumour burden, anaemia, infection, pulmonary embolism, treatment toxicity, anxiety or general physical deconditioning.

From an Ayurvedic perspective, the clinician may examine whether the movement of Prana Vayu is restricted, whether Kapha contributes to obstruction, whether pain aggravates Vata and whether severe depletion has reduced the patient’s capacity to sustain normal respiratory effort.

The concept of Srotodushti described in Charaka Samhita, Vimanasthana, Chapter 5, provides a framework for assessing obstruction, abnormal movement, altered flow and impaired nourishment within physiological channels [30].

This framework may help explain why the patient experiences restricted breathing, chest discomfort, fatigue during minimal exertion or worsening symptoms after meals or lying flat. Nevertheless, the cause of new or worsening breathlessness must be determined medically. Ayurvedic interpretation should never delay evaluation for pleural-fluid recurrence, infection, pulmonary embolism, pneumothorax or treatment-related lung inflammation.

Udakavaha and Rasavaha Considerations

Pleural fluid may invite consideration of Udakavaha and Rasavaha disturbances, but this interpretation requires caution.

Udakavaha assessment may include thirst, hydration, fluid distribution, dryness, oedema, urine output and the patient’s ability to maintain fluid balance. Rasavaha assessment may include appetite, nourishment, fatigue, complexion, circulation, general tissue nutrition and the early consequences of poor intake.

A patient may have a large pleural effusion while simultaneously being intravascularly depleted, dehydrated or nutritionally compromised. Visible or radiological fluid accumulation does not prove that the patient has excessive total-body hydration.

For this reason, treatment aimed at reducing fluid must not be undertaken without considering blood pressure, kidney function, electrolyte values, oral intake, urine output, albumin level and the medical plan for pleural drainage.

Unsupervised use of strong Mutrala or Rukshana measures may worsen dehydration, electrolyte imbalance, renal function and overall weakness. Malignant pleural fluid is not managed safely through diuretic herbs alone.

Annavaha Srotas and Agni

Agni assessment is essential because appetite and digestive tolerance strongly influence the patient’s ability to maintain weight, muscle and treatment resilience.

Pleural mesothelioma and its treatment may be associated with poor appetite, early satiety, nausea, taste changes, constipation, abdominal fullness, fatigue and difficulty eating because of breathlessness. Pain medicines, antibiotics, chemotherapy, immunotherapy and reduced activity may further alter digestion and bowel function.

The Ayurvedic clinician should assess whether Agni is Vishama, Manda, Tikshna or affected by treatment-related factors. The objective is not to force appetite through aggressive Deepana–Pachana in every patient. A severely depleted patient may not tolerate strong pungent, heating or drying medicines.

Food intake should be supported through appropriate meal timing, smaller portions, suitable texture, adequate protein and energy, and management of nausea, constipation, oral problems and breathlessness. Ayurvedic dietary planning should complement oncology nutrition guidance rather than replace it.

Where digestive weakness is present, treatment may begin with gentle measures intended to improve tolerance and regularity. Where severe cachexia is present, excessive restriction, fasting or prolonged Pachana may accelerate tissue loss.

Rasa, Rakta and Mamsa Dhatu Involvement

Rasa Dhatu may be affected through poor appetite, reduced intake, altered fluid balance, chronic inflammation and treatment-related exhaustion. Patients may describe fatigue, poor nourishment, dryness, heaviness or reduced capacity to recover after activity.

Rakta Dhatu requires attention when anaemia, inflammation, bleeding tendency, haemoptysis or treatment-related marrow suppression is present. These findings require laboratory assessment and medical management. Ayurvedic terminology should not be used to minimise potentially serious haematological abnormalities.

Mamsa Dhatu depletion may become clinically evident as loss of muscle mass, reduced grip strength, difficulty standing, slower walking, inability to climb stairs and greater dependence on caregivers.

Muscle loss may occur even when body weight appears stable because pleural fluid or oedema can conceal tissue depletion. The Ayurvedic assessment of Mamsa Kshaya should therefore be integrated with weight history, dietary assessment, physical examination and functional measures.

Progressive depletion may eventually affect Meda, Asthi, Majja, Shukra and Ojas conceptually, depending on the patient’s overall clinical condition. However, the most immediately measurable concerns are usually nutritional intake, muscle mass, physical function, treatment tolerance and quality of life.

The Role of Ama Must Be Determined, Not Assumed

The presence of cancer should not automatically be interpreted as proof of Ama. Ama is an Ayurvedic clinical concept and should be assessed through the patient’s digestive and systemic presentation.

Features that may suggest an Ama-associated state include marked anorexia, heaviness, coated tongue, poor digestion, nausea, foul-smelling stools, lethargy and intolerance to food. Some of these findings may also arise from infection, medication toxicity, constipation, liver dysfunction or dehydration.

The clinician should therefore investigate medical causes before attributing them to Ama.

Strong Ama-reducing treatment may be unsuitable in a patient with severe weight loss, dehydration, mucositis or poor organ reserve. The treatment intensity must be determined by Bala, Agni, disease stage and current oncology treatment.

Avarana and Margavarodha

The clinical pattern may include features resembling Margavarodha, in which normal movement is restricted by obstruction.

Pleural fluid, tumour-related restriction, pain and inflammatory changes can physically limit lung expansion. From an Ayurvedic perspective, this may be understood as interference with the normal movement of Vata within the respiratory pathways.

However, the structural obstruction remains a biomedical problem. If fluid is compressing the lung, the appropriate response may be medical drainage. Ayurvedic treatment cannot be relied upon to reverse mechanical compression.

After the acute obstruction has been medically addressed, supportive treatment may focus on reducing discomfort, maintaining bowel regularity, supporting sleep, improving food tolerance and helping the patient regain functional stability.

Rogi Bala Is More Important Than the Apparent Strength of the Disease

Charaka Samhita, Vimanasthana, Chapter 8, emphasises comprehensive examination of the patient and the disease before selecting treatment [32]. This principle is particularly important in advanced cancer care.

The clinician should assess Deha Bala, Agni Bala and Satva Bala. Physical strength, nutritional reserve, mobility, cardiopulmonary function, mental resilience, sleep and ability to tolerate treatment should all influence the plan.

A patient with severe cachexia, low albumin, anaemia, breathlessness at rest and poor oral intake should not receive the same treatment intensity as a patient who remains mobile, eats adequately and has stable organ function.

The apparent severity of Kapha-related symptoms should not lead to excessively reducing treatment when the patient’s Bala is low. Similarly, nourishing treatment should not be introduced indiscriminately when digestion is severely impaired or when acute instability remains unresolved.

The central Ayurvedic decision is not simply which Dosha appears dominant. It is whether the patient has sufficient strength to tolerate the proposed intervention.

Avastha-Based Samprapti

Samprapti should be reassessed according to the patient’s current Avastha.

During an acute fluid-dominant phase, the immediate priority may be hospital evaluation, oxygen assessment and pleural intervention. Ayurvedic treatment remains secondary.

During a treatment-toxicity-dominant phase, the focus may be nausea, appetite, bowel function, sleep, mucosal symptoms, fatigue and laboratory safety.

During a pain-dominant phase, the plan may require oncology or palliative analgesia, assessment of new disease complications and carefully selected supportive measures.

During a depletion-dominant phase, the emphasis may shift toward Brimhana, adequate protein and energy intake, sleep, gentle activity and preservation of Mamsa and Bala.

During a relatively stable phase, the plan may focus on maintaining function, improving treatment tolerance, preventing constipation, supporting appetite and monitoring symptoms.

The same patient may move through several of these stages. Treatment that was appropriate during one stage may become unsuitable during another.

The Samprapti-Ghataka Framework

For practical clinical documentation, the Ayurvedic assessment may record the dominant Dosha, associated Dosha, affected Dushya, involved Srotas, type of Srotodushti, state of Agni, presence or absence of Ama, site of symptom expression, route of progression, Rogi Bala, disease stage and major biomedical complications.

The likely Dosha pattern may include Vata–Kapha predominance, with Pitta or Rakta involvement where indicated. The Dushya assessment may give particular attention to Rasa, Rakta and Mamsa. The principal Srotas may include Pranavaha, Rasavaha, Udakavaha and Annavaha according to the presentation.

The Srotodushti pattern may include obstruction, disturbed movement, impaired nourishment or abnormal accumulation. Agni may be Manda or Vishama, but should be assessed individually. Bala may range from relatively preserved to severely depleted.

This framework should remain a working clinical hypothesis. It should be revised when the patient’s symptoms, laboratory results, scan findings or oncology treatment changes.

Samprapti Is Not a Claim About the Cause of Mesothelioma

The Ayurvedic assessment should not suggest that pleural mesothelioma occurred because the patient’s Doshas became imbalanced.

Pleural mesothelioma is strongly associated with asbestos exposure, although not every patient recalls a clear exposure history. The biological development of the disease involves genetic, cellular and environmental factors studied through modern oncology.

Samprapti in this context explains the individual patient’s current pattern of dysfunction, symptom burden and tissue depletion. It does not replace established knowledge about carcinogenesis.

This distinction protects scientific accuracy and helps prevent patients from feeling that they caused their disease through food, emotions or lifestyle.

How Samprapti Guides the Treatment Sequence

Once the immediate medical condition is stable, Samprapti helps determine the order and intensity of supportive treatment.

A patient with poor appetite, constipation and dehydration may first require correction of intake, bowel function and hydration. A patient with severe muscle loss may require early Brimhana and nutritional support rather than aggressive Langhana.

A patient with recurrent pleural fluid may still require nourishing care if Bala and Mamsa are declining. A patient with infection, fever or rapidly worsening breathlessness requires medical evaluation before any Ayurvedic treatment sequence is expanded.

The purpose of Samprapti-Vighatana is therefore not to attack the tumour through a standard formula. It is to interrupt the patient’s active cycle of obstruction, digestive impairment, inadequate nourishment, symptom distress, loss of strength and reduced functional capacity.

This treatment sequence must remain coordinated with oncology, pleural procedures, nutrition, physiotherapy and palliative care.

What This Assessment Should Produce

A complete Ayurvedic assessment should result in a clear written explanation of the patient’s current pattern and treatment priorities.

It should describe whether the patient is stable enough for supportive treatment, which symptoms are being targeted, whether treatment should be reducing, regulating or nourishing, which practices should be avoided and how safety will be monitored.

The plan should also specify how improvement will be evaluated. Depending on the patient, this may include appetite, food intake, bowel regularity, sleep, breathlessness, pain, fatigue, weight adjusted for fluid changes, muscle strength, mobility, treatment tolerance and laboratory stability.

Scan findings must remain under the interpretation of the oncology team. Symptom improvement should not automatically be presented as evidence that the tumour has reduced.

Ayurvedic Samprapti is most clinically useful when it produces a safer and more personalised supportive-care strategy. It should never be used to make unsupported claims of tumour dissolution, cure or guaranteed survival.

The Stabilisation Phase: Making the Patient Safe Before Deeper Treatment

In pleural mesothelioma, stabilisation is not a delay before the “real” treatment begins. It is the first treatment phase.

Before attempting Samprapti-Vighatana, Rasayana, Brimhana or symptom-specific Ayurvedic support, the clinician must establish whether the patient is medically stable enough to receive additional treatment. Breathlessness, pleural effusion, infection, dehydration, electrolyte disturbance, anaemia, treatment toxicity, severe constipation, uncontrolled pain and inadequate food intake can rapidly reduce Bala and alter the safety of every intervention that follows.

The purpose of stabilisation is not to treat the scan report in isolation. It is to protect Prana, establish the minimum conditions required for safe treatment and prevent a potentially reversible complication from being mistaken for ordinary progression of the disease.

A responsible integrative service should therefore begin with one question: does this patient require an Ayurvedic consultation today, or does the patient first require urgent hospital, oncology or pleural-team care?

Hospital Care Must Come Before Ayurvedic Treatment When Breathing Is Unstable

Sudden or severe breathlessness should never be interpreted only as an aggravation of Vata, Kapha or Pranavaha Srotas. In a patient with pleural mesothelioma, it may be caused by rapidly recurring pleural fluid, pulmonary embolism, infection, pneumothorax, anaemia, cardiac complications, treatment-related lung inflammation, mucus obstruction, pain or progression of the disease.

Sudden difficulty breathing, chest pain that worsens with breathing, coughing blood, fainting or near-fainting can occur with pulmonary embolism and require emergency assessment. Severe confusion, bluish lips, inability to speak in complete sentences or rapidly declining consciousness also require immediate hospital care [13, 35].

The patient should not wait for an online response, herbal prescription or clinic appointment when these warning signs are present.

فوری حفاظتی پیغام

اگر سانس اچانک یا بہت زیادہ پھولے، سینے میں درد ہو، خون والی کھانسی آئے، بے ہوشی، شدید چکر، الجھن یا ہونٹ نیلے پڑنے لگیں تو فوراً ایمرجنسی ڈیپارٹمنٹ جائیں۔ آیورویدک مشورے یا آن لائن جواب کا انتظار نہ کریں۔

رسالة أمان عاجلة

إذا حدث ضيق نفس مفاجئ أو شديد، أو ألم في الصدر، أو سعال مصحوب بالدم، أو إغماء، أو دوار شديد، أو ارتباك، أو ازرقاق الشفتين، فتوجّهوا فوراً إلى قسم الطوارئ. لا تنتظروا موعداً للأيورفيدا أو رداً عبر الإنترنت.

Pleural Effusion Must Be Stabilised Medically

Pleural effusion occurs when fluid accumulates in the space surrounding the lung. As the volume increases, the lung may have less room to expand, causing breathlessness, chest pressure, cough, disturbed sleep and reduced ability to eat or walk.

When pleural fluid is symptomatic, the medical team may perform therapeutic thoracentesis to remove fluid and determine whether drainage improves breathing and whether the lung re-expands. If the fluid repeatedly returns, an indwelling pleural catheter or pleurodesis may be considered. The choice depends on lung expandability, symptom burden, expected recurrence, general fitness and the patient’s preferences [7, 8].

Current pleural guidelines recognise indwelling pleural catheter placement and chemical pleurodesis as principal definitive options for eligible patients with symptomatic malignant pleural effusion.

Ayurvedic treatment should not be used as a trial intended to postpone drainage when fluid is compressing the lung or the patient’s breathing is deteriorating. Mutrala, Rukshana or Langhana measures cannot mechanically re-expand a compressed lung and cannot replace assessment for non-expandable lung, loculated effusion, infection or catheter blockage.

The Ayurvedic clinician should document whether pleural fluid is present, how often it has been drained, how much fluid is usually removed, whether relief follows drainage, whether an indwelling catheter is present and whether the character or volume of drainage has recently changed.

Increasing breathlessness despite drainage, inability to drain a previously functioning catheter, new redness, swelling, warmth, pain, foul-smelling discharge or fever may indicate a complication and should be reported promptly to the pleural team.

Breathlessness Requires Cause-Based Stabilisation

Breathlessness is a symptom, not a diagnosis. The stabilisation plan should identify and address reversible contributors before the symptom is attributed entirely to mesothelioma.

The clinical review may need to consider oxygen saturation, pleural fluid, haemoglobin, infection, pulmonary embolism, cardiac function, medication effects, pain, anxiety, constipation, abdominal distension and physical deconditioning. Cancer breathlessness guidelines recommend treating reversible causes while also using symptom-directed measures appropriate to the individual patient [11–13].

Prescribed oxygen is appropriate when clinically indicated, particularly when hypoxaemia is present. Oxygen should not be assumed to be necessary merely because the patient feels breathless, and prescribed oxygen flow should not be changed without medical advice.

Simple supportive measures may include upright positioning, a supported forward lean, cool airflow across the face, pacing of activity and calm breathing without strain. These measures may reduce the perception of breathlessness but do not remove pleural fluid or treat pulmonary embolism, infection or pneumothorax.

Forceful Kapalabhati, Bhastrika, prolonged Kumbhaka and breath-holding challenges should be avoided in a severely breathless, hypoxaemic, frail or unstable patient. Gentle breath awareness may be introduced only when the medical cause has been assessed and the patient can practise without distress.

Fever and Infection Must Be Treated as Potentially Urgent

People receiving chemotherapy or other cancer treatments may have reduced immune defence. Fever may be the first or only sign of infection, particularly when neutrophil counts are low.

A temperature of approximately 38°C or higher, chills, new cough, sore throat, diarrhoea, mouth ulcers, urinary symptoms or redness around a catheter should be reported promptly according to the oncology team’s emergency instructions. Infection during cancer treatment can become life-threatening and requires urgent medical attention [34].

The patient should not take antipyretic medicines merely to suppress fever before contacting the oncology team because lowering the temperature may conceal an important warning sign. The oncology service may have a specific fever threshold based on the treatment being given, and that individual instruction should take priority.

Ayurvedic medicines should not be used in place of antibiotics when bacterial infection is suspected or confirmed. Similarly, Jvara, Ama or Pitta terminology should not delay blood cultures, imaging, intravenous fluids or antimicrobial treatment when these are clinically required.

Hydration, Electrolytes and Organ Function Must Be Reviewed

A patient may have pleural fluid and still be dehydrated. Fluid around the lung does not necessarily mean that the circulating blood volume is adequate.

Poor intake, vomiting, diarrhoea, fever, diuretic medicines, repeated drainage and reduced kidney function may disturb sodium, potassium and other electrolytes. These changes can worsen weakness, confusion, constipation, cardiac rhythm and the ability to tolerate treatment.

The stabilisation review should therefore consider recent complete blood count, kidney function, liver function, electrolytes and any additional investigations requested by the oncology team. Albumin and nutritional assessment may also be useful when there is oedema, substantial weight loss or poor food intake.

Laboratory results should not be interpreted in isolation. A patient may have an apparently stable body weight while losing muscle because fluid accumulation masks tissue loss. The direction of change, recent treatment, hydration status and clinical symptoms all matter.

Strong drying, purgative or diuretic approaches should not be started without considering blood pressure, urine output, kidney function, electrolyte status and the pleural-management plan.

Food Intake and Bowel Function Are Part of Respiratory Stabilisation

A breathless patient may eat less because chewing, swallowing and breathing compete for effort. Large meals may increase abdominal pressure and make breathing feel more difficult. Pain medicines, reduced mobility and poor fluid intake may also cause constipation, which can worsen abdominal distension and respiratory discomfort.

The initial goal is not a perfect therapeutic diet. It is to establish a pattern of food and fluid intake that the patient can tolerate consistently.

Smaller, more frequent meals may be easier than large portions. Suitable protein and calorie intake should be protected, especially when weight and muscle are declining. A cancer dietitian can help adapt food choices to the patient’s treatment, organ function, cultural preferences and symptoms [15, 19].

Ayurvedic dietary planning may support meal timing, texture, warmth, digestibility and Satmya, but should not impose unnecessary restrictions. Juice-only diets, prolonged fasting, elimination of all protein sources and “starving the cancer” strategies are inappropriate when the patient is already losing weight or muscle.

Constipation should be addressed gently and systematically. The clinician should first review opioid use, hydration, bowel frequency, abdominal pain, vomiting and the possibility of obstruction. Strong purgation should not be used when bowel obstruction, severe dehydration, thrombocytopenia or marked weakness is possible.

Every Medicine and Supplement Must Be Reconciled Before Treatment Begins

The stabilisation phase should include a complete list of chemotherapy, immunotherapy, anticoagulants, steroids, antibiotics, analgesics, antiemetics, laxatives, cardiac medicines, diabetes medicines, supplements and existing Ayurvedic formulations.

Herbs and dietary supplements may alter the absorption, distribution, metabolism or elimination of anticancer medicines. They may also affect bleeding, liver function, kidney function or immune activity [24].

The purpose of reconciliation is not merely to identify obvious duplication. It is to determine whether an intervention is necessary, whether it is compatible with the current oncology plan, how its safety will be monitored and what would require it to be stopped.

During stabilisation, introducing several new products simultaneously should be avoided. If appetite, liver enzymes, diarrhoea or breathing subsequently worsens, it may become impossible to identify which product contributed.

A safer strategy is to use the minimum necessary intervention, introduce changes sequentially and document the intended outcome of each addition.

Classical Ayurvedic Foundation of the Stabilisation Phase

Examine Bala Before Selecting Treatment

The classical Ayurvedic foundation of stabilisation is not aggressive Dosha reduction. It is accurate examination of the patient’s capacity to tolerate treatment.

The Urdu and Arabic renderings below communicate the clinical meaning for patients and families. The Sanskrit text remains the authoritative classical source.

Classical Source

Charaka Saṃhitā, Vimāna Sthāna, Chapter 8, Rogabhishagjitiya Vimāna Adhyāya, passage 94. Article reference [32].

Sanskrit

तस्मादातुरं परीक्षेत प्रकृतितश्च, विकृतितश्च, सारतश्च, संहननतश्च, प्रमाणतश्च, सात्म्यतश्च, सत्त्वतश्च, आहारशक्तितश्च, व्यायामशक्तितश्च, वयस्तश्चेति, बलप्रमाणविशेषग्रहणहेतोः ॥९४॥

Roman Transliteration

tasmād āturaṃ parīkṣeta prakṛtitaś ca, vikṛtitaś ca, sārataś ca, saṃhananataś ca, pramāṇataś ca, sātmyataś ca, sattvataś ca, āhāraśaktitaś ca, vyāyāmaśaktitaś ca, vayastaś ceti, balapramāṇaviśeṣagrahaṇahetoḥ || 94 ||

English Translation

Therefore, the patient should be examined with regard to constitution, present morbidity, excellence of tissues, compactness of the body, bodily proportions, suitability and habituation, mental strength, capacity to take and digest food, capacity for physical activity and age, so that the degree of strength may be determined.

Urdu Translation

اس لیے مریض کا معائنہ اس کی پراکرتی، موجودہ بیماری کی کیفیت، دھاتوں کی مضبوطی، جسمانی ساخت، جسمانی تناسب، موافقت اور عادت، ذہنی قوت، غذا لینے اور ہضم کرنے کی صلاحیت، جسمانی مشقت کی صلاحیت اور عمر کے اعتبار سے کرنا چاہیے، تاکہ اس کی اصل قوت کا درست اندازہ کیا جا سکے۔

Arabic Translation

لذلك ينبغي فحص المريض من حيث طبيعته الدستورية، وحالته المرضية الحالية، وجودة أنسجته، وتماسك بنيته، وتناسب جسمه، ومدى ملاءمة الغذاء والعلاج له، وقوته النفسية، وقدرته على تناول الطعام وهضمه، وقدرته على المجهود، وعمره؛ حتى تُقدَّر درجة قوته بدقة.

This passage makes Bala assessment a prerequisite for determining treatment intensity.

In pleural mesothelioma, this principle translates into reviewing respiratory reserve, performance status, weight loss, muscle mass, food intake, organ function, mental resilience and current treatment toxicity before choosing any Ayurvedic intervention.

The Classical Warning Against Excessive Depletion in Breathlessness

Charaka includes excessive depletion and excessive purification among factors associated with Hikka and Shwasa. This verse should not be interpreted as an explanation for the cause of mesothelioma. Its relevance is narrower and clinically important: excessive undernourishment and over-treatment may worsen a patient who is already breathless and weak.

Classical Source

Charaka Saṃhitā, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verse 12. Article reference [33].

Sanskrit

आमप्रदोषादानाहाद्रौक्ष्यादत्यपतर्पणात् ।
दौर्बल्यान्मर्मणो घाताद् द्वन्द्वाच्छुद्ध्यतियोगतः ॥१२॥

Roman Transliteration

āmapradoṣād ānāhād raukṣyād atyapatarpaṇāt |
daurbalyān marmaṇo ghātād dvandvāc chuddhyatiyogataḥ || 12 ||

English Translation

Within the context of Hikka and Shwasa, these disorders may arise or worsen in association with disturbance of Ama, abdominal distension, excessive dryness, excessive depletion, weakness, injury to vital structures, exposure to opposing extremes and excessive use of purification procedures.

Urdu Translation

ہکّا اور شواس کے اس باب کے مطابق آما کی خرابی، پیٹ کے پھولنے، حد سے زیادہ خشکی، ضرورت سے زیادہ جسمانی کمی یا کم غذائیت، کمزوری، اہم اعضا کی چوٹ، متضاد عوامل اور تطہیری علاج کی زیادتی سے سانس کی تکلیف پیدا یا زیادہ ہو سکتی ہے۔

Arabic Translation

وفق سياق فصل الحازوقة وضيق النفس، قد تنشأ هذه الاضطرابات أو تشتد مع اضطراب الآما، وانتفاخ البطن، والجفاف المفرط، والاستنزاف الزائد، والضعف، وإصابة المواضع الحيوية، والتعرض للعوامل المتضادة، والإفراط في إجراءات التنقية.

The verse specifically includes Atyapatarpana, excessive depletion, and Shuddhyatiyoga, excessive purification. It therefore supports a cautious approach in a patient with advanced cancer, poor intake, dehydration, muscle loss or respiratory compromise.

It does not mean that all purification procedures are permanently prohibited in every person with cancer. It means that their appropriateness cannot be decided from Dosha terminology alone. During the stabilisation phase of a frail pleural mesothelioma patient, the threshold for avoiding depleting procedures should be high.

The Classical Signs of Excessive Langhana

The signs of over-administered Langhana described in Charaka overlap with several problems already common in advanced cancer, including cough, thirst, anorexia, weakness and loss of body strength. This makes careful distinction essential.

Classical Source

Charaka Saṃhitā, Sūtra Sthāna, Chapter 22, Laṅghanabṛṃhaṇīya Adhyāya, verses 36–37. Article reference [31].

Sanskrit

पर्वभेदोऽङ्गमर्दश्च कासः शोषो मुखस्य च ।
क्षुत्प्रणाशोऽरुचिस्तृष्णा दौर्बल्यं श्रोत्रनेत्रयोः ॥३६॥

मनसः सम्भ्रमोऽभीक्ष्णमूर्ध्ववातस्तमो हृदि ।
देहाग्निबलनाशश्च लङ्घनेऽतिकृते भवेत् ॥३७॥

Roman Transliteration

parvabhedo’ṅgamardaś ca kāsaḥ śoṣo mukhasya ca |
kṣutpraṇāśo’rucis tṛṣṇā daurbalyaṃ śrotranetrayoḥ || 36 ||

manasaḥ sambhramo’bhīkṣṇam ūrdhvavātas tamo hṛdi |
dehāgnibalanāśaś ca laṅghane’tikṛte bhavet || 37 ||

English Translation

When Langhana is carried beyond the appropriate limit, there may be joint pain, body ache, cough, dryness of the mouth, loss of hunger, aversion to food, thirst, weakness affecting hearing and vision, repeated mental disorientation, upward disturbance of Vata, a sensation of darkness or faintness in the cardiac region, and loss of body mass, digestive capacity and strength.

Urdu Translation

جب لنگھن حد سے زیادہ کیا جائے تو جوڑوں میں درد، بدن ٹوٹنا، کھانسی، منہ کا خشک ہونا، بھوک ختم ہونا، غذا سے بے رغبتی، پیاس، سماعت اور بصارت کی کمزوری، بار بار ذہنی انتشار، اوپر کی طرف وات کی بے ترتیبی، دل کے مقام پر تاریکی یا غشی کا احساس، اور جسم، اگنی اور قوت کا زوال ہو سکتا ہے۔

Arabic Translation

عند الإفراط في اللَّنغهانا، أي العلاج المُخفِّف أو المُقلِّل، قد يظهر ألم المفاصل، وآلام الجسم، والسعال، وجفاف الفم، وفقدان الجوع، والنفور من الطعام، والعطش، وضعف السمع والبصر، والاضطراب الذهني المتكرر، واضطراب حركة الفاتا إلى أعلى، وإحساس بالظلمة أو الإغماء في منطقة القلب، مع تراجع كتلة الجسم وقوة الهضم والقوة العامة.

The clinical message is direct: treatment should not produce progressive thirst, anorexia, cognitive disturbance, loss of body mass or decline in strength. These are not acceptable signs of “detoxification.” They are reasons to stop, reassess and investigate.

A patient who is already experiencing these features should not be placed on fasting, severe dietary restriction or intensive Rukshana merely because pleural fluid is present.

The Classical Caution Against Swedana in a Depleted Patient

Swedana is sometimes considered when Kapha and respiratory obstruction appear prominent. However, Charaka identifies circumstances in which it should not be administered.

Classical Source

Charaka Saṃhitā, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verse 82. Article reference [33].

Sanskrit

न स्वेद्याः पित्तदाहार्ता रक्तस्वेदातिवर्तिनः ।
क्षीणधातुबला रूक्षा गर्भिण्यश्चापि पित्तलाः ॥८२॥

Roman Transliteration

na svedyāḥ pittadāhārtā raktasvedātivartinaḥ |
kṣīṇadhātubalā rūkṣā garbhiṇyaścāpi pittalāḥ || 82 ||

English Translation

Sudation should not be administered to those distressed by Pitta and burning, those with excessive bleeding or sweating, those whose tissues and strength are depleted, those who are excessively dry, pregnant women and those with marked Pitta predominance.

Urdu Translation

پِتّ اور جلن سے متاثر افراد، زیادہ خون بہنے یا پسینہ آنے والے مریض، کمزور دھاتوں اور کم قوت والے، بہت زیادہ خشک جسم والے، حاملہ خواتین اور پِتّ غالب افراد کو سویدن نہیں دینا چاہیے۔

Arabic Translation

لا يُجرى السُّويدانا لمن يعاني من غلبة البيتا والحرقة، أو النزف أو التعرق المفرط، أو استنزاف الأنسجة والقوة، أو الجفاف الشديد، وكذلك للحامل ولمن تغلب عليها البيتا.

The stabilisation implication is that strong steaming, intense heat exposure or procedures designed to induce heavy sweating are inappropriate in a patient with depleted tissues, low strength, dehydration, bleeding risk or burning symptoms.

This warning is especially relevant in Gulf countries, where high environmental temperatures and dehydration may already increase physiological stress. The patient’s climate, fluid intake, renal function and ability to tolerate heat should be considered before any external heating procedure is recommended.

What Ayurvedic Care May Do During Stabilisation

Ayurvedic care during this phase should be Mridu, carefully targeted and compatible with the medical plan.

The initial objectives may be to improve food tolerance, maintain bowel regularity, support sleep, reduce avoidable sensory stress, organise rest and activity, and prevent additional depletion. The plan should prioritise Satmya, Bala and current Avastha rather than attempting an intensive correction of every identified Dosha.

A patient with nausea and poor intake may first require antiemetic optimisation, oral assessment and small tolerable meals. A patient with opioid-related constipation may need an oncology-approved bowel regimen before herbal measures are considered. A patient with insomnia and anxiety may benefit from calm routines and appropriately selected non-pharmacological support, whereas severe agitation or confusion requires medical evaluation.

Ayurvedic medicines, when used, should have a specific documented purpose. The clinician should be able to state whether the intended outcome is improved appetite, easier bowel movement, reduced nausea, better sleep or another measurable supportive objective.

The plan should also include a review date and clear stop criteria. If the intervention causes increasing nausea, diarrhoea, rash, bleeding, sedation, worsening breathlessness, reduced urine, jaundice or laboratory deterioration, it should be held and medically reviewed.

What Should Not Be Done During the Stabilisation Phase

Stabilisation is not the appropriate time for aggressive Vamana, Virechana, strong Niruha Basti, prolonged fasting, forced thirst, intensive Rukshana, heavy Swedana or exhausting exercise.

This is also not the time to begin several unfamiliar formulations, metal-containing products of uncertain quality, strong “immune stimulants” or remedies marketed as direct substitutes for oncology treatment.

Forceful Pranayama should not be prescribed to overcome a mechanically restricted lung. Restrictive diets should not be imposed on a patient with cachexia. Pleural drainage should not be deferred while attempting to reduce fluid through herbs.

Any intervention that further lowers intake, hydration, muscle strength, blood pressure or treatment tolerance is contrary to the purpose of stabilisation.

When Is the Patient Ready for the Next Phase?

The transition to Samprapti-Vighatana should be based on clinical readiness rather than a fixed number of days.

The patient may be considered sufficiently stable when acute breathlessness has been assessed, a plan for recurrent pleural fluid is in place, infection is not uncontrolled, oral intake is reasonably sustainable, bowel function is being managed, hydration and electrolytes are acceptable, recent blood counts and organ-function tests are available, and all medicines and supplements have been reconciled.

The patient and caregiver should understand which symptoms require oncology contact and which require emergency care. They should also know which Ayurvedic interventions are being used, why they are being used and when they must be stopped.

Stability does not mean that the cancer is stable on imaging. It means that immediate physiological risks have been addressed sufficiently to allow a more structured supportive plan to proceed.

The Outcome of Stabilisation Should Be Documented

A stabilisation record should describe the patient’s breathlessness at rest and on activity, pleural-fluid status, oxygen use, food and fluid intake, bowel function, weight trend, mobility, pain, sleep, temperature, relevant laboratory results and current medicines.

It should state what changed during the phase and whether the patient became safer, more nourished and better able to tolerate treatment.

The first successful outcome may be modest but clinically meaningful. It may be the ability to eat without severe breathlessness, sleep for several uninterrupted hours, pass stool comfortably, walk to the bathroom safely or complete a scheduled oncology appointment.

These outcomes do not prove tumour regression. They show that a destabilising cycle has been interrupted and that the patient may now be ready for a more individualised Samprapti-Vighatana plan.

Request a Stabilisation-Focused Case Review

A stabilisation-focused review is appropriate when the family is uncertain whether Ayurvedic treatment can be started safely, when pleural fluid is recurring, when the patient is losing weight or muscle, or when several medicines and supplements are already being used together.

The review should include the biopsy and immunohistochemistry report, latest scan, oncology treatment summary, pleural drainage or catheter record, recent complete blood count, kidney and liver investigations, electrolytes and the full list of medicines and supplements.

The purpose is not to issue a standard cancer prescription. It is to determine what requires hospital or oncology care, what must be stabilised first, what may safely be supported through Ayurveda and what should be avoided.

Only after this foundation is established should the treatment move into the active Samprapti-Vighatana phase.

Samprapti-Vighatana Treatment: Breaking the Active Disease Cycle Without Weakening the Patient

Samprapti-Vighatana begins only after the patient has passed through the immediate stabilisation phase. Acute breathlessness must have been assessed, symptomatic pleural fluid must have a medical management plan, infection must not be uncontrolled, and recent laboratory investigations must be available.

In pleural mesothelioma, Samprapti-Vighatana should not be interpreted as an Ayurvedic method for directly destroying the tumour. There is no reliable clinical evidence that an Ayurvedic intervention can independently dissolve pleural mesothelioma, permanently eliminate malignant pleural fluid or replace oncology treatment.

Its clinically defensible purpose is different. It aims to interrupt the active and potentially modifiable cycle through which breathlessness, disturbed digestion, constipation, poor intake, sleep disruption, anxiety, loss of muscle, treatment toxicity and declining Bala reinforce one another.

The biomedical and Ayurvedic treatment tracks should remain connected. Oncology is responsible for tumour-directed disease control. The pleural team is responsible for drainage and other pleural procedures. Nutrition and rehabilitation teams address cachexia, sarcopenia and function. Ayurvedic care may be added to support selected symptoms, digestive tolerance, bowel function, sleep, nourishment and recovery between treatment cycles.

The Treatment Target Is the Present Samprapti, Not the Diagnostic Label Alone

A diagnosis of pleural mesothelioma does not produce one standard Ayurvedic prescription.

One patient may have recurrent pleural fluid, chest heaviness, mucus, poor appetite and a relatively preserved body constitution. Another may have minimal mucus but severe dryness, pleuritic pain, constipation, anxiety, insomnia and progressive muscle loss. A third may have treatment-related nausea, diarrhoea, oral inflammation or disturbed liver function. Another may be extremely weak, breathless at minimal activity and unable to tolerate ordinary meals.

The Samprapti-Vighatana plan must therefore be designed according to the patient’s current Avastha, Bala, Agni, Dosha predominance, Dhatu status, Srotas involvement, organ function, oncology treatment and immediate goals.

The clinically important question is not merely whether Vata, Pitta or Kapha is present. The question is which disturbance is dominant, which disturbance is secondary, what is obstructed, what is depleted and how much intervention the patient can tolerate safely.

Three Broad Clinical Patterns May Be Recognised

An obstruction-dominant presentation may include chest heaviness, secretions, reduced appetite, sluggish digestion, abdominal distension and a feeling of restricted respiratory movement. In a patient with pleural mesothelioma, however, this pattern must never be assumed to explain all breathlessness. Pleural effusion, tumour-related restriction, infection, pulmonary embolism and treatment-related pneumonitis must be medically assessed.

A depletion-dominant presentation may include dry cough, marked weight or muscle loss, constipation, poor sleep, anxiety, fatigue, reduced exercise tolerance and declining tissue strength. In this situation, aggressive Langhana, Rukshana or Shodhana may worsen the patient even when some fluid or Kapha-like symptoms are also present.

A mixed presentation is common. The patient may have pleural fluid and chest heaviness while simultaneously being dehydrated, anaemic, hypoalbuminaemic and cachectic. Such a patient cannot be treated safely by selecting only a Kapha-reducing strategy. The obstruction must be managed medically while nutrition, hydration, bowel function and Bala are protected.

The Classical Foundation for Strength-Based Personalisation

The distinction between a strong Kapha-dominant patient and a weak, dry, Vata-dominant patient is described clearly in Charaka Saṃhitā, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verses 88–90 [33].

Sanskrit

हिक्काश्वासामयी ह्येको बलवान् दुर्बलोऽपरः ।
कफाधिकस्तथैवैको रूक्षो बह्वनिलोऽपरः ॥८८॥

कफाधिके बलस्थे च वमनं सविरेचनम् ।
कुर्यात् पथ्याशिने धूमलेहादिशमनं ततः ॥८९॥

वातिकान् दुर्बलान् बालान् वृद्धांश्चानिलसूदनैः ।
तर्पयेदेव शमनैः स्नेहयूषरसादिभिः ॥९०॥

Roman Transliteration

hikkāśvāsāmayī hy eko balavān durbalo’paraḥ |
kaphādhikas tathaivaiko rūkṣo bahvanilo’paraḥ || 88 ||

kaphādhike balasthe ca vamanaṃ savirecanam |
kuryāt pathyāśine dhūmalehādiśamanaṃ tataḥ || 89 ||

vātikān durbalān bālān vṛddhāṃścānilasūdanaiḥ |
tarpayed eva śamanaiḥ snehayūṣarasādibhiḥ || 90 ||

English Translation

Among patients affected by Hikka and Shwasa, one may be strong while another is weak. One may have predominance of Kapha, while another may be dry and affected predominantly by Vata.

For the strong patient with marked Kapha predominance, the classical text describes appropriately selected reducing and eliminative measures followed by pacifying treatment and a suitable diet.

Patients who are weak, Vata-dominant, very young or elderly should instead be supported with Vata-pacifying, nourishing and unctuous measures, including suitable soups and broths.

Urdu Translation

ہکّا اور شواس سے متاثر مریضوں میں ایک مریض طاقتور ہو سکتا ہے جبکہ دوسرا کمزور ہوتا ہے۔ ایک میں کَف کی زیادتی نمایاں ہو سکتی ہے، جبکہ دوسرے میں خشکی اور وات کی کثرت غالب ہو سکتی ہے۔

کَف کی زیادتی رکھنے والے طاقتور مریض کے لیے کلاسیکی متن مناسب انتخاب کے بعد تخفیفی اور تطہیری تدابیر بیان کرتا ہے، جن کے بعد موافق غذا اور شَمَن علاج اختیار کیا جاتا ہے۔

وات غالب، کمزور، کم عمر یا عمر رسیدہ مریضوں کو وات کو متوازن کرنے والی، غذائیت بخش اور مناسب چکنائی والی تدابیر، شوربوں اور قابل برداشت غذاؤں کے ذریعے سہارا دینا چاہیے۔

Arabic Translation

قد يكون أحد المرضى المصابين بالحازوقة وضيق النفس قوي البنية، بينما يكون آخر ضعيفاً. وقد تسود الكافا لدى أحدهما، في حين يغلب الجفاف والفاتا لدى الآخر.

في المريض القوي ذي غلبة الكافا، يصف النص الكلاسيكي تدابير تخفيفية وتنقية مختارة بعناية، يتبعها علاج مُهدِّئ وغذاء مناسب.

أما المريض الضعيف أو الذي تغلب عليه الفاتا، وكذلك صغار السن وكبار السن، فينبغي دعمه بتدابير مهدئة للفاتا ومغذية ولطيفة، مع أطعمة وحساءات مناسبة وقابلة للتحمل.

These verses provide a classical foundation for personalised treatment. They do not provide a literal mesothelioma protocol. Hikka and Shwasa are classical conditions and should not be considered identical to pleural mesothelioma.

The references to Vamana, Virechana and Dhuma should not be copied directly into the treatment of an advanced cancer patient. A person receiving chemotherapy, immunotherapy, anticoagulation or pleural procedures may have dehydration, thrombocytopenia, anaemia, organ dysfunction or severe cachexia. In such circumstances, strong purification or medicated smoking may be inappropriate or dangerous.

The transferable principle is that a strong, obstruction-dominant patient and a weak, dry, depleted patient must not receive the same treatment. The patient’s Bala and present Avastha determine treatment intensity. (Charak Samhita)

Strong Shodhana Is Not a Routine Part of Mesothelioma Care

Samprapti-Vighatana does not automatically mean that Doshas must be forcibly expelled.

In advanced pleural mesothelioma, strong Shodhana is generally unsuitable during acute breathlessness, uncontrolled pleural effusion, infection, dehydration, low blood pressure, severe anaemia, thrombocytopenia, renal or hepatic impairment, active treatment toxicity, poor intake or major muscle loss.

The classical warning is particularly direct in Charaka Saṃhitā, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verse 91 [33].

Sanskrit

अनुत्क्लिष्टकफास्विन्नदुर्बलानां विशोधनात् ।
वायुर्लब्धास्पदो मर्म संशोष्याशु हरेदसून् ॥९१॥

Roman Transliteration

anutkliṣṭakaphāsvinnadurbalānāṃ viśodhanāt |
vāyur labdhāspado marma saṃśoṣyāśu hared asūn || 91 ||

English Translation

If purification is administered to a weak patient in whom Kapha has not been appropriately mobilised and whose condition is unsuitable for the preceding procedures, aggravated Vata may gain an opportunity to affect vital structures, produce severe depletion and rapidly endanger life.

Urdu Translation

اگر ایسے کمزور مریض میں تطہیری علاج کیا جائے جس میں کَف مناسب طور پر متحرک نہ ہوا ہو اور جس کی حالت ابتدائی طریقۂ علاج برداشت کرنے کے قابل نہ ہو، تو بگڑا ہوا وات اہم حیاتی مقامات کو متاثر کر کے شدید خشکی اور کمزوری پیدا کر سکتا ہے اور جان کو خطرے میں ڈال سکتا ہے۔

Arabic Translation

إذا أُجري علاج التنقية لمريض ضعيف لم تُهَيَّأ حالته بصورة مناسبة ولم تتحرك الكافا لديه على النحو المطلوب، فقد تجد الفاتا المضطربة مجالاً للتأثير في المواضع الحيوية، وتؤدي إلى استنزاف شديد وتهديد سريع للحياة.

This classical warning is highly relevant to the modern patient with cancer-related depletion. It supports avoiding therapeutic aggression merely because obstruction or Kapha appears to be present.

In practical integrative oncology, Samprapti-Vighatana usually begins through Mridu, measurable and reversible interventions. The patient should not be subjected to a procedure that may reduce hydration, food intake, blood pressure, muscle strength or the capacity to complete oncology treatment. (Charak Samhita)

Nidana Parivarjana Is the First Active Treatment Principle

Once acute medical problems have been stabilised, the first active step is to identify and remove factors that are aggravating the patient’s current symptoms.

This principle is stated in Charaka Saṃhitā, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verse 138 [33].

Sanskrit

हिक्काश्वासविकाराणां निदानं यत् प्रकीर्तितम् ।
वर्ज्यमारोग्यकामैस्तद्धिक्काश्वासविकारिभिः ॥१३८॥

Roman Transliteration

hikkāśvāsavikārāṇāṃ nidānaṃ yat prakīrtitam |
varjyam ārogyakāmais tad dhikkāśvāsavikāribhiḥ || 138 ||

English Translation

A person affected by Hikka or Shwasa who wishes to regain health should avoid the causative and aggravating factors described for those conditions.

Urdu Translation

ہکّا یا شواس سے متاثر جو شخص صحت میں بہتری چاہتا ہو، اسے ان عوامل سے بچنا چاہیے جو ان کیفیات کو پیدا یا زیادہ کرتے ہیں۔

Arabic Translation

ينبغي لمن يعاني من الحازوقة أو ضيق النفس ويرغب في تحسن صحته أن يتجنب العوامل المعروفة بإحداث هذه الحالات أو زيادة شدتها.

In this article, Nidana Parivarjana does not mean claiming that food habits, emotions or Dosha imbalance caused the mesothelioma. It refers to reducing modifiable factors that are worsening the patient’s present condition.

Smoke, dust, incense, strong perfume, poorly ventilated rooms and extreme temperature exposure may worsen respiratory discomfort. Irregular meals, prolonged fasting, insufficient protein, dehydration, severe dietary restriction and unsuitable supplements may worsen nutritional decline. Constipation and abdominal distension may intensify the sensation of breathlessness. Sleep deprivation, uncontrolled pain, overexertion and repeated breath-holding exercises may further reduce functional reserve.

The patient should also avoid concealing herbs or supplements from the oncology team. An unreported product can become an avoidable source of drug interaction, liver injury, bleeding risk or diagnostic confusion. (Charak Samhita)

Correcting Agni Without Further Reducing the Patient

Agni support is often necessary, but it must be adapted to the patient’s strength.

Poor appetite in pleural mesothelioma may be related to cancer-associated inflammation, early satiety, breathlessness during meals, nausea, constipation, pain, anxiety, oral infection, taste changes, chemotherapy, immunotherapy or other medicines. These causes should be assessed rather than assuming that every loss of appetite is simply Manda Agni.

The aim of Deepana and Pachana in a depleted cancer patient is not to create intense hunger through strongly heating or drying medicines. The aim is to improve the patient’s ability to accept, digest and retain adequate nourishment.

A patient with dry mouth, mucositis, gastritis, diarrhoea, burning sensations, disturbed liver function or low body weight may not tolerate strong Katu, Ushna or Tikshna interventions. An excessively stimulating formula may further reduce intake instead of improving it.

Gentle Agni support may focus on regular meal timing, manageable portion size, food temperature, texture, taste tolerance, treatment of constipation, nausea control and reduction of abdominal distension. The intervention should be judged by whether intake improves without producing burning, diarrhoea, pain, insomnia or laboratory deterioration.

Treating Annavaha Srotas Is Part of Preserving Bala

When the patient cannot eat adequately, every subsequent treatment becomes more difficult to tolerate.

Breathless patients may find large meals exhausting. Smaller and more frequent meals may be more practical. Soft, moist or semi-solid foods may be easier when chewing and breathing together are difficult. The meal plan should provide adequate energy and protein while remaining compatible with renal function, liver function, diabetes, swallowing ability and personal Satmya.

Ayurvedic food planning should not be reduced to a list of prohibited foods. The more useful questions are whether the food is acceptable to the patient, whether it can be eaten without excessive breathlessness, whether it worsens nausea or constipation, and whether it contributes sufficient nutrition.

Cancer cachexia is a complex wasting syndrome involving muscle loss and metabolic changes. It may continue despite apparently adequate food intake and generally requires multimodal care rather than diet alone. Fluid accumulation can also conceal loss of lean tissue, so body weight must be interpreted together with muscle and functional measures [15–19]. (ESMO Open)

Vatanulomana Should Be Functional and Gentle

Vatanulomana in this setting does not mean that one medicine is expected to reverse the tumour or pleural restriction.

Its practical objectives may include relieving constipation, reducing abdominal distension, establishing regular meal and sleep timing, supporting comfortable movement, reducing pain-related guarding and improving the patient’s ability to rest.

Constipation deserves particular attention. Opioids, antiemetic medicines, reduced activity, dehydration and low food intake may all contribute. A distended abdomen can make breathing more uncomfortable and may reduce appetite further.

Before using an Ayurvedic bowel intervention, the clinician should exclude severe abdominal pain, persistent vomiting, absence of flatus, gastrointestinal bleeding and suspected obstruction. Strong purgation should not be used when the patient is dehydrated, thrombocytopenic, profoundly weak or at risk of bowel obstruction.

Successful Vatanulomana should produce comfortable and predictable bowel function without diarrhoea, cramping, electrolyte disturbance or loss of strength.

Kapha-Shamana Must Not Be Confused With Removing Malignant Pleural Fluid

Pleural effusion is not simply Kapha that should be dried.

Malignant pleural fluid may recur because of disease involving the pleural surfaces and disruption of normal fluid production and absorption. When the fluid causes breathlessness or lung compression, medical management may include thoracentesis, an indwelling pleural catheter or pleurodesis.

Ayurvedic measures should not be presented as alternatives to these procedures. A formulation may support selected symptoms, but it cannot be assumed to mechanically re-expand a compressed lung.

Kapha-related treatment should be limited to the patient’s actual clinical features, such as excessive secretions, heaviness, poor digestive tolerance or an obstruction-dominant pattern. Even then, treatment must be moderated by hydration, renal function, electrolyte status and Bala.

Strong Mutrala or Rukshana interventions may reduce circulating fluid without resolving the pleural disease. The result may be dehydration, hypotension, renal impairment or weakness while the pleural effusion remains.

Pitta and Rakta Features Require Medical Exclusion of Complications

Burning sensations, fever, haemoptysis, bleeding, jaundice, diarrhoea, rash or mucosal inflammation should not be managed solely as Pitta or Rakta aggravation.

These features may indicate infection, thrombocytopenia, liver injury, gastrointestinal toxicity, immune-related adverse effects or disease progression. Laboratory and medical assessment should come first.

Once dangerous causes have been excluded or treated, Ayurvedic supportive care may be selected according to the remaining symptom pattern. The treatment should be compatible with current blood counts, liver function and prescribed medicines.

New fever, coughing blood, black stools, rapidly spreading rash, jaundice, confusion or severe diarrhoea should trigger urgent oncology or hospital contact rather than routine Dosha correction.

Brimhana Is Often Central When Depletion Dominates

In a patient with progressive muscle loss, poor intake and declining function, the therapeutic direction may need to shift toward Brimhana and Balya rather than further reduction.

The desired result of appropriately administered Brimhana is described in Charaka Saṃhitā, Sūtra Sthāna, Chapter 22, Laṅghanabṛṃhaṇīya Adhyāya, verse 38 [31].

Sanskrit

बलं पुष्ट्युपलम्भश्च कार्श्यदोषविवर्जनम् ।
लक्षणं बृंहिते स्थौल्यमति चात्यर्थबृंहिते ॥३८॥

Roman Transliteration

balaṃ puṣṭyupalambhaś ca kārśyadoṣavivarjanam |
lakṣaṇaṃ bṛṃhite sthaulyam ati cātyarthabṛṃhite || 38 ||

English Translation

The signs of appropriate Brimhana are improvement in strength and nourishment and relief from the adverse effects of emaciation. Excessive Brimhana may lead to excessive bodily accumulation or corpulence.

Urdu Translation

مناسب برِمہن کی علامات میں قوت اور غذائیت میں اضافہ اور جسمانی لاغری سے پیدا ہونے والی تکالیف میں کمی شامل ہے۔ حد سے زیادہ برِمہن جسم میں غیر ضروری زیادتی یا موٹاپے کا سبب بن سکتا ہے۔

Arabic Translation

تتمثل علامات البرِمهانا المناسب في تحسن القوة والتغذية وتراجع الآثار الضارة للهزال. أما الإفراط في البرِمهانا فقد يؤدي إلى تراكم جسدي زائد أو سمنة مفرطة.

In pleural mesothelioma, Brimhana should not be judged only by an increase on the weighing scale. Pleural fluid, oedema and hydration changes may produce apparent weight gain without improvement in muscle mass.

Meaningful Brimhana outcomes may include more stable intake, improved grip strength, better ability to stand or walk, reduced dependence on caregivers, greater tolerance of oncology treatment and slower loss of skeletal muscle.

The treatment should remain digestible. Brimhana does not mean forcing heavy foods into a patient with severe nausea, early satiety or impaired Agni. Food quantity, texture and frequency should be increased according to tolerance.

Modern cancer nutrition guidance similarly emphasises assessment of energy intake, muscle mass, physical function, inflammation and symptoms rather than relying on body weight alone [15–19]. (Charak Samhita)

Balya Treatment Should Be Linked to Measurable Function

The term Balya should not remain an abstract promise that the patient will “feel stronger.”

The plan should define which expression of Bala is being targeted. For one patient, the objective may be to walk to the bathroom without assistance. For another, it may be to complete meals, sleep through the night or attend an oncology appointment without severe exhaustion.

Deha Bala may be monitored through mobility, grip strength, chair-rise ability, walking tolerance and dependence in daily activities. Agni Bala may be monitored through appetite, meal completion, nausea, abdominal comfort and bowel regularity. Satva Bala may be reflected in sleep, anxiety, treatment engagement and the ability to communicate needs.

Gentle physical rehabilitation may be introduced when medically safe. Prolonged bed rest can accelerate muscle loss. However, exercise intensity must reflect cardiopulmonary status, oxygen needs, bone involvement, anaemia, fatigue and fall risk.

The desired outcome is not physical exhaustion. It is preservation of the highest level of safe function available to that patient.

Rasayana Should Follow Stabilisation, Not Replace It

Rasayana should not be the first response to acute breathlessness, uncontrolled pleural fluid, infection or severe treatment toxicity.

It may be considered only after the patient’s immediate risks, Agni, bowel function, intake and organ function have been reviewed. The selected intervention should have a defined supportive purpose.

Terms such as “immune booster,” “cancer detoxifier” or “tumour dissolver” should be avoided. Immune activity is complex, particularly in patients receiving immune checkpoint inhibitors. An intervention that alters immune activity cannot automatically be assumed to be beneficial.

Rasayana in this context should be presented as a personalised supportive strategy intended to protect resilience, nutrition, sleep or recovery. It should not be presented as evidence-based tumour treatment for pleural mesothelioma.

Every formulation must be screened for possible interactions with chemotherapy, immunotherapy, anticoagulants, corticosteroids, antibiotics, analgesics and other medicines [24]. Herbs and supplements can affect cancer-drug absorption, metabolism, transport and excretion. (Cancer.gov)

A Formula Should Be Selected for a Documented Purpose

The safest integrative plan uses the minimum necessary complexity.

Every medicine should have a clearly stated objective. The clinician should be able to explain whether it is being considered for appetite, nausea, constipation, sleep, pain-related distress, digestive tolerance or another specific outcome.

Starting many products together makes clinical interpretation difficult. If the patient later develops diarrhoea, rash, bleeding, sedation, jaundice, reduced urine or worsening liver enzymes, it may be impossible to identify which product contributed.

Sequential introduction is generally more defensible. The patient, caregiver and clinical team should know when each intervention was started, its intended benefit, the monitoring required and the criteria for withholding it.

A product should not be continued merely because it is part of a fixed cancer package. If its objective is not being achieved, or if safety concerns develop, the plan should be reassessed.

Herb-Mineral Products Require an Additional Safety Threshold

Any formulation containing Bhasma, metal, mineral or potentially toxic ingredients requires greater scrutiny.

The clinician should document the exact ingredients, manufacturer, batch number, dose and quality-testing information. Kidney function, liver function, blood counts and the patient’s full medicine list should be considered before use.

Unlabelled powders, products purchased through informal channels and remedies that do not disclose their complete composition should not be used in a medically fragile patient.

Traditional identity alone does not prove contemporary manufacturing quality. The product must be assessed as an actual manufactured preparation, not only by the classical reputation of its ingredients.

The Gulf Patient Requires Climate and Fasting Adaptation

Patients living in Gulf countries may be exposed to high environmental temperatures, air conditioning, dry indoor environments and increased dehydration risk.

A treatment involving strong heating, sweating, fasting or drying measures may be particularly unsuitable when the patient already has poor intake, low blood pressure or impaired kidney function. Hydration planning should account for pleural management, cardiac function, renal function and oncology instructions rather than following a generic recommendation.

Patients intending to fast for religious reasons should discuss the plan before fasting begins. Treatment schedules, diabetes, kidney function, hydration, oral medicines, chemotherapy timing and overall Bala may affect whether fasting can be undertaken safely.

The clinical team should respect religious priorities while explaining the medical consequences clearly. The patient should not conceal fasting from the oncology or Ayurvedic clinician.

مریضوں کے لیے مختصر اردو وضاحت

سمپراپتی وِگھٹن کا مقصد یہ نہیں کہ آیورویدک دوا رسولی کو یقینی طور پر ختم کر دے۔ اس مرحلے کا مقصد مریض کی موجودہ تکالیف کے چکر کو توڑنا ہے، مثلاً سانس کی دشواری، کم بھوک، قبض، نیند کی خرابی، پٹھوں کی کمی اور علاج برداشت نہ کر پانا۔

کمزور اور لاغر مریض میں سخت لنگھن، رکشن یا شودھن نقصان دہ ہو سکتا ہے۔ علاج مریض کی قوت، غذا برداشت کرنے کی صلاحیت، خون کے ٹیسٹ، گردے اور جگر کی حالت اور موجودہ کینسر علاج کو دیکھ کر منتخب کیا جانا چاہیے۔

شرح مختصر للمريض باللغة العربية

لا يعني علاج سامبرابتي فيغهاتانا أن دواء الأيورفيدا سيزيل الورم بصورة مؤكدة. الهدف في هذه المرحلة هو كسر الحلقة النشطة التي تشمل ضيق النفس، وضعف الشهية، والإمساك، واضطراب النوم، وفقدان العضلات، وعدم القدرة على تحمل علاج السرطان.

قد تكون إجراءات التقليل أو التجفيف أو التنقية القوية ضارة للمريض الضعيف أو المصاب بالهزال. لذلك يجب اختيار العلاج وفق قوة المريض، وقدرته على تناول الطعام، ونتائج تحاليل الدم، ووظائف الكلى والكبد، والعلاج السرطاني المستخدم حالياً.

The Treatment Sequence Should Remain Flexible

The first active phase may focus on removing aggravating factors, reconciling medicines and establishing food and bowel tolerance.

The next phase may focus on gentle Agni support, Vatanulomana, sleep and symptom-specific care.

When intake is more stable, the emphasis may shift toward Brimhana, Balya and preservation of muscle and function.

Rasayana may be considered later when the patient is stable enough and when the proposed formulation is compatible with oncology treatment and organ function.

This sequence is not fixed. A new pleural effusion, infection, hospital admission, immune-related adverse effect or laboratory deterioration may require the plan to return immediately to stabilisation.

Treatment Response Must Be Evaluated at More Than One Level

The earliest outcomes may involve appetite, bowel regularity, nausea, sleep, pain-related distress and the patient’s ability to complete meals.

Functional outcomes may include walking tolerance, grip strength, ability to rise from a chair, performance status and dependence on caregivers.

Treatment-tolerance outcomes may include fewer interruptions caused by avoidable symptoms, better hydration, improved bowel management and the ability to attend scheduled oncology care.

Disease outcomes remain separate. Stable disease, tumour response, progression-free survival and overall survival must be assessed by the oncology team. A scan response occurring during chemotherapy or immunotherapy must not automatically be attributed to Ayurveda.

Similarly, improved appetite or sleep should not be presented as proof that the mesothelioma has reduced.

Clear Hold and Stop Criteria Are Part of Samprapti-Vighatana

Ayurvedic treatment should be withheld and medically reviewed when the patient develops new or worsening breathlessness, persistent vomiting, severe diarrhoea, gastrointestinal bleeding, coughing blood, jaundice, markedly reduced urine, confusion, excessive sedation, severe rash or signs of allergy.

The plan should also be reviewed when liver enzymes, kidney function, electrolytes or blood counts deteriorate unexpectedly.

A medicine should not be continued through an adverse event on the assumption that the patient is experiencing a healing reaction or detoxification. New deterioration must be investigated.

Emergency warning signs require hospital care. They should not be managed by changing the Ayurvedic dose through an online message.

What a Written Samprapti-Vighatana Plan Should Contain

The final plan should explain the patient’s dominant Ayurvedic pattern, current Bala, Agni, major Srotas involvement, degree of depletion and immediate medical risks.

It should state what oncology and pleural treatments must continue, which Ayurvedic measures may be added, what must be avoided and what outcomes will be monitored.

The plan should document the purpose of every formulation, the sequence of introduction, required laboratory monitoring and criteria for holding or discontinuing treatment.

It should also distinguish clearly between supportive outcomes and disease outcomes.

Request a Personalised Samprapti-Vighatana Review

A personalised review is appropriate after the patient has been medically stabilised and the family wants to understand how supportive Ayurvedic care may be integrated safely.

The review should include the biopsy and immunohistochemistry report, latest scan, oncology treatment summary, pleural-fluid history, current medicines, existing supplements, recent complete blood count, kidney and liver investigations, electrolytes, weight history and current symptom pattern.

The purpose is not to select a standard mesothelioma formula. It is to determine which active cycle is reducing the patient’s function, which interventions are medically necessary, which Ayurvedic principles are appropriate and how benefit and safety will be evaluated.

A responsible Samprapti-Vighatana plan should make the treatment more precise, not more aggressive.

Management of Breathlessness and Pleural Effusion: A Two-Level Treatment Plan

Breathlessness is often the symptom that most directly affects daily life in pleural mesothelioma. It may disturb sleep, reduce food intake, limit walking, increase anxiety and make the patient feel dependent on others.

When pleural fluid is present, patients and families may understandably search for a medicine that can “dry” or “remove” the fluid. However, malignant pleural effusion is not simply excess water in the body. It develops because disease involving the pleura can disturb the production, circulation and absorption of fluid around the lung.

Management therefore requires two coordinated levels of care.

The first level is medical and pleural management. Its purpose is to identify the cause of breathlessness, relieve mechanical compression of the lung when possible, manage recurrent pleural fluid and exclude emergencies.

The second level is supportive care. Its purpose is to reduce the distress associated with breathlessness, improve positioning, preserve food intake, maintain bowel function, support sleep, reduce panic and help the patient remain as functional as possible.

Ayurveda may contribute only to this second supportive level after urgent causes have been assessed. It cannot replace thoracentesis, pleurodesis, an indwelling pleural catheter, oxygen when medically indicated, antibiotics, anticoagulation or oncology treatment.

Breathlessness Is a Symptom, Not a Single Diagnosis

Breathlessness in pleural mesothelioma may arise from more than one cause at the same time.

Pleural fluid may compress the lung and interfere with respiratory mechanics. The tumour itself may restrict movement of the lung and chest wall. Pain may prevent the patient from taking a comfortable breath. Anaemia may reduce oxygen-carrying capacity. Infection, pulmonary embolism, cardiac disease, airway obstruction, treatment-related pneumonitis, muscle weakness and severe anxiety may also contribute.

Cancer breathlessness guidelines recommend systematic assessment of severity, duration, triggers, associated symptoms and potentially reversible causes. Pleural effusion, pneumonia, anaemia, pulmonary embolism and treatment-related lung inflammation are among the conditions that may require specific medical treatment [11–13]. (ascopost.com)

For this reason, a new or rapidly worsening episode should not automatically be labelled as Vata aggravation, Kapha obstruction or recurrence of pleural fluid.

The clinician must first determine what has changed.

Severe or Suddenly Worsening Breathlessness Requires Urgent Assessment

The patient requires urgent hospital evaluation when breathlessness is sudden, severe, rapidly progressive or accompanied by chest pain, coughing blood, fainting, confusion, bluish lips, severe restlessness or inability to speak in complete sentences.

Sudden breathlessness with chest pain, coughing blood or painful swelling of one leg may indicate pulmonary embolism. Fever, falling oxygen saturation, productive cough or new confusion may indicate infection. Sudden respiratory deterioration after a pleural procedure may require assessment for pneumothorax, bleeding or another procedure-related complication [13, 35].

Ayurvedic treatment should not be started, increased or changed through an online message in such circumstances.

فوری حفاظتی پیغام

اگر سانس اچانک یا بہت زیادہ پھولنے لگے، سینے میں درد ہو، خون والی کھانسی آئے، مریض بے ہوش ہو، شدید الجھن ہو، ہونٹ نیلے پڑ جائیں یا مریض پورا جملہ نہ بول سکے تو فوراً ایمرجنسی ڈیپارٹمنٹ جائیں۔

ایسی حالت کو صرف وات یا کَف کی خرابی سمجھ کر گھر پر علاج نہ کریں۔ آیورویدک دوا، بھاپ، جوشاندہ یا آن لائن مشورے کا انتظار نہ کریں۔

رسالة أمان عاجلة

إذا أصبح ضيق النفس مفاجئاً أو شديداً، أو صاحبه ألم في الصدر، أو سعال مع الدم، أو إغماء، أو ارتباك شديد، أو ازرقاق الشفتين، أو عدم القدرة على إكمال جملة أثناء الكلام، فيجب التوجه فوراً إلى قسم الطوارئ.

لا ينبغي تفسير هذه الحالة على أنها اضطراب في الفاتا أو الكافا فقط، ولا ينبغي انتظار دواء أيورفيدي أو جلسة بخار أو استشارة عبر الإنترنت.

Understanding Pleural Effusion in Mesothelioma

What Pleural Effusion Does to Breathing

The pleural space is the narrow space between the lung and the inner surface of the chest wall. When fluid accumulates in this space, it can alter the movement of the diaphragm, reduce the available space for lung expansion and increase the effort required for breathing.

The patient may experience breathlessness on walking, difficulty lying flat, chest pressure, dry cough, disturbed sleep, early satiety and inability to complete ordinary activities.

The severity of breathlessness does not always correspond directly to the amount of fluid seen on a scan. A smaller effusion may be highly symptomatic in a patient with poor lung reserve, while a larger effusion may develop gradually and initially produce less obvious discomfort.

Management should therefore be guided by symptoms, imaging, lung expandability, the speed of fluid recurrence, general health and the patient’s treatment goals—not by fluid volume alone [7, 8, 13]. (Cancer.gov)

Not Every Pleural Effusion in a Cancer Patient Has the Same Cause

A person with cancer may develop pleural fluid because of malignant pleural involvement, but other causes must also be considered.

Heart failure, pneumonia, pulmonary embolism, low albumin, malnutrition, kidney disease, treatment effects and other medical conditions can produce or contribute to pleural effusion. The management of these conditions differs from the management of a confirmed malignant pleural effusion [13]. (Cancer.gov)

The presence of mesothelioma should therefore not lead to the assumption that every new effusion represents simple tumour progression.

The clinical team may review imaging, pleural-fluid findings, symptoms, cardiac status, infection indicators and laboratory investigations before determining the cause and treatment strategy.

The First Therapeutic Drainage Can Answer Two Important Questions

When it is uncertain whether pleural fluid is responsible for the patient’s breathlessness, therapeutic thoracentesis may help answer whether breathing improves after fluid is removed.

It may also help determine whether the lung is able to expand. This information is important when the pleural team is considering pleurodesis.

Current pleural guidance supports large-volume therapeutic thoracentesis when it is unclear whether symptoms are caused by the effusion or when lung expandability needs to be assessed before a definitive procedure. If breathlessness does not meaningfully improve after drainage, other causes should be investigated rather than assuming that repeated drainage will solve the problem [8]. (American Thoracic Society)

The volume removed, speed of drainage and circumstances for stopping the procedure must be determined by the medical team. Patients and caregivers should not attempt to establish their own drainage targets.

Thoracentesis May Relieve Symptoms but May Not Prevent Recurrence

Thoracentesis removes pleural fluid through a needle or catheter and can provide rapid relief when the effusion is contributing significantly to breathlessness.

The procedure may be appropriate for initial symptom assessment, occasional recurrence, diagnostic evaluation or situations in which a more permanent intervention is not suitable.

However, malignant pleural fluid frequently returns after drainage. Repeated thoracenteses may expose the patient to additional procedures and risks such as pain, bleeding, infection or pneumothorax. The pleural team may therefore discuss a more definitive strategy when recurrence is frequent [8, 13]. (Cancer.gov)

Thoracentesis is a medical procedure. It cannot be replaced by diuretic herbs, sweating, fasting or attempts to “pull the water out” through external therapies.

Pleurodesis

Pleurodesis is a procedure intended to reduce the likelihood of recurrent fluid accumulation by causing the pleural surfaces to adhere.

For pleurodesis to work, the lung usually needs to expand sufficiently so that the visceral and parietal pleural surfaces can come into contact.

The procedure may involve drainage through a chest tube followed by introduction of a pleurodesis agent. Talc is commonly used in contemporary pleural practice.

Pleurodesis may reduce the need for continued home drainage, but it may require hospital care and can cause pain, fever or other complications. Suitability depends on lung expandability, functional status, local expertise and the patient’s goals.

Indwelling Pleural Catheter

An indwelling pleural catheter is a flexible tube placed through the chest wall and left in position so that recurrent pleural fluid can be drained periodically.

It may allow management in the home or community setting and may reduce the need for repeated hospital procedures. It can be particularly useful when the lung does not expand fully, when pleurodesis has failed or when the patient prefers an ambulatory option.

The catheter also creates responsibilities. The patient or caregiver may require training, sterile drainage supplies, nursing support and a clear process for reporting complications.

Current guidelines allow a choice between an indwelling pleural catheter and pleurodesis for many symptomatic patients with an expandable lung. When non-expandable lung, failed pleurodesis or a loculated effusion is present, an indwelling catheter is generally favoured over chemical pleurodesis [7, 8].

Pleurodesis and an Indwelling Catheter Are Not Competing “Good” and “Bad” Options

Both approaches may improve breathlessness and quality of life.

The TIME2 trial found that both an indwelling pleural catheter and talc pleurodesis relieved dyspnoea, without a significant difference in the primary breathlessness outcome during the early follow-up period [9]. (PubMed)

The AMPLE trial found fewer lifetime hospitalisation days and fewer additional pleural procedures with an indwelling catheter, but breathlessness and quality-of-life improvement were not significantly different between the two strategies [10]. (PubMed)

The appropriate choice depends on whether the lung expands, how frequently fluid returns, whether the patient can manage catheter drainage, how much hospital time is acceptable, local services and the patient’s preferences.

The article should not present one procedure as universally superior.

Non-Expandable or “Trapped” Lung

A lung may fail to expand fully after pleural fluid is removed. This can occur because the visceral pleura has become restricted by tumour or fibrosis or because of other mechanical factors.

Pleurodesis may be less likely to succeed when the pleural surfaces cannot come together. In this situation, an indwelling pleural catheter may provide symptom relief through intermittent drainage even though complete lung expansion is not possible.

The goal is not always to make the chest radiograph appear normal. The practical objective may be to reduce breathlessness with the least procedural burden.

Ayurvedic medicine cannot release a mechanically trapped lung. Claims that oils, heat, herbs or Pranayama can “open” the lung in this setting should be avoided.

Indwelling Pleural Catheter Care

Drainage Frequency Must Follow the Pleural Team’s Instructions

The frequency of catheter drainage varies according to symptoms, fluid production, the clinical objective and the type of drainage strategy selected.

Some patients follow a regular schedule. Others use a symptom-guided plan. More frequent drainage may sometimes be used when spontaneous pleurodesis is being pursued, but this should be decided by the pleural team.

Patients should not increase drainage frequency or attempt to remove unusually large volumes because breathlessness has worsened without first considering catheter blockage, loculation, infection, pulmonary embolism or another cause.

A drainage record can help the treating team understand changes over time. It may document the date of drainage, approximate amount removed, appearance of fluid, symptoms before and after drainage and any pain or difficulty during the process. BTS guidance supports patient and caregiver education, community nursing involvement and use of a drainage diary when appropriate [7].

When Catheter Problems Require Medical Review

New redness, warmth, swelling, increasing pain, discharge or fever may indicate infection.

A catheter that previously drained well but suddenly stops, particularly when breathlessness is increasing, may be blocked or associated with loculated fluid. New leakage, damage to the catheter, suspected fracture or persistent pain also requires assessment.

Current pleural guidance advises referral back to the pleural team when there is infection not responding to community management, suspected catheter damage, blockage, loculation or persistent breathlessness [7, 8].

The catheter should not be manipulated, flushed with unapproved substances or treated with oils, powders or herbal preparations at home.

Pleural Infection Is Not Managed With Ayurvedic Antimicrobials Alone

An infection around or within an indwelling pleural catheter requires medical evaluation and appropriate antimicrobial treatment.

In some cases, the catheter may remain in place while infection is treated. Catheter removal may be considered when infection fails to improve. This decision belongs to the pleural team [8]. (American Thoracic Society)

Ayurvedic terminology such as Pitta, Rakta Dushti, Ama or Vrana should not delay cultures, antibiotics, drainage or hospitalisation when these are required.

Classical Ayurvedic Understanding of Disturbed Respiration

Ayurvedic interpretation may help organise the patient’s symptom pattern, but it must not replace modern respiratory assessment.

The classical passages below describe disturbed respiration, urgency of treatment and positional relief. They do not identify pleural mesothelioma, malignant pleural effusion or pulmonary embolism. Their value lies in supporting careful observation of respiratory pattern, Bala and patient comfort.

Pranavaha Srotas: Classical Signs of Respiratory Disturbance

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 5, Srotovimāna Adhyāya, passage 8. Article reference [30].

Sanskrit

तत्र प्राणवहानां स्रोतसां हृदयं मूलं महास्रोतश्च, प्रदुष्टानां तु खल्वेषामिदं विशेषविज्ञानं भवति; तद्यथा— अतिसृष्टमतिबद्धं कुपितमल्पाल्पमभीक्ष्णं वा सशब्दशूलमुच्छ्वसन्तं दृष्ट्वा प्राणवहान्यस्य स्रोतांसि प्रदुष्टानीति विद्यात् ॥८॥

Roman Transliteration

tatra prāṇavahānāṃ srotasāṃ hṛdayaṃ mūlaṃ mahāsrotaś ca, praduṣṭānāṃ tu khalveṣām idaṃ viśeṣavijñānaṃ bhavati; tadyathā— atisṛṣṭam atibaddhaṃ kupitam alpālpam abhīkṣṇaṃ vā saśabdaśūlam ucchvasantaṃ dṛṣṭvā prāṇavahāny asya srotāṃsi praduṣṭānīti vidyāt || 8 ||

English Translation

The roots of the Pranavaha Srotas are described as the heart and Mahasrotas. Their disturbance should be recognised when respiration becomes excessively prolonged, markedly obstructed, distressed, shallow, repeatedly frequent, noisy or associated with pain.

Urdu Translation

پران واہ سروتس کا مول ہردیہ اور مہاسروتس بیان کیا گیا ہے۔ جب سانس بہت لمبی، بہت رکی ہوئی، بے ترتیب، تھوڑی تھوڑی اور بار بار، آواز کے ساتھ یا درد کے ساتھ آنے لگے تو پران واہ سروتس کی خرابی کو سمجھنا چاہیے۔

Arabic Translation

يُذكر أن أصل قنوات البرانا هو القلب والمجرى العظيم. ويُستدل على اضطرابها عندما يصبح التنفس مفرط الطول، أو شديد الانسداد، أو مضطرباً، أو سطحياً ومتكرراً، أو مصحوباً بصوت أو ألم.

The passage emphasises observation of respiratory pattern rather than using the general word “breathlessness” alone. Clinically, the treating team should document whether breathing is rapid, shallow, noisy, painful, interrupted or difficult during speech and activity. (Charak Samhita)

These classical observations should not be used to distinguish pleural effusion from pulmonary embolism, infection, pneumonitis or pneumothorax. Modern investigation remains essential.

The Classical Principle of Prompt Attention to Severe Shwasa

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka and completed by Dridhabala, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verse 69. Article reference [33].

Sanskrit

भेषजैः साध्ययाप्यांस्तु क्षिप्रं भिषगुपाचरेत् ।
उपेक्षिता दहेयुर्हि शुष्कं कक्षमिवानलः ॥६९॥

Roman Transliteration

bheṣajaiḥ sādhyayāpyāṃs tu kṣipraṃ bhiṣag upācaret |
upekṣitā daheyur hi śuṣkaṃ kakṣam ivānalaḥ || 69 ||

English Translation

The physician should promptly attend to forms of respiratory illness that are treatable or controllable. If neglected, they may progress rapidly, like fire spreading through dry grass.

Urdu Translation

طبیب کو سانس کی ایسی کیفیتوں کا فوری علاج کرنا چاہیے جو قابلِ علاج یا قابلِ قابو ہوں۔ اگر انہیں نظرانداز کیا جائے تو وہ خشک گھاس میں آگ کی طرح تیزی سے بڑھ سکتی ہیں۔

Arabic Translation

ينبغي للطبيب أن يعالج سريعاً حالات اضطراب التنفس القابلة للعلاج أو السيطرة. فإذا أُهملت، فقد تتفاقم بسرعة كما تنتشر النار في العشب الجاف.

The modern application of this verse is not to administer a classical respiratory formula immediately. Its safest application is that serious respiratory deterioration should never be ignored.

In a patient with pleural mesothelioma, prompt treatment may mean emergency imaging, pleural drainage, oxygen assessment, antibiotics, anticoagulation or palliative medication rather than an Ayurvedic medicine. (Charak Samhita)

Positional Relief Described in the Classical Text

Classical Source

Charaka Saṃhitā of Agniveśa, Cikitsā Sthāna, Chapter 17, Hikkā-Śvāsa Cikitsita Adhyāya, verses 59–60. Article reference [33].

Sanskrit

अथास्योद्ध्वंसते कण्ठः कृच्छ्राच्छक्नोति भाषितुम् ।
न चापि निद्रां लभते शयानः श्वासपीडितः ॥५९॥

पार्श्वे तस्यावगृह्णाति शयानस्य समीरणः ।
आसीनो लभते सौख्यमुष्णं चैवाभिनन्दति ॥६०॥

Roman Transliteration

athāsyoddhvaṃsate kaṇṭhaḥ kṛcchrāc chaknoti bhāṣitum |
na cāpi nidrāṃ labhate śayānaḥ śvāsapīḍitaḥ || 59 ||

pārśve tasyāvagṛhṇāti śayānasya samīraṇaḥ |
āsīno labhate saukhyam uṣṇaṃ caivābhinandati || 60 ||

English Translation

The throat becomes distressed and speech becomes difficult. The person troubled by breathlessness cannot sleep comfortably while lying down. When lying, discomfort affects the flanks, whereas sitting provides a degree of relief.

Urdu Translation

گلا متاثر ہو جاتا ہے اور بولنا مشکل ہو سکتا ہے۔ سانس کی تکلیف میں مریض لیٹنے کی حالت میں آرام سے سو نہیں پاتا۔ لیٹنے سے پہلوؤں میں تکلیف بڑھ سکتی ہے، جبکہ بیٹھنے سے کچھ سکون مل سکتا ہے۔

Arabic Translation

قد يتأذى الحلق ويصبح الكلام صعباً. ولا يستطيع المصاب بضيق النفس أن ينام براحة عند الاستلقاء، وقد يزداد الانزعاج في جانبي الصدر، بينما يمنحه الجلوس قدراً من الراحة.

These verses occur within the classical description of Tamaka Shwasa and should not be treated as a description of pleural mesothelioma. However, the observation that some breathless patients feel more comfortable sitting than lying down remains clinically relevant.

A supported upright or forward-leaning position may reduce the work and distress of breathing in some patients. It does not identify the cause of breathlessness and does not replace medical assessment. (Charak Samhita)

Supportive Management of Breathlessness

Positioning Can Reduce Distress

Many patients find it easier to breathe when sitting upright with the back, arms and head supported.

A supported forward lean may also be comfortable. The patient may sit with the forearms resting on a table, pillows or the arms of a chair. The shoulders should be relaxed rather than elevated.

In bed, additional pillows or an adjustable backrest may be used if lying flat worsens breathlessness. The patient should not be forced into a flat position for sleep merely because it appears more restful.

Positioning is a comfort measure. Increasing dependence on upright sleeping may also indicate worsening pleural fluid, heart failure or another medical change and should be reported.

Cool Airflow Across the Face

A handheld or table fan directed toward the cheek or lower face may reduce the subjective sensation of breathlessness in some patients.

The airflow should be comfortable and should not cause distress, excessive cooling or drying. In Gulf climates, the patient may already spend long periods in air-conditioned environments, so the intensity and duration should be adjusted according to comfort.

Cancer dyspnoea guidelines include facial airflow among the initial non-pharmacological measures that may be offered [11]. (ascopost.com)

A fan does not raise oxygen levels, remove pleural fluid or treat an emergency. Its role is to reduce the sensation of breathing discomfort.

Oxygen Is a Medical Treatment, Not a General Remedy for All Breathlessness

A person can feel severely breathless even when oxygen saturation is not markedly reduced.

Supplemental oxygen is most clearly indicated when hypoxaemia is present. Routine oxygen may not benefit every non-hypoxaemic patient and may create additional equipment burden.

The decision should be based on oxygen measurements, medical assessment, the clinical situation and the patient’s goals. The flow rate should not be increased or reduced without instructions from the prescribing team.

ASCO guidance recommends standard supplemental oxygen for breathless patients who are hypoxaemic, while non-pharmacological measures may be used when oxygen levels are adequate [11]. (ascopost.com)

Ayurvedic treatment should not be presented as a method for replacing prescribed oxygen.

Calm Breathing Should Not Become Forceful Pranayama

A breathless patient may begin breathing rapidly and become increasingly frightened. Fear increases muscle tension and respiratory effort, which can intensify the sensation of breathlessness.

Gentle breath awareness may help the patient slow down without forcing a deep breath. The patient may be encouraged to relax the shoulders, allow the abdomen to remain soft and lengthen the outgoing breath only if this feels comfortable.

The objective is comfort, not achievement of a breathing ratio.

Kapalabhati, Bhastrika, prolonged Kumbhaka, repeated maximal inhalation and breath-holding tests should be avoided in a severely breathless, hypoxaemic, frail or unstable patient.

A patient with pleural restriction should never be told to “push through” pain or respiratory distress to expand the lung.

Any breathing exercise should stop immediately if it causes dizziness, chest pain, coughing blood, severe cough, panic or worsening breathlessness.

Pain Control Is Part of Breathlessness Management

Chest-wall or pleural pain can make the patient guard the chest and take smaller breaths. Pain may also disturb sleep, reduce walking and worsen anxiety.

The oncology or palliative-care team should assess whether pain is related to tumour involvement, pleural procedures, musculoskeletal strain or another cause. Appropriate analgesia may improve the patient’s ability to breathe, rest and move more comfortably.

Ayurvedic external applications should not be placed over a catheter site, recent procedure wound, inflamed skin or suspected infection.

Strong massage over painful ribs or areas of possible bone involvement should be avoided until structural complications have been excluded.

Anxiety Must Be Treated Without Dismissing the Physical Cause

Anxiety can amplify breathlessness, but breathlessness should not be dismissed as “only anxiety.”

The appropriate sequence is to assess physical causes, address reversible conditions and then add measures for panic, fear and emotional distress.

Clear explanations, a calm caregiver, predictable care routines, relaxation, psychological support and early palliative-care involvement may reduce the emotional burden of breathlessness. Interdisciplinary palliative-care referral is strongly supported in advanced cancer with significant dyspnoea [11, 14]. (ascopost.com)

Medication for persistent breathlessness or anxiety may be considered by the oncology or palliative-care team according to the patient’s overall condition.

Ayurvedic medicines that cause sedation should not be added casually when the patient is already using opioids, anxiolytics, sleep medicines or other central nervous system depressants.

Clinician-Prescribed Palliative Medication May Be Appropriate

When breathlessness remains distressing after reversible causes and non-pharmacological measures have been addressed, the palliative-care team may consider medicines intended to reduce the perception of respiratory distress.

This decision requires clinical assessment, particularly when the patient is frail, has kidney or liver impairment or is already receiving sedating medicines.

The role of Ayurveda is not to persuade the patient to avoid appropriately prescribed palliative medication.

Supportive care should be judged by relief of suffering and preservation of safety, not by whether every conventional medicine can be discontinued.

Food Intake Should Be Adapted to Breathlessness

Eating can become difficult because chewing, swallowing and breathing must occur together.

Large meals may increase abdominal fullness and worsen respiratory discomfort. Smaller and more frequent meals may be easier to manage.

Soft, moist and energy-dense foods may reduce the effort required for eating. The patient may need rest before and after meals and may benefit from eating while sitting upright.

Food should not be offered during a severe respiratory episode when the patient cannot coordinate swallowing safely.

Ayurvedic dietary individualisation may consider Satmya, temperature, texture, appetite and digestive tolerance. However, the plan must still provide adequate energy and protein.

Constipation Can Intensify Respiratory Discomfort

Constipation and abdominal distension can increase discomfort under the diaphragm, worsen early satiety and make breathing feel more restricted.

Opioids, antiemetics, dehydration, reduced activity and poor intake may all contribute.

Bowel management should be preventive rather than delayed until severe constipation develops. The oncology or palliative-care plan may include prescribed laxatives, particularly when opioid medicines are used.

Before recommending an Ayurvedic bowel intervention, the clinician should exclude severe abdominal pain, repeated vomiting, absence of flatus, gastrointestinal bleeding and suspected obstruction.

The goal is comfortable bowel regularity, not repeated purgation.

The Appropriate Ayurvedic Role

Ayurveda May Support the Patient, but It Cannot Drain the Pleural Space

Ayurvedic treatment may be considered for selected supportive objectives after the medical cause of breathlessness has been assessed.

The plan may address poor appetite, digestive intolerance, constipation, sleep disruption, treatment-associated discomfort, anxiety-related distress and progressive loss of Bala.

It may also help personalise food timing, food texture, daily routine, rest and gentle activity.

Ayurvedic treatment should not claim to extract pleural fluid, reopen a mechanically restricted lung or eliminate the malignant process.

A patient may feel more comfortable after constipation is relieved, sleep improves or anxiety decreases. This is a meaningful supportive outcome, but it is not equivalent to radiological reduction of pleural disease.

Pleural Fluid Should Not Be Treated as Kapha Alone

The presence of fluid may suggest Kapha, Kleda, Udakavaha or Rasavaha involvement within an Ayurvedic assessment.

However, the patient may simultaneously have Rukshata, Trishna, low blood pressure, reduced urine output, electrolyte disturbance, hypoalbuminaemia and severe Mamsa Kshaya.

Strong Kapha-reducing or fluid-reducing treatment may therefore worsen the patient’s general condition without resolving the pleural effusion.

The clinical decision must consider whether the fluid is compressing the lung, whether medical drainage is needed, whether the patient is dehydrated and whether kidney and electrolyte status permit any intervention affecting fluid balance.

Mutrala Therapy Requires Particular Caution

A diuretic effect on urine output is not the same as drainage of fluid from the pleural cavity.

Unsupervised Mutrala treatment may reduce circulating volume, lower blood pressure, disturb electrolytes and worsen renal function. The pleural fluid may remain because the underlying pleural process has not changed.

Mutrala formulations should not be added merely because a scan mentions pleural effusion.

Any consideration of a product affecting fluid balance must account for kidney function, sodium, potassium, blood pressure, urine output, prescribed diuretics, cardiac status and the pleural-management plan.

Strong Swedana Is Not a Pleural-Fluid Treatment

Sweating does not remove malignant pleural fluid from around the lung.

Strong steam exposure may worsen dehydration, dizziness, hypotension and fatigue. It may be particularly unsuitable in hot climates, in a patient with low intake or when renal function is impaired.

Gentle local comfort measures may be considered only when they are safe and do not involve the catheter site, recent procedure wounds, inflammation, fever or skin damage.

The patient should never be advised to “sweat out” the effusion.

Medicated Smoke and Strong Aromatic Exposure Should Be Avoided

Classical respiratory chapters may contain references to Dhuma. These instructions should not be transferred directly into the care of a patient with pleural mesothelioma.

Smoke, incense, strong perfume, essential-oil vapour and other airborne irritants may provoke cough or worsen respiratory discomfort.

This is particularly important in indoor environments where incense, bakhoor, oud smoke or strong fragrances are commonly used.

A Gulf-focused patient instruction should clearly state that cultural fragrance practices may need to be modified when they aggravate cough or breathlessness.

Gulf Patient Guidance in Urdu

پلورل فلوئڈ کو صرف کَف یا جسم میں پانی کی زیادتی نہ سمجھیں۔ پھیپھڑے کے اردگرد جمع ہونے والا سرطان سے متعلق پانی بعض اوقات نکالنا ضروری ہوتا ہے۔

پیشاب آور آیورویدک ادویات، زیادہ پسینہ لانے والی بھاپ یا سخت لنگھن اس پانی کا قابلِ اعتماد متبادل نہیں ہیں۔ یہ بلڈ پریشر، گردوں اور نمکیات کی حالت کو خراب کر سکتے ہیں۔

بخور، عود، لوبان، اگر بتی، سگریٹ کا دھواں اور تیز خوشبو سانس اور کھانسی کو بڑھا سکتی ہے۔ اگر ان سے تکلیف بڑھے تو انہیں فوراً بند کریں۔

إرشادات للمريض في دول الخليج

لا ينبغي اعتبار السائل الجنبي مجرد زيادة في الكافا أو زيادة عامة في ماء الجسم. فقد يحتاج السائل المرتبط بالسرطان حول الرئة إلى تصريف طبي.

الأدوية الأيورفيدية المدرّة للبول، أو التعرق الشديد، أو الصيام العلاجي القاسي ليست بديلاً موثوقاً عن تصريف السائل. وقد تؤدي إلى انخفاض ضغط الدم، أو اضطراب الأملاح، أو تدهور وظائف الكلى.

قد يزيد دخان البخور والعود واللبان والسجائر والعطور القوية من السعال وضيق النفس. فإذا ازدادت الأعراض بعد التعرض لها، فينبغي إيقافها وتجنبها.

Monitoring Breathlessness and Pleural Fluid

Breathlessness Should Be Measured in a Consistent Way

The patient should be asked about breathlessness at rest, during speaking, while eating, during washing or dressing and during walking.

The same symptom scale should be used over time where possible. A numerical scale from zero to ten may be practical, provided the patient understands it.

The record should also describe whether the patient can sleep lying down, whether additional pillows are required, whether walking distance is declining and whether more caregiver help is needed.

A single oxygen-saturation reading does not fully describe breathlessness. Symptom severity, activity level and the cause must also be considered.

Response to Drainage Should Be Documented

The clinical team should know whether the patient’s breathing improves after pleural drainage, how quickly the benefit occurs and how long it lasts.

If fluid is removed but breathlessness changes very little, the clinician should investigate other causes rather than assuming that further drainage is necessarily the answer.

If relief is substantial but short-lived, a more definitive pleural strategy may be discussed.

The success of pleural management may be evaluated through symptom relief, lung expansion where relevant, time before recurrence, need for repeat procedures, hospital days and patient burden [7–10, 13].

A Pleural Catheter Record Should Show More Than Fluid Volume

Drainage amount is useful, but it should not be interpreted alone.

The record should include breathlessness before and after drainage, drainage appearance, pain, cough during drainage, catheter-site condition and any difficulty completing the procedure.

A gradual reduction in output may reflect reduced fluid production or spontaneous pleurodesis, but it may also reflect catheter blockage or loculation. Clinical interpretation is necessary.

Symptom Improvement Does Not Prove Tumour Regression

Breathlessness may improve after drainage even when the mesothelioma itself has not reduced.

The patient may also breathe more comfortably after pain control, anxiety reduction, correction of anaemia or improved bowel function.

These are valuable outcomes, but they should not be represented as evidence that an Ayurvedic formulation has shrunk the tumour.

Tumour response remains a separate outcome assessed through oncology imaging and specialist interpretation.

Realistic Outcomes of Breathlessness and Effusion Management

Medical Pleural Outcomes

Realistic pleural outcomes may include reduced breathlessness after drainage, longer time before fluid recurrence, fewer repeat procedures, successful pleurodesis, manageable home drainage and reduced hospital time.

Not every patient will achieve complete fluid control. A successful plan may instead reduce symptom burden with the least invasive and least disruptive approach.

Supportive Outcomes

Supportive outcomes may include the ability to sleep in a more comfortable position, complete a meal, walk a short distance safely, speak without severe distress, reduce panic during breathlessness and maintain bowel regularity.

These outcomes can be recorded before and after an intervention.

Outcomes That Should Not Be Promised

No responsible article should promise that Ayurveda will permanently remove malignant pleural fluid, prevent every recurrence, reopen a trapped lung, eliminate the need for pleural drainage or reverse the mesothelioma.

No patient should be encouraged to cancel a medically indicated pleural procedure because an Ayurvedic medicine is expected to “dry the fluid.”

When to Contact the Pleural or Oncology Team

The patient should contact the treating team promptly when breathlessness is increasing over hours or days, drainage no longer relieves symptoms, catheter output changes unexpectedly, the catheter stops draining, fever develops or the catheter site becomes painful, red, swollen or discharging.

New oxygen requirements, repeated night-time breathlessness, inability to complete meals and marked decline in walking ability should also be reported.

These changes may indicate pleural-fluid recurrence, catheter complications, infection, anaemia, treatment toxicity or disease progression.

When to Go Directly to Hospital

Sudden severe breathlessness, chest pain, coughing blood, fainting, confusion, bluish lips, severe drowsiness or inability to speak because of breathlessness requires emergency care.

A patient with these symptoms should not first contact an Ayurvedic clinic for a medicine adjustment.

Request a Breathlessness and Pleural-Effusion Review

A focused review may help when the patient has recurrent pleural fluid, an indwelling catheter, persistent breathlessness after drainage or uncertainty about which supportive Ayurvedic measures can be used safely.

The review should include the latest chest imaging, pleural-procedure records, drainage history, oxygen measurements where available, current oncology treatment, complete medicine list, recent blood count, kidney and liver investigations, electrolytes and a description of breathlessness at rest and during activity.

The purpose of the review is to separate problems that require pleural or emergency treatment from symptoms that may be supported through personalised Ayurvedic care.

A responsible plan should state clearly what the pleural team must manage, what supportive measures may be added, what practices must be avoided and how improvement will be measured.

Weight and Muscle Preservation: Protecting Mamsa Dhatu, Bala and Treatment Tolerance

Weight loss in pleural mesothelioma should not be treated as a cosmetic concern or accepted as an unavoidable sign of advanced disease. Loss of body weight may indicate reduced food intake, uncontrolled symptoms, systemic inflammation, treatment toxicity, dehydration or progressive cancer cachexia. More importantly, the patient may be losing skeletal muscle even when the number on the weighing scale appears unchanged.

The treatment objective is therefore not simply to “increase weight.” The more meaningful goal is to preserve or improve Mamsa, Bala, food intake, mobility, respiratory reserve and the ability to tolerate oncology treatment.

Cancer nutrition guidelines recommend that nutritional assessment begin early and continue alongside anticancer treatment. Intake, weight change, body mass index, nutrition-impact symptoms, muscle mass and physical performance should be reviewed repeatedly rather than waiting until severe wasting has developed [15, 16, 19]. (espen.org)

Why the Weighing Scale Can Give a Misleading Picture

A patient with pleural mesothelioma may lose muscle while maintaining the same body weight because pleural fluid, peripheral oedema or other fluid accumulation conceals the loss.

The opposite may also occur. A noticeable reduction in body weight after pleural drainage may represent removal of fluid rather than sudden loss of muscle or fat. For this reason, a single weight measurement cannot show whether nutritional treatment is working.

National Cancer Institute guidance recognises that fluid accumulation can mask weight loss and that changes in hydration, oedema or other fluid shifts may alter body weight without reflecting actual changes in fat or lean body mass [19]. (Cancer.gov)

Weight should therefore be interpreted with the timing and volume of pleural drainage, the presence of leg swelling, hydration status, food intake, muscle strength and functional ability.

A more useful record states whether the weight was measured before or after drainage, whether oedema was present and whether the patient’s walking, grip, appetite and meal completion were improving or declining.

Malnutrition, Sarcopenia and Cachexia Are Related but Not Identical

Malnutrition develops when the body does not receive or retain sufficient energy, protein or other nutrients. It may arise from poor appetite, nausea, vomiting, painful swallowing, early satiety, breathlessness during meals, constipation, restrictive diets or treatment-related problems.

Sarcopenia refers to clinically important loss of skeletal muscle mass and function. A person may have sarcopenia despite having a normal or high body weight. This is particularly important in patients whose weight is increased by body fat, oedema or pleural fluid.

Cancer cachexia is a more complex metabolic syndrome involving progressive loss of skeletal muscle, with or without loss of fat. It is influenced by inflammation, altered metabolism, reduced intake and the biological effects of the cancer. It may not be fully reversed by simply increasing calories.

This distinction prevents patients and caregivers from being blamed when weight continues to decline despite serious efforts to provide food. Cachexia is not always the result of inadequate family care or a lack of willpower. It requires early, multimodal management involving symptom control, nutritional support, physical rehabilitation and treatment of the underlying cancer where possible [16, 17, 19]. (PMC)

Muscle Loss May Begin Before Severe Thinness Becomes Visible

The earliest signs of muscle loss may be functional rather than visual.

The patient may take longer to rise from a chair, require the arms to push upward, walk more slowly, struggle to climb steps, need assistance during bathing or become exhausted while dressing. Carrying a plate, opening a bottle or maintaining an upright posture may become increasingly difficult.

These changes should not be dismissed as ordinary tiredness. They may represent declining skeletal-muscle strength, worsening cardiopulmonary reserve, anaemia, treatment toxicity or disease progression.

Loss of muscle is clinically important because it can be associated with poorer physical function, greater treatment toxicity, more interruptions in treatment and reduced quality of life. Nutritional assessment should therefore include muscle and functional measures rather than body weight alone [15, 19]. (espen.org)

Nutritional Screening Should Begin Before Severe Wasting Develops

The first assessment should reconstruct the patient’s weight and food-intake history.

The clinician should record the usual pre-illness weight, current weight, recent percentage of unintentional weight loss and whether the weight changed around pleural drainage or oedema. Appetite, meal size, protein intake, fluid intake and the number of meals completed each day should also be documented.

The review should identify symptoms interfering with nutrition, including breathlessness, early satiety, nausea, vomiting, constipation, diarrhoea, mouth ulcers, dry mouth, taste changes, swallowing difficulty, pain, fatigue, anxiety and depression.

Muscle function may be assessed through handgrip strength, the ability to rise from a chair, walking tolerance or another repeatable functional measure. Existing CT scans may sometimes provide additional information about skeletal-muscle mass, although interpretation should be performed by an appropriately trained clinical team.

ESPEN recommends regular evaluation of intake, weight change and body mass index beginning at cancer diagnosis. When screening is abnormal, the assessment should extend to nutrition-impact symptoms, muscle mass, physical performance and systemic inflammation [15]. (espen.org)

Percentage Weight Loss Is More Informative Than Kilograms Alone

A loss of 5 kilograms has a different clinical meaning in a person who previously weighed 50 kilograms than in someone who weighed 120 kilograms.

The percentage of weight lost and the speed of that loss are therefore important. Rapid unintentional loss over a few weeks may be more concerning than the same loss occurring gradually over a long period.

However, percentage weight loss must still be interpreted with fluid status. A person undergoing repeated pleural drainage may appear to lose several kilograms even when nutritional tissues have not changed by the same amount.

The record should therefore distinguish estimated fluid removal from probable loss of muscle and fat.

Appetite Is Only One Part of the Assessment

A patient may say that appetite is present but still fail to consume adequate nutrition.

Breathlessness may interrupt meals. Early satiety may allow only a few mouthfuls. Fatigue may make food preparation impossible. Dry mouth, painful swallowing or taste changes may reduce the range of acceptable foods. Constipation may create abdominal pressure and nausea. Financial, cultural or caregiver limitations may also restrict access to suitable meals.

The clinician should ask not only, “Are you hungry?” but also, “How much can you actually eat, how long does a meal take, and what stops you from finishing it?”

This distinction helps identify whether the main intervention should target appetite, nausea, breathlessness, meal preparation, swallowing, constipation or another limiting factor.

Breathlessness Must Be Considered During Meal Planning

Eating requires coordination between chewing, swallowing and breathing. A person with significant respiratory restriction may become exhausted while eating even when appetite is reasonable.

Large meals can increase abdominal fullness and make breathing feel more difficult. Smaller and more frequent meals may be better tolerated. Soft, moist foods may require less chewing, while energy-dense portions can provide more nutrition without requiring a large volume.

The patient may benefit from resting before meals, sitting upright while eating and avoiding unnecessary conversation during swallowing. Oxygen, when prescribed, should be used according to the treating team’s instructions.

A patient who becomes severely breathless, repeatedly coughs or chokes during meals requires medical and swallowing assessment. Food should not be forced during a severe respiratory episode.

Nutrition Targets Must Be Individualised

Energy and protein requirements should ideally be estimated by a cancer dietitian or another appropriately trained clinician.

As a general clinical starting point when individual energy expenditure has not been measured, ESPEN describes an estimated energy range of approximately 25–30 kilocalories per kilogram of body weight per day. Protein intake is generally recommended above 1 gram per kilogram per day and, where clinically appropriate and possible, up to approximately 1.5 grams per kilogram per day [15]. (espen.org)

These figures are not a universal prescription. They must be adjusted according to kidney function, liver function, body composition, age, current intake, diabetes, activity level, fluid status, treatment plan and overall goals of care.

The calculation is only useful when it can be translated into food or medical nutrition that the patient can actually tolerate.

A theoretically perfect plan that produces nausea, abdominal fullness or refusal to eat is not clinically successful.

Protein Must Be Protected When Muscle Is Declining

Protein provides amino acids required for maintenance and repair of skeletal muscle and other tissues. However, increasing protein without sufficient total energy may not achieve the intended result because the body may use some of that protein as an energy source.

The plan should therefore provide both adequate energy and appropriate protein.

Depending on cultural preference, digestion, organ function and medical advice, protein may be obtained from eggs, fish, poultry, meat, milk, yoghurt, cheese, lentils, beans, chickpeas, soy foods, nuts, seeds or suitable oral nutritional supplements.

No single food is essential for every patient. Vegetarian, halal and other culturally defined dietary patterns can be accommodated when the overall plan meets nutritional requirements.

Protein powders should not be added automatically. Some contain large amounts of sugar, potassium, phosphorus, herbs, stimulants or undisclosed proprietary ingredients. The exact product should be reviewed when the patient has kidney disease, diabetes, electrolyte disturbance or concurrent cancer treatment.

Protein Distribution May Be More Practical Than One Large Serving

A breathless patient may not be able to consume a large protein-rich meal.

Smaller servings distributed across breakfast, lunch, dinner and tolerated snacks may be easier to complete. A compact protein source may be added to food the patient already accepts rather than introducing an unfamiliar diet.

The emphasis should be on repeatable intake. A small nourishing meal consumed consistently may be more useful than a large therapeutic meal that the patient cannot finish.

The patient’s taste and dignity should also be respected. Nutrition should not become a daily conflict between the patient and family.

Food Fortification May Increase Nutrition Without Increasing Meal Volume

When the patient can eat but manages only small portions, familiar foods may sometimes be fortified to increase energy and protein density.

The exact approach depends on Satmya, medical restrictions and cultural preferences. Suitable additions may include tolerated dairy, egg, nut or seed preparations, oils, protein-rich pastes or prescribed nutritional supplements.

This does not mean that every meal should become excessively oily, sweet or heavy. Fortification should improve nutritional value without worsening nausea, reflux, diarrhoea, bloating or early satiety.

A dietitian can help determine which additions are clinically appropriate.

Oral Nutritional Supplements May Be Useful When Food Alone Is Insufficient

Oral nutritional supplements may be considered when ordinary food and dietary counselling do not provide adequate intake.

The product should be selected according to protein and energy needs, volume tolerance, flavour preference, glucose control, kidney function and electrolyte requirements. Some patients tolerate small, concentrated supplements better than large drinks.

The supplement should support meals rather than unintentionally replacing all ordinary food unless a medical nutrition plan specifically requires this.

ESPEN recommends dietary counselling, treatment of symptoms impairing intake and oral nutritional supplements when an enriched diet remains insufficient. If oral intake continues to be inadequate, enteral or parenteral nutrition may be considered in selected patients through the treating medical team [15].

Medical Nutrition Requires a Goals-of-Care Discussion

Tube feeding or intravenous nutrition is not automatically appropriate for every patient with advanced cancer.

The decision depends on whether the gastrointestinal tract can be used, the expected duration of inadequate intake, treatment goals, functional status, likely benefit, potential complications and the patient’s preferences.

Medical nutrition may be appropriate when inadequate intake is caused by a potentially manageable problem and when nutritional support is expected to contribute meaningfully to treatment, function or quality of life.

In a patient approaching the final stage of life, the goals may change from tissue rebuilding to relief of thirst, mouth care, comfort and avoidance of burdensome procedures.

These decisions should be made with the oncology, nutrition and palliative-care teams rather than through a standard Ayurvedic protocol.

Severe Undernutrition Must Not Be Corrected Too Rapidly

A person who has consumed very little food for a prolonged period may be at risk of refeeding syndrome when nutrition is increased rapidly.

Refeeding can cause dangerous shifts in phosphate, potassium, magnesium, glucose and fluid balance. It may affect cardiac, respiratory and neurological function.

In a severely depleted patient, nutritional intake may need to be increased gradually with medical monitoring. Recent electrolytes and the duration of poor intake should be reviewed before attempting rapid Brimhana.

ESPEN specifically recommends slow escalation of nutrition and additional precautions when food intake has been severely reduced for a prolonged period [15].

Ayurvedic practitioners should recognise that aggressive feeding is not automatically safer than aggressive fasting. Both can be harmful when the patient’s physiological state has not been assessed.

Restrictive “Anti-Cancer” Diets Can Accelerate Depletion

Patients are frequently advised to eliminate sugar, grains, dairy, fruit, pulses, oils or other major food groups in an attempt to starve the cancer.

There is no diet proven to reproducibly cure cancer or prevent recurrence. In patients who are already malnourished or at risk of malnutrition, unnecessary dietary restriction can reduce energy, protein and micronutrient intake and accelerate weight and muscle loss.

ESPEN recommends against dietary approaches that restrict energy intake in patients who are malnourished or at risk of malnutrition [15].

The presence of cancer does not mean that every carbohydrate must be removed. The priority is a nutritionally adequate and metabolically appropriate diet that the patient can tolerate.

Diabetes and steroid-related hyperglycaemia still require management, but glucose control should be achieved through individualised planning rather than starvation.

Fasting Should Not Be Romanticised During Active Wasting

Prolonged fasting, juice-only plans and repeated detoxification days may worsen negative energy balance in a patient who is already losing weight or muscle.

Fasting around chemotherapy or immunotherapy should not be undertaken without discussion with the oncology and nutrition teams. Current evidence does not establish prolonged fasting as a routine treatment for pleural mesothelioma, while inadequate intake creates a clear risk in a patient with cachexia.

Religious fasting should be approached respectfully and individually. The medical team should understand the planned fasting duration, treatment schedule, hydration status, diabetes, kidney function, body weight and current Bala.

Where fasting poses a significant medical risk, the patient should receive clear clinical advice and may also wish to discuss permitted exemptions or alternatives with a trusted religious authority.

Symptoms Preventing Nutrition Must Be Treated Directly

Nutrition cannot improve when the cause of poor intake remains untreated.

Nausea requires review of antiemetic treatment and possible medication toxicity. Constipation may require a preventive bowel plan, especially when opioids are used. Mouth ulcers, oral infection, dry mouth and swallowing problems require appropriate examination. Pain and breathlessness should be controlled sufficiently for the patient to eat.

Early satiety may improve when constipation and abdominal distension are addressed. Depression, anxiety and sleep disturbance may also reduce interest in food and require supportive treatment.

Ayurvedic care may assist with selected symptoms, but serious or persistent symptoms should not be attributed only to Agni or Ama. Their biomedical cause must be investigated.

Appetite Stimulants Do Not Necessarily Restore Muscle

Some prescribed medicines may temporarily improve appetite or body weight in selected patients, but an increase on the scale does not always represent an increase in muscle.

For example, appetite-stimulating treatment may increase fat or fluid without restoring lean body mass. Some agents also carry risks such as thromboembolism, infection, insulin resistance or further muscle wasting.

The decision to use an appetite stimulant belongs to the oncology or palliative-care team and should be linked to a clearly defined objective [15, 17].

Ayurvedic treatment should similarly not be judged only by whether appetite increases for a few days. The more important question is whether intake, strength and function improve without unacceptable adverse effects.

Muscle Preservation Requires Movement as Well as Nutrition

Food provides the substrate for muscle maintenance, but muscle also requires an appropriate physical stimulus.

Complete inactivity accelerates deconditioning. At the same time, exercise that exceeds the patient’s respiratory or cardiovascular reserve may cause harm.

The appropriate activity may range from assisted movement in bed to short walks, repeated sit-to-stand practice or individualised resistance exercise. The starting point depends on breathlessness, oxygen requirement, pain, balance, anaemia, bone involvement, catheter placement and overall functional status.

Cancer nutrition and exercise guidelines support maintenance of physical activity and individualised resistance exercise to preserve muscle mass, strength and function where clinically safe [15, 18].

Exercise Must Be Prescribed According to the Patient’s Present Capacity

A patient who is breathless at rest should not be given the same exercise programme as a patient who can walk independently.

The physiotherapist or rehabilitation team should identify a safe starting level. For a severely weak patient, success may mean sitting unsupported for a short period, transferring safely from bed to chair or standing with assistance.

For a more stable patient, the plan may gradually include walking and light resistance activity. The patient should be able to recover without prolonged respiratory distress.

Exercise should stop if it causes chest pain, dizziness, faintness, new palpitations, coughing blood, severe breathlessness or a marked fall in oxygen saturation according to the medical team’s parameters.

The goal is not exhaustion. It is to provide enough stimulus to slow disuse-related muscle loss while preserving safety.

The Classical Ayurvedic Foundation of Brimhana

Ayurvedic management of weight and muscle depletion should be based on Brimhana, Balya, Agni, Satmya and the patient’s present Bala.

Brimhana does not mean giving large quantities of milk, ghee, sugar or heavy food to every patient. It refers to a broader treatment direction intended to support nourishment, tissue recovery and strength.

The classical decision must still be translated into the patient’s modern clinical context. Kidney function, liver function, diabetes, swallowing capacity, oncology treatment, pleural fluid and cachexia all influence what can be used safely.

Classical Indications for Brimhana

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Sūtra Sthāna, Chapter 22, Laṅghanabṛṃhaṇīya Adhyāya, verse 26. Article reference [31]. (Charak Samhita)

Sanskrit

क्षीणाः क्षताः कृशा वृद्धा दुर्बला नित्यमध्वगाः ।
स्त्रीमद्यनित्या ग्रीष्मे च बृंहणीया नराः स्मृताः ॥२६॥

Roman Transliteration

kṣīṇāḥ kṣatāḥ kṛśā vṛddhā durbalā nityamadhvagāḥ |
strīmadyanityā grīṣme ca bṛṃhaṇīyā narāḥ smṛtāḥ || 26 ||

English Translation

People who are depleted, injured, emaciated, elderly, weak or exhausted by continual exertion are considered suitable for nourishing treatment. The verse also includes those depleted by habitual excesses and people requiring additional nourishment during the summer season.

Urdu Translation

جو افراد جسمانی طور پر کم ہو چکے ہوں، زخمی ہوں، بہت دبلے ہوں، عمر رسیدہ ہوں، کمزور ہوں یا مسلسل مشقت اور سفر سے تھک چکے ہوں، ان کے لیے برِمہن یعنی غذائیت اور قوت بڑھانے والا علاج مناسب سمجھا گیا ہے۔ اس شلوک میں حد سے زیادہ جسمانی یا دیگر عادات سے کمزور ہونے والے افراد اور گرمی کے موسم میں اضافی تغذیہ کی ضرورت رکھنے والوں کا بھی ذکر ہے۔

Arabic Translation

يُعَدّ العلاج المُغذّي، أو البرِمهانا، مناسباً لمن يعانون من الاستنزاف، أو الإصابة، أو الهزال، أو كِبَر السن، أو الضعف، أو الإرهاق الناتج عن الجهد والسفر المتواصل. كما يذكر النص من أُنهكوا بسبب الإفراط في بعض العادات، ومن يحتاجون إلى دعم غذائي إضافي في فصل الصيف.

The transferable principle is that Kshina, Krisha and Durbala states require a nourishing direction.

In pleural mesothelioma, these states may correspond clinically to involuntary weight loss, muscle depletion, poor intake, low physical function and weakness following prolonged illness or oncology treatment.

The verse does not establish a treatment for mesothelioma. It supports selecting Brimhana when depletion is dominant rather than continuing indiscriminate Langhana or Rukshana.

Nourishment for a Disease-Depleted Patient Should Remain Digestible

Classical Source

Charaka Saṃhitā of Agniveśa, Sūtra Sthāna, Chapter 22, Laṅghanabṛṃhaṇīya Adhyāya, verse 27. Article reference [31]. (Charak Samhita)

Sanskrit

शोषार्शोग्रहणीदोषैर्व्याधिभिः कर्शिताश्च ये ।
तेषां क्रव्यादमांसानां बृंहणा लघवो रसाः ॥२७॥

Roman Transliteration

śoṣārśograhaṇīdoṣair vyādhibhiḥ karśitāś ca ye |
teṣāṃ kravyādamāṃsānāṃ bṛṃhaṇā laghavo rasāḥ || 27 ||

English Translation

For people emaciated by wasting disorders and other illnesses, the text describes light and digestible nourishing broths prepared from specified meats.

Urdu Translation

جو افراد شوش، ارش، گرہنی کی خرابیوں یا دوسری بیماریوں سے بہت کمزور اور دبلے ہو گئے ہوں، ان کے لیے کلاسیکی متن مخصوص گوشت سے تیار کیے گئے ہلکے اور آسانی سے ہضم ہونے والے غذائیت بخش شوربوں کا ذکر کرتا ہے۔

Arabic Translation

يذكر النص للأشخاص الذين أصابهم الهزال بسبب أمراض الاستنزاف أو اضطرابات الهضم أو غيرها من الأمراض، مرقاتٍ مغذية خفيفة وسهلة الهضم تُحضَّر تاريخياً من أنواع محددة من اللحوم.

The clinically important phrase is Laghavo Rasah: nourishment may need to be light and digestible.

This principle is highly relevant to a breathless patient with poor Agni and early satiety. Brimhana should not overwhelm digestion.

The historical food example is not a compulsory prescription. Modern nourishment may be vegetarian or non-vegetarian, and any meat used should comply with the patient’s cultural, ethical and religious requirements. For Gulf patients, halal requirements must be respected.

The underlying principle can be fulfilled through any medically appropriate, protein- and energy-containing preparation that is digestible, culturally acceptable and compatible with the patient’s organ function.

The Classical Signs of Proper Brimhana

Classical Source

Charaka Saṃhitā of Agniveśa, Sūtra Sthāna, Chapter 22, Laṅghanabṛṃhaṇīya Adhyāya, verse 38. Article reference [31]. (Charak Samhita)

Sanskrit

बलं पुष्ट्युपलम्भश्च कार्श्यदोषविवर्जनम् ।
लक्षणं बृंहिते स्थौल्यमति चात्यर्थबृंहिते ॥३८॥

Roman Transliteration

balaṃ puṣṭyupalambhaś ca kārśyadoṣavivarjanam |
lakṣaṇaṃ bṛṃhite sthaulyam ati cātyarthabṛṃhite || 38 ||

English Translation

The signs of appropriate Brimhana are an improvement in strength and nourishment and relief from the adverse effects of emaciation. Excessive Brimhana may produce excessive bodily accumulation.

Urdu Translation

مناسب برِمہن کی علامات یہ ہیں کہ مریض کی قوت اور غذائیت میں اضافہ ہو اور لاغری سے پیدا ہونے والی تکالیف کم ہوں۔ حد سے زیادہ برِمہن جسم میں غیر ضروری زیادتی یا موٹاپا پیدا کر سکتا ہے۔

Arabic Translation

تتمثل علامات البرِمهانا المناسب في تحسن القوة والتغذية وتراجع المشكلات الناتجة عن الهزال. أما الإفراط في البرِمهانا فقد يؤدي إلى تراكم جسدي زائد أو سمنة مفرطة.

This verse provides a useful outcome framework. Appropriate Brimhana should improve Bala and Pushti and reduce the consequences of Karshya.

It should not be judged merely by a higher number on the scale. In pleural mesothelioma, an increase caused by pleural fluid or oedema does not represent successful Brimhana.

The modern clinical equivalents of improved Bala and Pushti may include greater meal completion, improved grip strength, safer walking, better ability to rise from a chair, less dependence in daily activities, improved treatment tolerance and stabilisation of muscle loss.

Brimhana Does Not Mean Overfeeding

The same classical verse warns against excessive Brimhana.

A patient with poor Agni, early satiety or severe nausea may become more uncomfortable when forced to consume heavy food. Excessive ghee, sugar, milk or large meal volumes may worsen reflux, bloating, diarrhoea, glucose control or food aversion.

Brimhana must be Matra- and Kala-sensitive. The appropriate quantity depends on digestive tolerance, treatment timing, bowel function and respiratory effort.

A small, digestible and nutritionally concentrated meal may represent better Brimhana than a large meal that remains unfinished.

Brimhana Must Be Adapted When Pleural Fluid and Depletion Coexist

A patient may have Bahu Kleda or fluid accumulation while also having Mamsa Kshaya and low Bala.

This is not an uncommon contradiction in advanced cancer. The patient may have pleural effusion, leg oedema or low albumin while losing skeletal muscle rapidly.

The correct response is not to choose between “drying everything” and “nourishing everything.” Pleural fluid must be managed medically, while nutritional tissues are protected through carefully selected intake and rehabilitation.

Strong Rukshana may worsen dehydration and muscle loss. Excessively heavy Brimhana may worsen digestive intolerance without improving muscle.

The plan must separate fluid management from tissue nourishment.

Agni Determines How Brimhana Is Delivered

Brimhana requires the ability to receive and process nourishment.

When Agni is markedly impaired, the first step may be to treat nausea, constipation, oral problems, early satiety or medication-related digestive disturbance. Gentle support may be required before nutritional quantity can increase.

The treatment should not rely on strong Deepana or Pachana that further dries or irritates a depleted patient. The purpose is to improve tolerance, not to produce an artificially intense appetite.

The clinician should observe whether the selected food or formulation improves meal intake without producing burning, diarrhoea, abdominal pain, excessive thirst or sleep disturbance.

Mamsa Dhatu Preservation Should Be Measured Functionally

Mamsa Dhatu cannot be evaluated only through appearance.

The patient’s ability to stand, walk, maintain posture, grip an object and perform daily activities provides practical information about muscle function.

The clinician may combine Ayurvedic assessment of Mamsa Sara and Bala with modern measurements such as handgrip strength, chair-rise ability, walking distance and imaging-based body-composition assessment where available.

This creates a more objective bridge between classical and modern clinical monitoring.

Balya Treatment Must Produce a Defined Functional Benefit

The word Balya should not be used as an unmeasured promotional claim.

Before starting treatment, the clinician should state what improvement is being sought. The target may be completing a meal, walking to the bathroom, standing without assistance, sleeping more effectively or attending scheduled oncology treatment.

At follow-up, the same function should be reassessed.

If a product is described as Balya but the patient continues to lose strength, intake or mobility, the treatment should be reviewed rather than continued automatically.

Rasayana Is Not a Substitute for Adequate Energy and Protein

A Rasayana formulation cannot compensate for a severe deficit in food intake.

When the patient is consuming very little protein and energy, the priority is to identify why intake is inadequate and correct it where possible. Rasayana may be considered only as an additional supportive measure after nutrition, hydration, bowel function and medical safety have been assessed.

The term Rasayana should not be used to imply that a formulation will rebuild muscle independently of adequate nourishment and appropriate movement.

Every herb should also be reviewed for possible interactions with oncology medicines and for renal, hepatic or bleeding risks.

Ghee, Milk and Sugar Are Not Universal Brimhana Medicines

Classical Brimhana descriptions include substances such as milk, ghee and sweet foods. These examples must not be converted into a fixed cancer diet.

Milk may be unsuitable in lactose intolerance or when it worsens nausea, mucus sensation or diarrhoea. Ghee may increase energy density but may aggravate early satiety or digestive discomfort when used excessively. Sugar-heavy preparations may be unsuitable in diabetes, steroid-induced hyperglycaemia or poor glucose control.

The treatment principle is nourishment according to Satmya, Agni, Bala and Avastha—not compulsory consumption of a particular ingredient.

Gulf Climate Requires Additional Attention to Hydration and Food Tolerance

High outdoor temperatures and dry indoor air-conditioning may increase thirst, mouth dryness and dehydration risk. However, fluid intake cannot be standardised because some patients may also have kidney disease, heart disease, oedema or a medically prescribed fluid plan.

The patient should not reduce drinking simply because pleural fluid is present. Pleural effusion is not corrected by intentionally dehydrating the body.

Hydration should be individualised according to blood pressure, kidney function, electrolytes, urine output, pleural management and medical advice.

Food plans should also accommodate halal requirements, Ramadan practices, local foods, family meal patterns and the availability of suitable nutritional supplements.

اردو میں مریض اور خاندان کے لیے اہم پیغام

صرف وزن بڑھانا علاج کا مقصد نہیں ہے۔ پھیپھڑے کے اردگرد پانی یا جسم کی سوجن کی وجہ سے وزن بڑھ سکتا ہے، جبکہ اندر سے پٹھے مسلسل کم ہو رہے ہوں۔

مناسب برِمہن کا مطلب یہ ہے کہ مریض کی قوت، غذائیت، چلنے پھرنے کی صلاحیت اور روزمرہ کام کرنے کی طاقت بہتر ہو۔ صرف گھی، دودھ، چینی یا بھاری غذا دینا ہر مریض کے لیے مناسب نہیں۔

اگر مریض کو سانس پھولنے، متلی، قبض یا جلد پیٹ بھرنے کی وجہ سے کھانا مشکل ہو تو پہلے ان مسائل کا علاج کرنا ضروری ہے۔ چھوٹی مقدار میں بار بار، ہضم ہونے والی اور پروٹین و توانائی سے بھرپور غذا زیادہ قابلِ برداشت ہو سکتی ہے۔

پلورل فلوئڈ کم کرنے کے لیے مریض کو جان بوجھ کر پیاسا رکھنا، سخت روزہ کروانا یا جسم کو خشک کرنے والی دوائیں دینا خطرناک ہو سکتا ہے۔

رسالة مهمة للمريض والأسرة باللغة العربية

لا يكون الهدف مجرد زيادة الرقم على الميزان. فقد يزداد الوزن بسبب السائل حول الرئة أو تورم الجسم، بينما تستمر خسارة العضلات في الداخل.

البرِمهانا المناسب يعني تحسن القوة والتغذية والقدرة على الحركة والقيام بالأنشطة اليومية. ولا يعني إعطاء كميات كبيرة من السمن أو الحليب أو السكر أو الأطعمة الثقيلة لكل مريض.

إذا كان ضيق النفس، أو الغثيان، أو الإمساك، أو الشبع المبكر يمنع المريض من تناول الطعام، فينبغي علاج هذه المشكلات أولاً. وقد تكون الوجبات الصغيرة المتكررة، سهلة الهضم والغنية بالطاقة والبروتين، أكثر قابلية للتحمل.

لا ينبغي تعمّد تعطيش المريض، أو فرض صيام قاسٍ، أو إعطاء علاجات شديدة التجفيف بهدف تقليل السائل الجنبي، لأن ذلك قد يسبب الجفاف والضعف واضطراب وظائف الكلى والأملاح.

Monitoring Weight, Muscle and Nutritional Recovery

Weight Should Be Recorded in Context

Weight should ideally be measured using the same scale, under similar conditions and at a consistent time of day.

The record should note recent pleural drainage, drainage volume where known, oedema and major changes in hydration.

A trend over time is more useful than one isolated measurement.

Food Intake Should Be Quantified

The clinician should document how much of each meal is being consumed, how many meals are completed and whether oral nutritional supplements are being tolerated.

Statements such as “the patient is eating better” are not sufficiently precise unless they are linked to measurable intake.

A simple caregiver record may indicate whether the patient completed approximately one quarter, one half, three quarters or all of a meal. The purpose is not to create anxiety but to detect deterioration early.

Muscle and Function Should Be Followed Repeatedly

The same functional measures should be reassessed at follow-up.

These may include handgrip strength, chair-rise ability, walking distance, dependence during bathing or dressing and the ability to perform transfers safely.

Where appropriate, the treating team may also review muscle measurements available from CT imaging or another validated body-composition method.

Laboratory Tests Support but Do Not Replace Clinical Assessment

Complete blood count, kidney function, liver function and electrolytes may identify factors contributing to fatigue, poor intake or unsafe nutrition strategies.

Albumin may contribute to the broader clinical picture but should not be treated as an isolated nutrition score. It can be influenced by inflammation, fluid distribution and organ function.

Laboratory data should therefore be interpreted alongside intake, weight history, muscle function and clinical symptoms.

The Patient’s Experience Must Also Be Measured

Nutritional success includes more than laboratory values.

The patient should be asked whether eating has become easier, whether breathlessness interrupts fewer meals, whether nausea or constipation has improved and whether the person feels less exhausted during daily activity.

These patient-reported outcomes may reveal a meaningful benefit before large changes in body composition become visible.

Realistic Outcomes of a Weight and Muscle Preservation Plan

A realistic early outcome may be stopping rapid weight loss rather than producing immediate weight gain.

Another meaningful outcome may be improved food intake, more consistent protein consumption, reduced constipation, better meal tolerance or preservation of walking ability.

Over a longer period, the plan may aim for improved grip strength, safer transfers, reduced dependence on caregivers, maintenance of muscle on imaging and greater ability to tolerate oncology treatment.

Not every patient will regain all previously lost muscle. Advanced cachexia may continue despite appropriate nutritional care.

The value of the plan lies in addressing reversible problems, slowing avoidable decline and preserving the greatest achievable level of function and comfort.

Outcomes That Should Not Be Promised

No responsible article should promise that an Ayurvedic diet or Brimhana formulation will reverse all cancer cachexia, rebuild muscle regardless of disease activity or guarantee completion of chemotherapy or immunotherapy.

An increase in weight should not automatically be advertised as successful treatment because it may represent pleural fluid, oedema, fat or water rather than muscle.

Similarly, improved appetite does not prove that the tumour has reduced.

Disease response must remain separate from nutritional and functional recovery.

Warning Signs Requiring Prompt Medical Review

The oncology or nutrition team should be contacted promptly when the patient is unable to maintain food or fluids, repeatedly vomits, develops severe diarrhoea, has painful or difficult swallowing, coughs or chokes during meals, produces very little urine or becomes increasingly weak or confused.

Rapid weight gain associated with swelling or worsening breathlessness may represent fluid accumulation rather than nutritional improvement.

Severe abdominal pain, persistent vomiting, absence of stool and flatus, gastrointestinal bleeding or inability to swallow requires urgent medical assessment.

Ayurvedic medicines should not be increased to manage these warning signs without identifying their cause.

Request a Weight, Muscle and Bala Preservation Review

A focused review is appropriate when the patient is losing weight, becoming physically weaker, eating less, developing oedema or showing increasing dependence in daily activities.

The review should include the recent weight history, timing of pleural drainage, food-intake record, current symptoms, complete medicine and supplement list, oncology treatment schedule, blood counts, kidney and liver investigations, electrolytes and available scan reports.

The purpose is to distinguish fluid-related weight change from true nutritional improvement, identify the symptoms limiting intake, determine whether medical nutrition or dietitian referral is required and establish a safe Brimhana and Balya strategy.

The final plan should explain what the patient needs to eat, what symptoms must be treated, how movement will be preserved, which Ayurvedic measures may be considered and how weight, muscle, Bala and treatment tolerance will be monitored.

Personalised Medicine Strategy: Two Clinical Lenses, One Coordinated Treatment Plan

Personalised medicine does not mean prescribing more medicines. It means selecting fewer, better-justified interventions for the correct patient, at the correct stage, in the correct dose and with a clearly defined monitoring plan.

In pleural mesothelioma, no treatment should be personalised from the diagnosis alone. The same histopathological diagnosis may occur in patients with very different tumour subtypes, disease extent, pleural-fluid patterns, organ function, treatment exposure, nutritional reserve, functional capacity and personal goals.

Modern oncology individualises treatment according to factors such as histological subtype, stage, performance status, previous treatment, organ reserve and the expected balance between benefit and harm. Stage, performance status and histology are also recognised as important prognostic factors in pleural mesothelioma [1–3]. (Cancer.gov)

Ayurveda adds a different but complementary form of individualisation through assessment of Prakriti, Vikriti, Agni, Koshta, Satmya, Sara, Samhanana, Bala, Sattva, Dosha–Dushya involvement, Srotas, Avastha and the patient’s capacity to tolerate treatment.

These two systems should not be merged carelessly. Histology is not Dosha. Tumour stage is not equivalent to Dhatu Kshaya. Pleural effusion is not simply Kapha. A laboratory abnormality should not be renamed using Ayurvedic terminology and then treated without understanding its biomedical significance.

The correct approach is to allow each clinical system to answer the questions it is qualified to answer.

Oncology determines the diagnosis, tumour-directed options, scan interpretation and management of medical complications. Ayurveda may help individualise supportive treatment according to digestion, nourishment, bowel function, sleep, symptom pattern, strength and treatment tolerance.

The final result should be one coordinated plan rather than two disconnected prescriptions.

Personalisation Begins With Diagnostic Certainty

Before an Ayurvedic treatment plan is created, the diagnosis should be supported by histopathology and appropriate immunohistochemistry.

The review should identify whether the tumour is epithelioid, biphasic or sarcomatoid, because histology may influence prognosis, oncology treatment selection and interpretation of expected outcomes. The latest CT, PET-CT or other relevant imaging should be reviewed together with previous scans so that the direction of disease can be understood.

The plan should document whether the disease is newly diagnosed, stable, responding, progressing or being evaluated after a treatment break. It should also record why surgery was considered unsuitable. Technical unresectability, poor cardiopulmonary reserve, severe frailty and an unfavourable risk–benefit assessment represent different clinical situations and should not be grouped together under the single word “inoperable.”

When pathology is uncertain, imaging is outdated or the surgical decision has not been reviewed by an experienced mesothelioma team, clarification should come before an extensive Ayurvedic prescription.

Personalised treatment cannot compensate for an uncertain diagnosis.

Precision Oncology and Ayurvedic Personalisation Are Not the Same

Precision oncology may use histopathology, molecular findings, inherited-risk assessment and other tumour characteristics to guide medical decisions. Genetic counselling or testing may also be considered by the oncology team when clinically appropriate.

Ayurvedic personalisation is based on the patient’s constitution, present imbalance, strength, digestion, tissue status, suitability, environment, season and disease stage.

The two approaches operate at different clinical levels.

A person may have the same tumour histology as another patient but differ greatly in appetite, bowel pattern, sleep, anxiety, pain, muscle loss and tolerance of systemic treatment. Ayurveda may help explain why the same supportive intervention is not suitable for both patients.

Conversely, two patients may appear similar from an Ayurvedic perspective but require different oncology treatments because their histology, disease extent or previous treatment differs.

The safest strategy preserves these distinctions while coordinating the decisions.

The Same Diagnosis Can Produce Completely Different Treatment Plans

A patient receiving first-line immunotherapy who remains mobile, eats adequately and has stable kidney and liver function may require a relatively conservative supportive plan. The principal objectives may be bowel regularity, sleep, meal tolerance and early recognition of treatment toxicity.

A second patient may have recurrent pleural effusion, an indwelling pleural catheter, breathlessness during meals and progressive muscle loss. This patient requires close coordination between pleural management, nutrition, physiotherapy and gentle Ayurvedic support.

A third patient may have completed several lines of oncology treatment and now prioritise comfort, home-based care and relief of distressing symptoms. The treatment intensity, monitoring burden and definition of success will differ substantially.

A fourth patient may be medically stable but already using numerous supplements, herbal powders and proprietary products obtained from several clinicians. For this patient, the first personalised intervention may be simplification rather than addition.

Personalised medicine begins by identifying which of these situations is actually present.

The Eight-Domain Personalised Assessment

Diagnostic and Tumour Profile

The first domain includes the pathology report, immunohistochemistry, histological subtype, stage, disease distribution and scan trend.

The review should identify the date and findings of the latest scan, whether previous images are available for comparison and whether the current report describes progression, stability or response.

The reason surgery is not being performed should be documented in the patient’s own treatment record. The patient and family should understand whether the decision is based on tumour extent, medical fitness, expected benefit or personal preference.

This domain remains under the authority of the oncology and thoracic teams.

Current Disease-Control Strategy

The second domain identifies the patient’s present oncology phase.

The patient may be awaiting treatment, receiving chemotherapy, receiving immunotherapy, recovering between cycles, undergoing radiotherapy, being observed after treatment, receiving treatment for progression or following a comfort-focused plan.

The exact generic names of oncology medicines should be recorded rather than writing only “chemotherapy” or “immunotherapy.” The dose schedule, cycle number, most recent treatment date and anticipated next treatment date are clinically relevant.

This information affects when supportive interventions may be introduced, which symptoms require urgent reporting and which laboratory abnormalities may be treatment-related.

The Ayurvedic clinician should also know whether corticosteroids, antibiotics, anticoagulants, analgesics, antiemetics, laxatives or other supportive medicines are being used.

The purpose is not to challenge the oncology prescription. It is to avoid duplication, interaction and incorrect attribution of symptoms.

Respiratory and Pleural Profile

The third domain describes the patient’s breathing and pleural-fluid pattern.

The review should establish whether breathlessness occurs only during exertion or also at rest, whether the patient can lie flat, whether supplemental oxygen has been prescribed and whether speaking or eating is interrupted by respiratory distress.

Pleural history should include previous thoracentesis, pleurodesis, catheter placement, frequency of drainage, usual drainage volume, symptom response after drainage and any catheter-related complications.

A patient whose breathing improves substantially after drainage has a different management requirement from one whose breathlessness persists despite fluid removal.

The review should also consider pain, anaemia, infection, pulmonary embolism, cardiac disease, treatment-related pneumonitis and physical deconditioning as possible contributors.

No Ayurvedic formulation should be personalised for breathlessness until serious and mechanically treatable causes have been considered.

Organ Function and Treatment-Safety Profile

The fourth domain establishes whether the patient can safely metabolise, tolerate and eliminate any proposed intervention.

Recent complete blood count, kidney function, liver function and electrolytes should be reviewed. Additional investigations may be required according to the oncology treatment, symptoms and products being considered.

Anaemia may contribute to breathlessness and fatigue. Thrombocytopenia may increase bleeding risk. Neutropenia may increase infection risk. Renal impairment may alter the safety of medicines or supplements that are ordinarily eliminated through the kidneys. Liver abnormalities may reflect disease, infection, prescribed treatment or supplement-related injury.

The presence of normal laboratory values on one occasion does not guarantee continued safety. Trends are often more informative than isolated results.

The review should also record allergies, previous adverse drug reactions, diabetes, hypertension, cardiac disease, kidney disease, liver disease, autoimmune illness and bleeding or clotting history.

Ayurvedic treatment must be adjusted to the patient who actually exists, not to an idealised patient assumed to have normal organ function.

Medicine, Herb and Supplement Interaction Profile

The fifth domain creates one complete treatment list.

This should include prescription medicines, over-the-counter medicines, inhalers, injections, vitamins, protein supplements, herbal teas, powders, tablets, Bhasma-containing preparations, traditional remedies and products taken only occasionally.

Patients often omit supplements because they do not consider them to be medicines. However, herbs and dietary supplements may affect drug absorption, metabolism, transport, excretion, bleeding risk and other pharmacological processes. Information regarding many specific combinations remains limited, which makes disclosure and cautious monitoring essential [24]. (Cancer.gov)

The treatment list should document the exact product name, complete ingredient list, manufacturer, batch information where available, dose, frequency, start date and intended purpose.

Statements such as “one immunity powder” or “an Ayurvedic tonic” are not sufficiently precise for interaction screening.

When a product has an undisclosed proprietary composition, uncertain manufacturing quality or no reliable ingredient information, the safest personalised decision may be not to use it.

Nutrition, Muscle and Functional Profile

The sixth domain evaluates whether the patient is nutritionally stable, losing tissue or already experiencing clinically important cachexia or sarcopenia.

Current weight should be interpreted with pleural drainage, oedema and hydration. The review should include previous usual weight, recent percentage weight loss, appetite, actual meal completion, protein intake and symptoms limiting food consumption.

Functional assessment should record whether the patient can walk independently, rise from a chair, bathe, dress, use the toilet and attend appointments without assistance.

A patient who weighs the same but has lost grip strength and walking ability may be deteriorating despite apparently stable body weight.

The plan should also establish whether the patient is physically inactive because of breathlessness, pain, fear, severe fatigue or lack of rehabilitation guidance.

Nutrition, Mamsa preservation and Bala cannot be personalised by body weight alone.

Ayurvedic Clinical Profile

The seventh domain evaluates the patient through a structured Ayurvedic examination.

Prakriti describes baseline constitutional tendencies. Vikriti describes the present deviation from that baseline. Agni reflects digestive and metabolic capacity. Koshta contributes to understanding bowel behaviour and response to treatment. Satmya identifies what the patient has adapted to and can tolerate.

Sara and Samhanana contribute to assessment of tissue quality and structural strength. Sattva reflects psychological resilience and the patient’s ability to cope with symptoms and treatment decisions. Ahara Shakti and Vyayama Shakti provide information about food tolerance and functional capacity.

The clinician should then document the dominant Dosha pattern, affected Dushya, involved Srotas, type of Srotodushti, presence or absence of clinically assessed Ama, degree of Dhatu Kshaya and current Avastha.

This assessment should not become a decorative list of Ayurvedic terms. Every recorded finding should influence a treatment decision.

If Bala is low, treatment intensity should be reduced. If Agni is unstable, heavy Brimhana may need modification. If constipation and abdominal distension are worsening breathlessness, Vatanulomana may become an early objective. If progressive Mamsa Kshaya dominates, further Rukshana may be inappropriate.

Patient Goals, Family Capacity and Cultural Context

The eighth domain establishes what the patient considers most important.

One patient may prioritise continuing disease-control treatment. Another may prioritise staying out of hospital. Another may value independent walking, the ability to eat with family or enough symptom control to sleep.

Treatment decisions should also consider caregiver availability, financial limitations, travel distance, access to laboratory monitoring, language, health literacy, religious practices and the patient’s willingness to take medicines.

A theoretically excellent plan is not personalised when the patient cannot understand, obtain, tolerate or monitor it.

For Gulf patients, the review should consider high environmental temperature, air-conditioned indoor environments, hydration, Ramadan fasting, halal requirements, gelatin or alcohol-containing excipients, use of bukhoor or strong fragrances, travel between countries and continuity of oncology care.

These factors should be discussed respectfully rather than treated as peripheral details.

The Classical Foundation of Patient-by-Patient Treatment

The Best Physician Examines Each Patient Individually

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Sūtra Sthāna, Chapter 1, Dīrghañjīvitīya Adhyāya, verse 123. Article reference [38].

Sanskrit

योगमासां तु यो विद्याद्देशकालोपपादितम् ।
पुरुषं पुरुषं वीक्ष्य स ज्ञेयो भिषगुत्तमः ॥१२३॥

Roman Transliteration

yogam āsāṃ tu yo vidyād deśakālopapāditam |
puruṣaṃ puruṣaṃ vīkṣya sa jñeyo bhiṣaguttamaḥ || 123 ||

English Translation

The best physician is one who understands how medicines should be used according to place and time and administers them only after examining each patient individually.

Urdu Translation

بہترین طبیب وہ ہے جو دوا کے استعمال کو مقام، ماحول اور وقت کے مطابق سمجھتا ہو اور ہر مریض کا انفرادی معائنہ کرنے کے بعد ہی علاج تجویز کرے۔

Arabic Translation

أفضل الأطباء هو من يعرف كيفية استخدام الدواء وفق المكان والزمان، ولا يصفه إلا بعد فحص كل مريض بصورة فردية.

The verse places Desha, Kala and individual examination at the centre of treatment selection. It does not support a single formulation being prescribed to every person with the same diagnosis.

For a Gulf patient, Desha may include climate, heat exposure, indoor air-conditioning, local dietary habits and access to medical care. Kala includes season, time of day, stage of disease and position within the oncology-treatment cycle.

Puruṣaṃ Puruṣaṃ Vīkṣya requires the physician to examine each patient separately. A diagnosis may be shared, but the prescription should not be automatically shared. (Charak Samhita)

Personalisation Is More Than Choosing a Prakriti-Based Formula

Prakriti is relevant, but it is only one part of the assessment.

A Vata-predominant person may currently have significant Kapha-related obstruction. A Kapha-predominant person may become severely dry, depleted and Vata-aggravated after prolonged illness and treatment.

The present Avastha may therefore be more important than constitution when immediate treatment is being selected.

Similarly, a patient who previously tolerated strong medicines may no longer tolerate them after weight loss, renal impairment or repeated oncology treatment.

Personalisation requires repeated reassessment. It is not a permanent label assigned during the first consultation.

Evidence Should Come From More Than One Source

Ayurveda itself cautions against reaching a conclusion from only one form of knowledge.

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 4, Trividha Roga Viśeṣa Vijñānīya Vimāna, verse 3. Article reference [40].

Sanskrit

त्रिविधं खलु रोगविशेषविज्ञानं भवति; तद्यथा—आप्तोपदेशः, प्रत्यक्षम्, अनुमानं चेति ॥३॥

Roman Transliteration

trividhaṃ khalu rogaviśeṣavijñānaṃ bhavati; tadyathā—āptopadeśaḥ, pratyakṣam, anumānaṃ ceti || 3 ||

English Translation

Specific knowledge of a disease is obtained through three means: authoritative instruction, direct observation and inference.

Urdu Translation

کسی بیماری کی مخصوص اور درست سمجھ تین ذرائع سے حاصل ہوتی ہے: معتبر علمی ہدایت، براہِ راست مشاہدہ اور منطقی استنباط۔

Arabic Translation

تُكتسب المعرفة الدقيقة بخصائص المرض من ثلاثة مصادر: التعليم الموثوق، والملاحظة المباشرة، والاستدلال المنطقي.

In a modern integrative setting, Āptopadeśa includes reliable clinical guidelines, pathology principles, pharmacology, classical texts and appropriately qualified expert opinion.

Pratyaksha includes the patient’s symptoms, physical findings, food intake, mobility, weight, catheter status and observable treatment effects.

Anumana includes clinically reasoned interpretation of scan trends, laboratory changes, possible interactions and the relationship between an intervention and a subsequent outcome.

The chapter further explains that complete knowledge should not be claimed from only one component of examination. The sources should be considered together before treatment decisions are made. (Charak Samhita)

This principle prevents several common errors.

A formulation should not be declared effective merely because it is praised in a traditional source. A scan response should not be attributed to Ayurveda merely because Ayurvedic treatment was being used at the same time. A new symptom should not be labelled a healing reaction without investigating medication toxicity, infection or disease progression.

Personalised medicine requires evidence to be assembled, compared and interpreted—not selected according to preference.

Tenfold Examination Must Come Before Treatment Action

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 8, Rogabhiṣagjitīya Vimāna Adhyāya, passage 79. Article reference [32].

Sanskrit

एतद्दशविधमग्रे परीक्ष्यं, ततोऽनन्तरं कार्यार्था प्रवृत्तिरिष्टा ।
तस्माद्भिषक् कार्यं चिकीर्षुः प्राक् कार्यसमारम्भात् परीक्षया केवलं परीक्ष्यं परीक्ष्य कर्म समारभेत कर्तुम् ॥७९॥

Roman Transliteration

etad daśavidham agre parīkṣyaṃ, tato’nantaraṃ kāryārthā pravṛttir iṣṭā |
tasmād bhiṣak kāryaṃ cikīrṣuḥ prāk kāryasamārambhāt parīkṣayā kevalaṃ parīkṣyaṃ parīkṣya karma samārabheta kartum || 79 ||

English Translation

The ten relevant factors should first be examined, and only afterward should action be undertaken. Therefore, a physician who intends to perform treatment should begin only after properly examining everything that requires examination.

Urdu Translation

علاج شروع کرنے سے پہلے دس متعلقہ عوامل کا مکمل معائنہ کرنا چاہیے۔ اس کے بعد ہی طبیب کو علاج کی کارروائی شروع کرنی چاہیے۔

Arabic Translation

ينبغي فحص العوامل العشرة ذات الصلة أولاً، ولا يبدأ التدخل العلاجي إلا بعد استكمال هذا الفحص بصورة صحيحة.

The same chapter later describes examination of the patient through Prakriti, Vikriti, Sara, Samhanana, Pramana, Satmya, Sattva, Ahara Shakti, Vyayama Shakti and Vaya for assessment of Bala [32]. (Charak Samhita)

In pleural mesothelioma, this examination should be connected to modern clinical data.

Prakriti and Vikriti should be considered alongside the patient’s present treatment phase. Sara and Samhanana should be considered alongside muscle status and functional reserve. Ahara Shakti should be considered alongside actual meal intake, weight change and nutrition-impact symptoms. Vyayama Shakti should be considered alongside breathlessness, oxygen requirements and mobility.

These are complementary assessments, not one-to-one substitutions.

The modern laboratory report does not replace examination of the patient. The Ayurvedic examination does not replace pathology, imaging or laboratory investigations.

Personalised Care Requires a Coordinated Healthcare Team

Complex mesothelioma care cannot be delivered safely by one practitioner working in isolation.

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Sūtra Sthāna, Chapter 9, Khuḍḍākacatuṣpāda Adhyāya, verse 3. Article reference [39].

Sanskrit

भिषग्द्रव्याण्युपस्थाता रोगी पादचतुष्टयम् ।
गुणवत् कारणं ज्ञेयं विकारव्युपशान्तये ॥३॥

Roman Transliteration

bhiṣagdravyāṇyupasthātā rogī pādacatuṣṭayam |
guṇavat kāraṇaṃ jñeyaṃ vikāravyupaśāntaye || 3 ||

English Translation

The physician, medicine, attendant and patient constitute the four components of treatment. When each possesses the required qualities, they contribute to successful management of disease.

Urdu Translation

طبیب، دوا، نگہداشت کرنے والا فرد اور مریض علاج کے چار بنیادی اجزا ہیں۔ جب ہر جز اپنی مطلوبہ خوبیوں کے ساتھ کام کرے تو بیماری کے مؤثر انتظام میں مدد ملتی ہے۔

Arabic Translation

يشكّل الطبيب والدواء ومقدّم الرعاية والمريض الأركان الأربعة للعلاج. وعندما تتوافر الصفات المطلوبة في كل ركن، فإنها تسهم في حسن تدبير المرض.

The classical Chatushpada model provides a useful foundation for coordinated care. In modern mesothelioma practice, the treatment team may include the oncologist, thoracic physician, pleural specialist, radiologist, pathologist, palliative-care clinician, dietitian, physiotherapist, nurse, caregiver and Ayurvedic physician.

This is an expanded modern application rather than a claim that the classical verse specifically describes present-day oncology.

The principal message is that good treatment depends on more than the medicine itself. The quality of clinical judgment, nursing and caregiver support, patient communication and monitoring all affect safety. (Charak Samhita)

A proprietary formulation cannot compensate for an absent pleural plan, delayed emergency care, poor nutrition or lack of treatment monitoring.

One Patient Should Have One Coordinated Treatment Record

Separate prescriptions from several clinicians can create duplication and interaction risk.

The patient should maintain one current record containing the diagnosis, oncology treatment, pleural procedures, allergies, recent laboratory results, all conventional medicines, all Ayurvedic formulations, supplements and emergency contact instructions.

Every clinician involved should be encouraged to review the same list.

The record should also state which clinician is responsible for each part of treatment. The oncologist directs tumour treatment. The pleural team directs drainage and catheter care. The palliative-care team may manage complex pain or breathlessness. The dietitian directs medical nutrition. The Ayurvedic clinician directs only those complementary interventions that fall within the agreed supportive plan.

Clear responsibility prevents the patient from receiving conflicting instructions.

The Five-Part Personalised Treatment Output

A useful personalised consultation should produce five explicit decisions: what must continue, what may be added, what should be avoided, what must be monitored and when care must be escalated.

Continue

The written plan should identify treatments that must continue unless the responsible medical team changes them.

These may include chemotherapy, immunotherapy, prescribed corticosteroids, anticoagulation, analgesia, antiemetics, laxatives, antibiotics, oxygen, nutritional supplements, pleural drainage and physiotherapy.

An Ayurvedic consultation should not create uncertainty about medically necessary treatment.

When a patient wishes to stop or alter an oncology medicine, the concern should be communicated to the treating oncologist rather than acted upon independently.

Add

Any added Ayurvedic intervention should have one or more clearly documented supportive objectives.

The objective may be improved food tolerance, easier bowel function, better sleep, reduced treatment-associated discomfort or preservation of daily routine.

The plan should explain why the intervention was selected for this particular patient, how it will be taken, when it will begin, what improvement is expected and how safety will be assessed.

The phrase “for immunity” is not sufficiently precise.

A supportive objective should be capable of being measured. The clinician should be able to determine at follow-up whether the intervention achieved its intended purpose.

Avoid

The plan should explicitly identify treatments and practices that are unsafe or unsuitable.

These may include unlabelled products, duplicate formulations, strong purification in a depleted patient, prolonged fasting during cachexia, forceful breathing exercises during respiratory instability, heavy Swedana during dehydration or attempts to delay pleural drainage.

The avoid section should also identify food–drug, herb–drug and supplement–drug concerns specific to the patient’s medicine list.

A personalised plan becomes more valuable when it prevents unnecessary treatment rather than merely adding products.

Monitor

The plan should state which symptoms, functions, laboratory values and imaging findings will be followed.

Symptom monitoring may include breathlessness, pain, nausea, appetite, bowel function, sleep, fatigue, rash, diarrhoea and oral intake.

Functional monitoring may include walking tolerance, chair-rise ability, meal completion and caregiver dependence.

Laboratory monitoring may include complete blood count, renal function, liver function and electrolytes, with additional tests determined by the oncology team and the products used.

Patient-reported symptom tools can help capture frequency, severity and interference of treatment-related symptoms. The National Cancer Institute’s PRO-CTCAE system was developed for structured self-reporting of symptomatic adverse events and is available in numerous validated languages [22]. (healthcaredelivery.cancer.gov)

Escalate

The plan should define when the Ayurvedic intervention must stop and when the oncology team, pleural team or emergency department must be contacted.

Sudden severe breathlessness, chest pain, coughing blood, fainting, confusion and bluish lips require emergency assessment.

Fever during cancer treatment, worsening catheter-site redness, new jaundice, severe diarrhoea, persistent vomiting, markedly reduced urine, uncontrolled bleeding or rapidly increasing weakness also require prompt medical review.

Escalation criteria should be provided in language the patient and caregiver can understand.

For Gulf patients, the most important warnings should be available in English, Urdu and Arabic where required.

The Minimum Effective Complexity Principle

Personalisation should reduce unnecessary complexity.

Starting five or six formulations simultaneously may appear comprehensive, but it makes clinical interpretation difficult. If the patient develops diarrhoea, rash, sedation, liver abnormalities or worsening appetite, it may be impossible to identify which product contributed.

A safer plan introduces only interventions with a clear purpose. Changes should be made sequentially wherever the clinical situation allows.

The minimum effective complexity principle asks whether every medicine is necessary, whether two products serve the same purpose and whether an intervention can be monitored meaningfully.

A patient receiving intensive oncology treatment may benefit more from one carefully selected and monitored supportive measure than from a large package of powders, tablets, decoctions and supplements.

The value of a personalised plan should be judged by clarity, safety and measurable benefit—not by the number of products prescribed.

Personalised Dose, Timing and Duration

The same formulation may require different dosing decisions in different patients.

Dose may be influenced by age, body size, Bala, Agni, Koshta, renal and hepatic function, current medicines, previous tolerance and treatment phase.

The timing of administration may also matter. A medicine that worsens nausea should not be given immediately before a critical meal. A sedating intervention may be unsuitable before walking or bathing. A product that influences bowel function should be planned around travel, hospital appointments and catheter care.

The treatment cycle must also be considered. Symptoms immediately after chemotherapy may differ from symptoms occurring before the next cycle. A new rash or diarrhoea during immunotherapy may require urgent oncology assessment rather than routine Ayurvedic adjustment.

Duration should be defined in advance. A formulation should not continue indefinitely merely because it was initially well tolerated.

The review should determine whether the intended outcome occurred, whether the intervention remains necessary and whether laboratory monitoring supports continuation.

A Medicine Can Help or Harm According to How It Is Used

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Sūtra Sthāna, Chapter 1, Dīrghañjīvitīya Adhyāya, verses 124 and 126. Article reference [38].

Sanskrit

यथा विषं यथा शस्त्रं यथाऽग्निरशनिर्यथा ।
तथौषधमविज्ञातं विज्ञातममृतं यथा ॥१२४॥

योगादपि विषं तीक्ष्णमुत्तमं भेषजं भवेत् ।
भेषजं चापि दुर्युक्तं तीक्ष्णं सम्पद्यते विषम् ॥१२६॥

Roman Transliteration

yathā viṣaṃ yathā śastraṃ yathā’gnir aśanir yathā |
tathauṣadham avijñātaṃ vijñātam amṛtaṃ yathā || 124 ||

yogād api viṣaṃ tīkṣṇam uttamaṃ bheṣajaṃ bhavet |
bheṣajaṃ cāpi duryuktaṃ tīkṣṇaṃ sampadyate viṣam || 126 ||

English Translation

A medicine used without proper understanding may act like poison, a weapon, fire or a thunderbolt; when correctly understood, it may act like nectar.

Even a potent poison may become a useful medicine when properly prepared and administered, while a good medicine used improperly may become harmful like poison.

Urdu Translation

جو دوا صحیح علم اور سمجھ کے بغیر استعمال کی جائے وہ زہر، ہتھیار، آگ یا بجلی کی طرح نقصان پہنچا سکتی ہے، جبکہ درست علم کے ساتھ استعمال کی گئی دوا امرت جیسا فائدہ دے سکتی ہے۔

مناسب تیاری اور درست استعمال سے ایک تیز زہریلا مادہ بھی دوا بن سکتا ہے، لیکن اچھی دوا بھی غلط طریقے سے استعمال کی جائے تو زہر کی طرح نقصان دہ ہو سکتی ہے۔

Arabic Translation

قد يعمل الدواء المستخدم من دون معرفة صحيحة كالسم أو السلاح أو النار أو الصاعقة، بينما قد يكون نافعاً كالرحيق إذا استُخدم بعلم ودقة.

وقد تتحول مادة شديدة السمية إلى دواء نافع إذا أُعدّت واستُخدمت بصورة صحيحة، في حين قد يصبح الدواء الجيد مؤذياً كالسم إذا أسيء استعماله.

These verses directly challenge the assumption that a product is safe merely because it is natural, classical or traditionally used.

The identity, composition, preparation, dose, patient selection and method of administration all matter. (Charak Samhita)

In an oncology patient, safe use also requires consideration of blood counts, kidney and liver function, concurrent medicines, bleeding risk, treatment schedule and ability to report adverse effects.

The correct personalised question is not, “Is this herb generally good for cancer?” It is, “Is this exact product appropriate for this patient, for this purpose, at this time?”

Product Quality Is Part of Personalisation

A personalised prescription is incomplete when the actual product cannot be identified reliably.

The clinician should review the botanical or pharmaceutical identity, complete ingredients, dosage form, manufacturer, batch number, expiry date and available quality documentation.

Products containing metals or minerals require an additional threshold of scrutiny. Unlabelled powders and products obtained from informal sources should not be used in a medically vulnerable patient.

The route of administration also matters. A patient with swallowing difficulty may not tolerate large tablets. A patient with nausea may not tolerate a strong decoction. A patient with diabetes may need to avoid sugar-dense Avaleha preparations. A patient with lactose intolerance may not tolerate milk-based administration.

A formulation is not personalised merely because the patient’s name appears on the label.

The actual pharmaceutical form must match the patient’s clinical capacity.

Personalisation During Chemotherapy

During chemotherapy, treatment planning should account for nausea, mucositis, bowel changes, fatigue, blood-count suppression, renal function and liver function.

A symptom appearing after treatment may be an expected adverse effect, a serious complication, an infection or an unrelated condition. It should not automatically be labelled Ama accumulation or detoxification.

Any Ayurvedic intervention intended to support chemotherapy tolerance should have a defined symptom target and clear laboratory monitoring.

A formulation should be held when significant vomiting, severe diarrhoea, inability to drink, fever, bleeding, jaundice or unexpected laboratory deterioration develops.

The oncology team should be informed about all supplements being used.

Personalisation During Immunotherapy

Immunotherapy requires particular caution because immune-related adverse effects can affect the lungs, bowel, liver, endocrine organs, skin and other systems.

New cough, worsening breathlessness, persistent diarrhoea, significant rash, jaundice, unusual weakness or other new symptoms may require prompt oncology assessment.

Such symptoms should not be treated solely as Dosha aggravation.

The term “immune booster” is especially unsuitable in this context. Immune function is not a single process that should always be stimulated.

Any supportive intervention during immunotherapy should be selected conservatively, documented clearly and reviewed for interactions and diagnostic confusion.

Personalisation When Tumour-Directed Treatment Is Not Being Given

Some patients may be too frail for further systemic treatment or may decide not to pursue it.

Personalised care remains important, but the priorities may change.

The plan may focus on relief of breathlessness, pleural-fluid management, pain control, food tolerance, bowel regularity, sleep, anxiety, caregiver support and the patient’s preferred place of care.

Palliative care should be introduced early rather than reserved only for the final days of life [14].

Ayurvedic support may be considered when it reduces burden rather than adding complexity. A patient with limited energy should not be expected to follow a demanding schedule of multiple medicines, dietary restrictions and procedures.

Comfort-focused treatment is still active treatment when it is directed toward relieving suffering and preserving dignity.

Personalisation According to the Patient’s Goals

The clinician should ask the patient what improvement would make the greatest difference.

The answer may be the ability to sleep without panic, eat with the family, walk to the bathroom, attend a family event, tolerate the next oncology cycle or remain at home.

These goals should be documented before treatment begins.

The goals should also be revisited when the disease or treatment situation changes. A patient who initially prioritised maximum disease control may later prioritise comfort. Another patient may become stronger after stabilisation and wish to reconsider rehabilitation.

Personalised medicine is not a one-time prescription. It is a continuing process of aligning treatment with the patient’s changing condition and values.

Gulf-Focused Personalisation

Climate and Hydration

High environmental temperatures may increase dehydration risk, particularly when the patient has poor intake, vomiting, diarrhoea or medicines affecting fluid balance.

At the same time, pleural effusion, oedema, cardiac disease or kidney impairment may require an individualised fluid plan.

The patient should not deliberately restrict drinking simply because fluid exists around the lung. Pleural effusion is not corrected by general dehydration.

Hydration recommendations should follow kidney function, electrolytes, urine output, cardiovascular status and the advice of the treating medical team.

Ramadan and Religious Fasting

The patient should tell the oncology and Ayurvedic clinicians about any intention to fast.

The decision should consider treatment schedules, diabetes, kidney function, hydration, oral medicines, body weight, muscle loss and Bala.

A patient with severe wasting, unstable breathlessness, dehydration or active treatment complications may face significant risk from prolonged fasting.

Respectful discussion should begin before Ramadan rather than after the patient becomes unwell. The patient may also seek guidance from a trusted religious authority concerning exemptions or alternative observances when illness makes fasting unsafe.

Halal and Pharmaceutical Ingredients

Some capsules, nutritional products and medicines may contain gelatin, alcohol-derived excipients or other ingredients of concern to the patient.

The clinician should review product composition and offer suitable alternatives where available.

The patient should not have to choose between religious values and treatment because ingredient information was never discussed.

Smoke, Bukhoor and Strong Fragrances

Bukhoor, oud smoke, incense, perfumes and other strong aromatic exposures may aggravate cough or breathlessness in some patients.

Avoidance should be based on the patient’s actual response. Cultural practices should be modified respectfully when they clearly worsen symptoms.

Medicated smoke or strong aromatic vapours should not be prescribed as respiratory treatment in a patient with pleural mesothelioma.

Language and Caregiver Communication

Emergency instructions, medicine schedules and stop criteria should be available in the language understood by the patient and primary caregiver.

Providing only an English prescription to an Arabic- or Urdu-speaking household can create preventable dosing and emergency-response errors.

The final plan should identify medicine names clearly, preferably using generic names for conventional treatments. Similar-looking containers and unlabelled powders should be avoided.

Travel Between Countries

Many Gulf patients receive oncology care in one country while obtaining complementary treatment from another.

The treatment record should therefore be portable and understandable to all clinicians involved.

The patient should carry the pathology report, current scan summary, oncology prescription, pleural-catheter information, laboratory results and complete supplement list.

Ayurvedic treatment should not depend on products that cannot be sourced consistently, verified or monitored in the patient’s country of residence.

مختصر اردو وضاحت: ذاتی نوعیت کا علاج کیا ہے؟

ذاتی نوعیت کے علاج کا مطلب زیادہ دوائیں دینا نہیں ہے۔ اس کا مطلب یہ ہے کہ صحیح مریض کے لیے صحیح وقت پر صرف وہی علاج منتخب کیا جائے جس کا واضح مقصد اور نگرانی کا طریقہ موجود ہو۔

علاج سے پہلے بایوپسی، رسولی کی قسم، اسکین، کینسر کا موجودہ علاج، پھیپھڑے کے اردگرد پانی، خون کے ٹیسٹ، گردے اور جگر کی حالت، وزن، پٹھوں کی طاقت اور تمام استعمال ہونے والی دواؤں کا جائزہ ضروری ہے۔

آیورویدک معائنہ میں پراکرتی، وِکرتی، اگنی، کوشٹھ، بالم، ساتمیہ، نیند، بھوک، پاخانے کی کیفیت اور موجودہ سمپراپتی کو دیکھا جاتا ہے۔

ہر مریض کے لیے منصوبے میں واضح ہونا چاہیے کہ کون سا علاج جاری رکھنا ہے، کیا شامل کیا جا سکتا ہے، کن چیزوں سے بچنا ہے، کیا مانیٹر کرنا ہے اور کن علامات میں فوراً ہسپتال جانا ہے۔

شرح مختصر باللغة العربية: ما المقصود بالعلاج الشخصي؟

لا يعني العلاج الشخصي إعطاء عدد أكبر من الأدوية. بل يعني اختيار التدخل المناسب للمريض المناسب، في الوقت المناسب، مع هدف واضح وخطة محددة للمتابعة.

ينبغي قبل بدء العلاج مراجعة الخزعة، ونوع الورم، والصور الشعاعية، وعلاج السرطان الحالي، والسائل الجنبي، وتحاليل الدم، ووظائف الكلى والكبد، والوزن، وقوة العضلات، وجميع الأدوية والمكملات المستخدمة.

يشمل التقييم الأيورفيدي دراسة البراكريتي، والفيكريتي، والأغني، والكوشثا، والبلا، والساتميا، والنوم، والشهية، وحركة الأمعاء، وحالة السامبرابتي الحالية.

يجب أن توضح الخطة لكل مريض ما الذي ينبغي الاستمرار عليه، وما الذي يمكن إضافته، وما الذي يجب تجنبه، وما الذي يحتاج إلى متابعة، ومتى يجب التواصل مع فريق الأورام أو التوجه إلى المستشفى.

Two Examples of Genuine Personalisation

A Medically Fit Patient Receiving Immunotherapy

Consider a patient who remains independently mobile, has stable pleural disease after catheter placement, maintains food intake and has acceptable renal, hepatic and haematological investigations.

The principal problems may be constipation, disturbed sleep and anxiety before treatment visits.

The personalised Ayurvedic plan may remain deliberately limited. The objectives may be bowel regularity, sleep support and a stable daily routine. The plan should avoid unnecessary immune-stimulating claims and should include instructions to report new diarrhoea, cough, rash or jaundice to the oncology team.

A large cancer package would not make this plan more personalised.

A Frail Patient With Recurrent Effusion and Severe Muscle Loss

Consider another patient who is breathless during meals, requires repeated pleural drainage, has lost substantial weight and now needs help to stand.

The priorities are completely different.

The patient first requires optimisation of pleural care, medical assessment of breathlessness, dietitian involvement, symptom control and a safe rehabilitation plan.

Ayurvedic support should be Mridu and should prioritise food tolerance, bowel function, sleep and prevention of further depletion.

Strong Langhana, Rukshana, Swedana or purification would be inappropriate even if chest heaviness and fluid are present.

These two patients share the same cancer diagnosis but require different therapeutic directions.

Monitoring Is What Makes Personalisation Accountable

A personalised plan should define baseline measurements before treatment begins.

These may include breathlessness score, appetite, meal completion, bowel frequency, sleep duration, pain, fatigue, weight interpreted with fluid status, grip strength, walking ability and caregiver dependence.

Relevant laboratory results should be documented. The dates of scans, oncology cycles and pleural procedures should also be recorded.

At follow-up, the same measurements should be repeated.

Treatment should not be declared successful merely because the patient says, “I feel somewhat better.” The clinician should ask what specifically improved, by how much, for how long and whether any new problem appeared.

Similarly, treatment should not be declared ineffective solely because a scan shows no tumour shrinkage when the predefined purpose was symptom support. Disease outcomes and supportive outcomes must remain separate.

Personalisation Includes Stop Rules

A genuinely personalised plan explains not only how treatment begins but also how it ends.

An intervention may be stopped because its objective has been achieved, because it produced no meaningful benefit, because the patient’s condition changed or because a safety concern developed.

It may also need to be stopped temporarily around a medical procedure, hospital admission or new oncology treatment.

No formulation should become permanent merely because it was once prescribed.

The patient and caregiver should understand that stopping an unsuitable product is not treatment failure. It is part of safe clinical decision-making.

The Limits of Online Personalisation

Medical reports can be reviewed remotely, but an online consultation cannot perform every component of respiratory and physical examination.

Auscultation, oxygen assessment during activity, catheter-site examination, evaluation of oedema, muscle testing and investigation of acute symptoms may require an in-person clinician.

A remote Ayurvedic review should therefore work with the patient’s local oncology and medical teams.

Severe or changing symptoms should not be managed entirely through text messages, photographs or video calls.

The availability of a remote consultation should never become a reason to delay local emergency care.

What the Patient Should Receive After the Review

The final document should identify the confirmed diagnosis, current oncology status, immediate safety concerns, principal supportive goals and the Ayurvedic assessment.

It should explain which conventional treatments must continue and who is responsible for them.

Every added Ayurvedic formulation should have a stated purpose, dose, timing, duration, monitoring requirement and stop criterion.

The plan should identify unsafe supplements, unnecessary duplication, dietary restrictions to avoid and circumstances requiring laboratory review.

It should also contain clear oncology-contact and hospital-escalation instructions.

A personalised plan is complete only when the patient and caregiver understand it.

Request a Personalised Pleural Mesothelioma Review

A personalised review is appropriate when the patient and family want to understand how Ayurvedic supportive care may be coordinated with oncology treatment without creating unnecessary interaction or delay.

The review should include the histopathology and immunohistochemistry report, latest and previous scan reports, reason surgery was not recommended, current oncology prescription, pleural-procedure history, recent complete blood count, kidney and liver investigations, electrolytes, weight history, functional changes and a complete list of medicines and supplements.

The purpose is not to select a standard pleural mesothelioma package.

The purpose is to determine what must continue, what may safely be added, what should be avoided, what must be monitored and when treatment should be escalated.

A responsible personalised strategy makes care more coordinated, more measurable and less burdensome.

Monitoring With Scans and Laboratory Investigations: Making Every Treatment Decision Accountable

Monitoring is not an administrative step added after treatment. It is part of treatment itself.

In pleural mesothelioma, a patient may feel better while the tumour remains unchanged, feel worse because of a reversible complication despite stable disease, or show laboratory deterioration before serious symptoms become obvious. A scan may demonstrate stable tumour measurements while breathlessness worsens because pleural fluid has returned. Conversely, breathlessness may improve after drainage even though the pleural tumour has not reduced.

For this reason, monitoring must answer three different questions.

The first question is whether the mesothelioma is responding, remaining stable or progressing. This is primarily answered through oncology-led imaging and clinical assessment.

The second question is whether chemotherapy, immunotherapy, prescribed medicines or Ayurvedic interventions are being tolerated safely. This is assessed through symptoms, physical examination and laboratory investigations.

The third question is whether the patient’s daily function is improving, remaining stable or declining. This requires monitoring of breathlessness, appetite, sleep, bowel function, weight, muscle strength, mobility, pain, fatigue and dependence on caregivers.

These three questions must remain separate. Improvement in one area does not automatically prove improvement in another.

A Baseline Must Be Established Before Ayurvedic Treatment Is Added

The effectiveness or safety of an integrative treatment cannot be evaluated when the patient’s condition was not documented before it began.

The baseline should include the confirmed histopathological diagnosis, immunohistochemistry, histological subtype, current stage or disease extent, latest scan report, previous comparison scan and the oncology treatment being given or planned.

The clinician should also document pleural-fluid status, previous thoracentesis, pleurodesis, indwelling pleural catheter, oxygen use, recent hospital admissions and any history of infection, pulmonary embolism or treatment-related lung complications.

Recent complete blood count, kidney function, liver function and electrolytes should be available. Additional investigations should be recorded according to the oncology regimen, symptoms and medicines being considered.

The baseline symptom record should describe breathlessness at rest and on exertion, pain, cough, appetite, nausea, bowel pattern, sleep, fatigue, food intake, weight, muscle loss, walking ability and dependence during daily activities.

The complete medicine record should include chemotherapy, immunotherapy, anticoagulants, corticosteroids, antibiotics, analgesics, antiemetics, laxatives, inhalers, nutritional supplements, herbal products, proprietary Ayurvedic medicines and home remedies.

The exact date of each medicine or supplement should be recorded. Without dates, it becomes difficult to determine whether a new symptom preceded or followed an intervention.

A statement such as “the patient was weak before treatment” is insufficient. The baseline should describe what weakness meant in practical terms. It may mean that the patient could walk only ten metres, needed assistance to rise from a chair, completed only half of each meal or slept for only two hours because of breathlessness.

This level of documentation allows future change to be measured rather than guessed.

Monitoring Disease Status With Imaging

CT Is the Principal Imaging Tool for Longitudinal Assessment

Computed tomography is the principal imaging method used to assess the anatomical extent and progression of pleural mesothelioma. Contrast-enhanced CT is commonly used when clinically appropriate because it helps differentiate pleural tumour from adjacent fluid, chest-wall structures and other tissues.

The exact scan area, contrast use and technical protocol are determined by the oncology and radiology teams. Kidney function, previous contrast reactions and other contraindications must be considered before intravenous contrast is administered.

MRI or PET-CT may be used for selected clinical questions, such as clarification of local invasion, staging, treatment planning or investigation of findings not adequately resolved by CT. They should not be ordered routinely by an Ayurvedic clinic or used as automatic substitutes for the oncology team’s preferred follow-up modality [1–3]. CT remains the main longitudinal imaging method for most patients with pleural mesothelioma. (annalsofoncology.org)

Scan Timing Must Follow the Oncology Treatment Plan

There is no single scan interval suitable for every patient.

The timing depends on the systemic treatment being used, the stage and speed of disease, recent clinical changes, previous response, treatment toxicity, clinical-trial requirements and the purpose of the scan.

A patient receiving active chemotherapy or immunotherapy may be scanned according to the treatment protocol. A patient following a comfort-focused approach may have imaging only when the result is likely to alter management. A patient with sudden deterioration may require investigation before the next routine scan date.

An Ayurvedic clinician should not independently postpone an oncology scan because the patient appears symptomatically better. The clinician should also not request repeated scans at very short intervals simply to demonstrate that a formulation is working.

Unnecessary imaging can increase cost, travel burden, anxiety and exposure to contrast or radiation without providing clinically useful information.

Comparable Scans Are More Valuable Than Frequent Incomparable Scans

Serial imaging is most informative when the same or a comparable modality and technical protocol are used.

Important technical factors may include the body region covered, contrast phase, patient positioning, reconstruction method, slice thickness and image-display parameters. Ideally, comparison should be made with the original images rather than only with the written report.

The same pleural sites should be evaluated over time wherever possible. Consistent imaging methods reduce the risk that an apparent change is caused by a different scanning technique rather than a true biological change.

When a patient receives care in different hospitals or countries, the family should retain the complete DICOM imaging files in addition to the report. A photograph of one CT image or a cropped screenshot is not sufficient for reliable comparison.

Modified RECIST 1.1 for mesothelioma was developed partly to improve consistency in tumour measurement and response classification. It addresses measurable pleural disease, non-pleural lesions, lymph nodes, bilateral disease and the definition of progression [20]. (Europe PMC)

Why Pleural Mesothelioma Is Difficult to Measure

Many solid tumours form approximately spherical or oval masses that can be followed by measuring their longest diameter.

Pleural mesothelioma often grows as irregular pleural thickening along the chest wall, diaphragm and mediastinal surfaces. It may form a rind-like pattern around the lung. A simple measurement of one longest diameter may therefore fail to represent the total disease accurately.

Modified RECIST for mesothelioma assesses pleural tumour thickness perpendicular to the chest wall or mediastinum at reproducible locations. Measurable non-pleural lesions and pathological lymph nodes may also contribute to the total disease assessment.

The measurements require radiological expertise. Patients and non-radiology clinicians should not attempt to determine response by measuring visible areas on screenshots or comparing isolated images.

The purpose of modified RECIST is to make response assessment more standardised. It does not remove all measurement variability, and the oncology team must interpret the images together with clinical findings [20]. (ScienceDirect)

Pleural Fluid Is Not the Same as Measurable Pleural Tumour

Pleural effusion is clinically important, but it is generally considered non-measurable disease within formal tumour-response systems.

A reduction in pleural fluid may occur after drainage, pleurodesis or catheter management without corresponding shrinkage of the tumour. An increase in fluid may occur even when measurable tumour thickness has changed very little.

Pleural-fluid volume should therefore be documented separately from measurable tumour burden.

The scan report may describe pleural thickening, nodularity, chest-wall involvement, diaphragmatic disease, lymph nodes, lung expansion and pleural-fluid volume. Each of these findings contributes different information.

An Ayurvedic treatment should never be advertised as having reduced the tumour merely because less pleural fluid was seen after a drainage procedure.

Understanding Complete Response, Partial Response, Stable Disease and Progression

Oncology reports may classify disease as complete response, partial response, stable disease or progressive disease.

A complete response requires disappearance of measurable disease according to the applicable response criteria. This is uncommon in advanced pleural mesothelioma and should not be claimed from symptom improvement alone.

A partial response means that the measurable tumour burden has reduced sufficiently to meet the defined radiological threshold.

Stable disease means that the measurements do not meet the criteria for either sufficient reduction or definite progression. Stable disease can be a clinically valuable outcome in an aggressive cancer, particularly when it is accompanied by preserved function and acceptable treatment tolerance.

Progressive disease may be identified through sufficient increase in measured tumour burden, new measurable lesions or other recognised evidence of progression.

These categories must be assigned by the oncology and radiology teams. They should not be modified in promotional material to create categories such as “near complete response,” “biological cure” or “Ayurvedic regression” without recognised medical evidence.

Imaging During Immunotherapy Requires Specialist Interpretation

Immune checkpoint inhibitors can produce inflammatory changes and response patterns that may be more complex than those seen with conventional chemotherapy.

New cough, worsening breathlessness, fever or changes on imaging may represent cancer progression, infection, pleural complications or immune-related inflammation. They should not automatically be interpreted as a temporary healing response.

Similarly, apparent radiological progression should not be dismissed casually as pseudoprogression. The treating oncologist must decide whether treatment should continue, be held, be changed or require additional investigation.

An Ayurvedic clinician should not advise a patient to continue immunotherapy despite suspected serious toxicity, or to stop immunotherapy because of one scan report, without coordination with the oncology team.

Scan Response and Symptom Response May Move in Different Directions

A patient may breathe more comfortably after pleural drainage while tumour measurements remain unchanged.

Pain control may improve sleep and mobility without altering the tumour. Correction of anaemia may improve fatigue and exertional tolerance even when the scan is stable. Relief of constipation may reduce abdominal pressure and make breathing and eating easier.

The reverse can also occur. A scan may demonstrate stable disease while the patient becomes weaker because of infection, treatment toxicity, cachexia, electrolyte disturbance or progressive deconditioning.

For this reason, a scan should never be used as the only measure of whether the overall treatment plan is helping.

Disease control, symptom control, treatment safety and functional recovery must be reported separately.

Laboratory Investigations for Treatment Safety

Laboratory Monitoring Must Be Individualised

There is no single laboratory panel appropriate for every patient with pleural mesothelioma.

The required investigations depend on the oncology regimen, comorbid illnesses, current symptoms, organ function, nutritional state and any complementary products being used.

Blood tests do not directly show whether a pleural tumour has shrunk. Their principal role is to assess the patient’s physiological condition, identify treatment toxicity, detect complications and determine whether medicines can be given safely.

Blood chemistry tests provide information about kidney, liver and other organ function, while abnormal findings may reflect disease or treatment-related effects. (Cancer.gov)

Complete Blood Count

A complete blood count usually includes haemoglobin, red-cell indices, total white-cell count, differential white-cell count and platelets.

Low haemoglobin may contribute to breathlessness, weakness, dizziness, rapid heart rate and reduced exercise tolerance. The cause may include chronic inflammation, marrow suppression, bleeding, nutritional deficiency, kidney dysfunction or other factors.

A low neutrophil count can increase susceptibility to serious infection. Fever during neutropenia may require urgent hospital assessment rather than an Ayurvedic medicine for Jvara or Ama.

A low platelet count can increase bleeding risk. This is particularly important when the patient is using anticoagulants, antiplatelet medicines or products that may affect coagulation.

An unexpected fall in blood counts should not be described as the body “clearing toxins.” It requires clinical interpretation.

Kidney Function

Kidney-function assessment commonly includes serum creatinine and an estimated glomerular filtration rate. Urea and urinalysis may also be relevant depending on the clinical situation.

Kidney function can be affected by dehydration, infection, prescribed medicines, systemic cancer treatment, contrast exposure, obstruction and other illnesses.

Reduced kidney function may alter the clearance and toxicity of both conventional medicines and herbal constituents.

A formulation that appeared well tolerated when renal function was normal may become unsafe after dehydration, repeated vomiting or a decline in kidney function.

Markedly reduced urine output, blood in the urine, new swelling or rapid deterioration in renal results requires medical review. Immunotherapy can also produce inflammatory kidney injury in some patients. (Cancer.gov)

Liver Function

Liver monitoring may include alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin and other tests selected by the medical team.

Abnormal liver results may be caused by prescribed cancer treatment, infection, dehydration, biliary obstruction, disease involvement, alcohol, conventional medicines, herbs or supplements.

A rise in liver enzymes after an Ayurvedic product is introduced should not be assumed to represent detoxification.

The product should be held where clinically appropriate, the oncology team should be informed and the cause should be investigated.

Jaundice, dark urine, increasing nausea, right-upper abdominal pain, confusion or abnormal bleeding may indicate significant liver dysfunction and require prompt medical assessment. Immunotherapy can produce inflammatory liver injury, while supplements may also interact with cancer medicines or contribute to organ toxicity. (Cancer.gov)

Electrolytes and Fluid Balance

Sodium, potassium, calcium, magnesium and other electrolytes may be monitored according to the treatment regimen and clinical condition.

Vomiting, diarrhoea, poor intake, diuretic medicines, dehydration, renal dysfunction and repeated pleural drainage can alter electrolyte balance.

Electrolyte disturbance may contribute to weakness, confusion, constipation, muscle cramps, abnormal heart rhythm and reduced treatment tolerance.

A patient may have pleural fluid and still be intravascularly depleted. The presence of fluid around the lung does not prove that the body has excessive usable fluid.

This is why strong Mutrala, Rukshana or fluid-reducing treatment must not be started merely because a scan mentions pleural effusion.

Albumin and Nutritional Interpretation

Albumin may contribute to the assessment of nutrition, inflammation, liver function and fluid distribution, but it should not be interpreted as a stand-alone nutrition score.

Low albumin may occur with inflammation, poor intake, liver dysfunction, kidney loss or disease-related metabolic changes. It may also contribute to oedema and complicate interpretation of body weight.

Improvement in albumin does not prove tumour response. A normal albumin value does not exclude muscle loss or inadequate intake.

The result should be interpreted together with food intake, weight history, pleural drainage, oedema, muscle function and inflammatory state.

Inflammatory Markers Are Not Mesothelioma Response Tests

Tests such as C-reactive protein and erythrocyte sedimentation rate may reflect inflammation, but they are not specific for cancer activity.

They may rise with infection, treatment-related inflammation, pleural procedures, autoimmune toxicity or other medical conditions.

A falling inflammatory marker may accompany clinical improvement, but it should not be advertised as proof that an Ayurvedic formulation has reduced the tumour.

Similarly, a rising inflammatory marker requires interpretation rather than automatic classification as disease progression.

Glucose and Endocrine Monitoring

Blood glucose may be affected by diabetes, corticosteroids, infection, reduced intake, nutritional supplements and other treatments.

Patients receiving immune checkpoint inhibitors may also require monitoring for endocrine complications according to the oncology protocol and symptoms. Thyroid, pituitary, adrenal or glucose-related abnormalities may present with fatigue, weakness, weight change, dizziness, altered blood pressure or confusion.

These symptoms should not automatically be attributed to Vata, Agni Mandya or general cancer fatigue.

The oncology team determines which endocrine investigations are required and how abnormalities should be treated.

Laboratory Trends Are More Informative Than One Isolated Result

A single mildly abnormal test may have a different meaning from a rapidly worsening trend.

The clinician should compare current results with previous values, treatment dates, hydration, pleural procedures, infections and newly introduced medicines.

Each laboratory report should be preserved with the collection date, units and reference ranges.

When reports come from different countries, the same test may be presented in different units. Results should not be compared numerically until the units have been checked.

An Ayurvedic clinic receiving reports from Gulf countries, India and other locations should record both the original value and unit rather than transcribing only the number.

Monitoring Ayurvedic Treatment Safety

Every Added Product Should Have a Baseline and a Review Point

Before an Ayurvedic formulation is started, the clinician should document why it is being used, which outcome it is expected to influence and which safety measures are required.

A medicine intended to support appetite should be evaluated through actual food intake, meal completion, nausea, weight interpreted with fluid status and digestive tolerance.

A bowel-support intervention should be evaluated through stool frequency, comfort, abdominal distension, diarrhoea and electrolyte safety.

A sleep-support intervention should be evaluated through sleep duration, night-time awakenings, morning alertness, falls and interaction with opioids or sedative medicines.

A formulation described as Balya should be evaluated through function, such as walking tolerance, chair-rise ability, meal completion or dependence on caregivers.

The review should occur at a clinically appropriate interval rather than after an open-ended course.

Medicine Changes Should Be Introduced Sequentially

When several formulations are started together, it becomes difficult to know which intervention produced benefit or harm.

Sequential introduction is generally safer when the patient’s condition allows it.

The date, dose and batch of each product should be documented. Changes in symptoms and laboratory values should then be related to the actual timeline.

If liver enzymes rise after three products were started on the same day, determining causality becomes unnecessarily difficult.

A personalised plan should reduce this uncertainty rather than create it.

Herb–Drug Interaction Monitoring Is Essential

Herbs and dietary supplements may alter the absorption, metabolism, transport, pharmacological activity or elimination of cancer medicines.

The risk cannot be assessed from the plant name alone. Dose, extract concentration, formulation, route, manufacturer, accompanying ingredients and patient organ function all matter.

The complete oncology medicine list should therefore be checked before each new product is added. A product should also be reviewed when chemotherapy, immunotherapy, anticoagulation or another major medicine changes.

The National Cancer Institute recognises that combining dietary supplements or herbs with cancer medicines can affect pharmacokinetics or pharmacodynamics and may produce adverse outcomes [24]. (Cancer.gov)

Herb-Mineral and Bhasma-Containing Products Require a Higher Safety Threshold

When a product contains metals, minerals or Bhasma ingredients, the clinician should document its full composition, manufacturer, batch, dose and available quality-testing information.

Baseline and follow-up kidney, liver and blood investigations may be required according to the product and patient.

Unlabelled powders, mixtures with incomplete ingredients and products supplied in containers without batch identification should not be used in a medically vulnerable patient.

The traditional reputation of an ingredient does not establish the quality of the manufactured product actually being consumed.

A serious adverse event should be documented and reported appropriately rather than explained as a temporary cleansing reaction.

Hold and Stop Criteria Must Be Written Before Treatment Begins

The patient and caregiver should know when an Ayurvedic product must be stopped and medically reviewed.

New jaundice, marked reduction in urine, persistent vomiting, severe diarrhoea, gastrointestinal bleeding, coughing blood, rapidly spreading rash, facial swelling, severe drowsiness, confusion, new chest pain or worsening breathlessness requires prompt assessment.

Unexpected deterioration in blood counts, kidney function, liver function or electrolytes should also trigger reassessment.

The treatment should not be continued through deterioration on the assumption that a healing crisis is occurring.

Tumour Markers and Blood-Based Monitoring

No Blood Test Can Replace Imaging and Clinical Assessment

Patients often ask whether a tumour marker can show whether mesothelioma is improving without repeating scans.

Several circulating biomarkers have been studied, including soluble mesothelin-related peptides. However, biomarker expression varies between patients and histological subtypes.

The 2025 ASCO guideline update states that non-tissue biomarkers under evaluation do not have sufficient sensitivity or specificity to predict outcomes or reliably monitor response as stand-alone tools. They should not replace imaging, pathology and specialist clinical assessment [1]. (ASC Publications)

When an oncologist chooses to follow a biomarker in an individual patient, the result should be interpreted as one part of the total clinical picture.

A falling biomarker value should not override clear radiological or clinical progression. A normal value does not exclude active mesothelioma.

General Laboratory Improvement Is Not Tumour Regression

Improved haemoglobin, albumin, sodium, liver enzymes or inflammatory markers may represent clinically meaningful recovery.

These improvements can help the patient tolerate treatment and maintain function.

They do not demonstrate that the mesothelioma has shrunk.

The article and clinical service should report these outcomes accurately as physiological, nutritional or treatment-tolerance improvements.

They should not be converted into tumour-response claims.

Monitoring Symptoms, Function and Quality of Life

The Patient’s Experience Must Be Recorded Systematically

Laboratory and imaging reports cannot fully describe the patient’s daily experience.

Breathlessness, pain, fatigue, appetite, nausea, bowel function, sleep, anxiety and treatment interference are often best described by the patient.

The National Cancer Institute’s PRO-CTCAE system was developed to capture symptomatic adverse events directly from patients and assesses dimensions such as frequency, severity, interference and presence or absence. It is available in more than 60 validated languages, which supports culturally and linguistically diverse monitoring [22]. (healthcaredelivery.cancer.gov)

A clinic does not need to reproduce the full research instrument for every consultation. It may use a concise, consistent symptom record inspired by the same principle.

The important point is to ask the same question in the same way at repeated intervals.

Breathlessness Should Be Measured at Rest and During Activity

A single statement that breathlessness is “better” or “worse” provides limited information.

The patient should be asked whether breathlessness occurs at rest, during speaking, while eating, during bathing, when walking to the bathroom and when lying down.

The record should note oxygen use, number of pillows required for sleep, walking distance and whether pleural drainage changes the symptom.

The same numerical or verbal severity scale should be used over time when possible.

A fall in breathlessness after pleural drainage should be recorded as a pleural-management response, not automatically as an Ayurvedic response.

Pleural Drainage Should Have Its Own Monitoring Record

For a patient with an indwelling pleural catheter, the drainage record should include the date, approximate volume, fluid appearance, pain, cough during drainage, catheter-site condition and breathlessness before and after the procedure.

A reduction in drainage volume may reflect reduced fluid production or spontaneous pleurodesis, but it may also reflect catheter blockage or loculation.

The treating pleural team should interpret unexpected changes.

Ayurvedic oils, powders or topical preparations should never be placed on or around the catheter site unless explicitly approved by the responsible medical team.

Food Intake Must Be Recorded More Precisely Than Appetite Alone

The patient may report having an appetite but still consume very little because of breathlessness, early satiety, nausea, dry mouth, taste changes or fatigue.

Monitoring should therefore include the proportion of meals completed, number of meals or snacks, protein-containing foods, oral nutritional supplements and symptoms interrupting eating.

The purpose is not to make the patient feel watched or blamed. It is to detect decline early and identify the actual barrier to nutrition.

Weight Must Be Interpreted With Fluid Status

Weight should ideally be measured on the same scale and under similar conditions.

The record should state whether measurement occurred before or after pleural drainage and whether oedema was present.

An increase in weight may represent improved nutrition, fat gain, oedema or pleural fluid. A decrease may represent tissue loss, dehydration or removal of fluid.

Weight should therefore be interpreted with muscle strength, food intake, walking ability, drainage volume and clinical examination.

Function Is One of the Most Meaningful Outcomes

Functional monitoring should describe what the patient can actually do.

The record may include the ability to rise from a chair, walk independently, bathe, dress, use the toilet, climb steps, prepare food or attend an oncology appointment.

The same activity should be reassessed over time.

A patient may not gain weight but may become safer when walking and less dependent during transfers. This can represent a meaningful functional benefit.

Conversely, a stable scan does not mean the supportive plan is succeeding when the patient is progressively losing mobility and muscle.

Sleep and Mental Distress Should Be Monitored Separately

Sleep disturbance may be caused by breathlessness, pain, anxiety, corticosteroids, nocturnal cough, catheter discomfort or the need to remain upright.

The record should identify sleep duration, number of awakenings and the cause of awakening.

Anxiety should be assessed without dismissing physical respiratory symptoms. Panic may intensify breathlessness, but breathlessness should never be labelled as psychological before medical causes are considered.

Any sedating Ayurvedic intervention should be evaluated for morning drowsiness, confusion, falls and interaction with opioids or other sedatives.

The Classical Ayurvedic Foundation of Repeated Monitoring

Ayurveda does not support prescribing treatment once and assuming that the patient will remain in the same Avastha.

Classical examination requires authoritative knowledge, direct observation, inference and repeated reassessment of the patient’s changing state.

The Sanskrit passage remains the authoritative source. The Urdu and Arabic translations communicate its clinical meaning to patients and caregivers.

Three Sources of Clinical Knowledge

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 4, Trividha Roga Viśeṣa Vijñānīya Vimāna, verse 3. Article classical reference [40].

Sanskrit

त्रिविधं खलु रोगविशेषविज्ञानं भवति; तद्यथा— आप्तोपदेशः, प्रत्यक्षम्, अनुमानं चेति ॥३॥

Roman Transliteration

trividhaṃ khalu rogaviśeṣavijñānaṃ bhavati; tadyathā— āptopadeśaḥ, pratyakṣam, anumānaṃ ceti || 3 ||

English Translation

Specific knowledge of a disease is obtained through three means: authoritative instruction, direct observation and inference.

Urdu Translation

کسی بیماری کے بارے میں مخصوص اور درست علم تین ذرائع سے حاصل ہوتا ہے: معتبر علمی ہدایت، براہِ راست مشاہدہ اور شواہد کی بنیاد پر منطقی استنباط۔

Arabic Translation

تُكتسب المعرفة الدقيقة بخصائص المرض من ثلاثة مصادر: التعليم الموثوق، والملاحظة المباشرة، والاستدلال المبني على الأدلة.

In a modern integrative setting, Aptopadesha includes reliable oncology guidelines, pathology, radiology, pharmacology and the classical Ayurvedic texts.

Pratyaksha includes direct observation of the patient’s breathing, voice, colour, mobility, oedema, appetite, food intake, bowel pattern, strength and response to treatment.

Anumana includes reasoned interpretation of scan trends, laboratory trends, possible medicine interactions and the relationship between the timing of an intervention and the subsequent change.

No single component is sufficient.

A scan without clinical examination may miss severe functional decline. Symptoms without imaging cannot establish tumour response. A classical description without laboratory assessment cannot exclude organ toxicity.

The three sources must be considered together. (Charak Samhita)

The Patient Must Be Observed Repeatedly as the Avastha Changes

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 8, Rogabhiṣagjitīya Vimāna Adhyāya, passage 128. Article reference [32].

Sanskrit

आतुरावस्थास्वपि तु कार्याकार्यं प्रति कालाकालसञ्ज्ञा; तद्यथा— अस्यामवस्थायामस्य भेषजस्याकालः, कालः पुनरन्यस्येति; एतदपि हि भवत्यवस्थाविशेषेण; तस्मादातुरावस्थास्वपि हि कालाकालसञ्ज्ञा। तस्य परीक्षा— मुहुर्मुहुरातुरस्य सर्वावस्थाविशेषावेक्षणं यथावद्भेषजप्रयोगार्थम्। न ह्यतिपतितकालमप्राप्तकालं वा भेषजमुपयुज्यमानं यौगिकं भवति; कालो हि भैषज्यप्रयोगपर्याप्तिमभिनिर्वर्तयति ॥१२८॥

Roman Transliteration

āturāvasthāsvapi tu kāryākāryaṃ prati kālākālasañjñā; tadyathā— asyāmavasthāyāmasya bheṣajasyākālaḥ, kālaḥ punaranyasyeti; etadapi hi bhavatyavasthāviśeṣeṇa; tasmādāturāvasthāsvapi hi kālākālasañjñā | tasya parīkṣā— muhurmuhurāturasya sarvāvasthāviśeṣāvekṣaṇaṃ yathāvadbheṣajaprayogārtham | na hyatipatitakālamaprāptakālaṃ vā bheṣajamupayujyamānaṃ yaugikaṃ bhavati; kālo hi bhaiṣajyaprayogaparyāptimabhinirvartayati || 128 ||

English Translation

Whether a treatment should or should not be given depends on the patient’s present stage. A medicine may be unsuitable in one state and suitable in another. Therefore, the physician should repeatedly observe every change in the patient’s condition so that treatment is applied correctly. A medicine given too early or too late may not be appropriate, because correct timing determines the suitability of therapy.

Urdu Translation

علاج دینا چاہیے یا نہیں، اس کا فیصلہ مریض کی موجودہ حالت اور مرحلے کے مطابق ہونا چاہیے۔ ایک دوا کسی حالت میں نامناسب اور دوسری حالت میں مناسب ہو سکتی ہے۔ اس لیے طبیب کو مریض کی بدلتی ہوئی کیفیت کا بار بار جائزہ لینا چاہیے تاکہ علاج صحیح وقت پر اور صحیح طریقے سے دیا جا سکے۔ بہت جلد یا بہت دیر سے دی گئی دوا مناسب ثابت نہیں ہو سکتی۔

Arabic Translation

يعتمد إعطاء العلاج أو عدم إعطائه على حالة المريض ومرحلته الحالية. فقد يكون دواء ما غير مناسب في حالة معينة، بينما يكون دواء آخر مناسباً. لذلك ينبغي للطبيب أن يراقب تغيرات حالة المريض بصورة متكررة حتى يُستخدم العلاج في الوقت والطريقة المناسبين. وقد لا يكون الدواء ملائماً إذا أُعطي قبل أوانه أو بعد فوات الوقت المناسب.

The phrase muhur muhur āturasya sarvāvasthāviśeṣāvekṣaṇam supports repeated observation rather than one-time assessment.

In pleural mesothelioma, the patient’s Avastha may change after chemotherapy, immunotherapy, drainage, infection, weight loss, hospital admission or progression.

A formulation appropriate during a stable phase may become inappropriate when diarrhoea, jaundice, neutropenic fever, renal impairment or rapidly increasing breathlessness develops.

Monitoring is therefore a classical requirement as well as a modern safety requirement. (Charak Samhita)

Classical Signs of Improvement Must Be Multidimensional

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 8, Rogabhiṣagjitīya Vimāna Adhyāya, passage 89. Article reference [32].

Sanskrit

कार्यं धातुसाम्यं, तस्य लक्षणं विकारोपशमः। परीक्षा त्वस्य— रुगुपशमनं, स्वरवर्णयोगः, शरीरोपचयः, बलवृद्धिः, अभ्यवहार्याभिलाषः, रुचिराहारकाले, अभ्यवहृतस्य चाहारस्य काले सम्यग्जरणं, निद्रालाभो यथाकालं, वैकारिणां च स्वप्नानामदर्शनं, सुखेन च प्रतिबोधनं, वातमूत्रपुरीषरेतसां मुक्तिः, सर्वाकारैर्मनोबुद्धीन्द्रियाणां चाव्यापत्तिरिति ॥८९॥

Roman Transliteration

kāryaṃ dhātusāmyaṃ, tasya lakṣaṇaṃ vikāropaśamaḥ | parīkṣā tvasya— rugupaśamanaṃ, svaravarṇayogaḥ, śarīropacayaḥ, balavṛddhiḥ, abhyavahāryābhilāṣaḥ, rucirāhārakāle, abhyavahṛtasya cāhārasya kāle samyagjaraṇaṃ, nidrālābho yathākālaṃ, vaikāriṇāṃ ca svapnānāmadarśanaṃ, sukhena ca pratibodhanaṃ, vātamūtrapurīṣaretasāṃ muktiḥ, sarvākārairmanobuddhīndriyāṇāṃ cāvyāpattiriti || 89 ||

English Translation

The therapeutic objective is restoration of physiological balance, recognised by alleviation of the disorder. Its assessment includes relief of pain or illness, normalisation of voice and complexion, improved bodily nourishment, increased strength, desire for food, appropriate appetite at mealtime, proper digestion, timely sleep, absence of disturbing dreams, easy awakening, comfortable elimination of flatus, urine and stool, and unimpaired functioning of the mind, intellect and senses.

Urdu Translation

علاج کا مقصد جسمانی توازن کی بحالی ہے، جس کی پہچان بیماری اور تکلیف میں کمی سے ہوتی ہے۔ اس کا جائزہ درد یا مرض میں کمی، آواز اور رنگت کی بہتری، جسمانی غذائیت، قوت میں اضافہ، غذا کی خواہش، کھانے کے وقت مناسب بھوک، غذا کا درست ہضم، وقت پر نیند، پریشان کن خوابوں کی عدم موجودگی، آسانی سے بیدار ہونا، ہوا، پیشاب اور پاخانے کا آرام سے خارج ہونا، اور ذہن، عقل اور حواس کے درست کام کرنے سے کیا جاتا ہے۔

Arabic Translation

يتمثل الهدف العلاجي في استعادة التوازن الفسيولوجي، ويُستدل عليه بتراجع الاضطراب. ويشمل تقييمه تخفيف الألم أو المرض، وتحسن الصوت واللون، وتحسن تغذية الجسم، وزيادة القوة، والرغبة في الطعام، ووجود شهية مناسبة وقت الوجبة، والهضم السليم، والنوم في الوقت المناسب، وعدم وجود أحلام مزعجة، والاستيقاظ بسهولة، وخروج الغازات والبول والبراز براحة، وسلامة وظائف العقل والإدراك والحواس.

This passage supports multidimensional monitoring.

Improvement is not represented by one vague claim that the patient has “positive energy.” It is assessed through symptoms, nourishment, strength, food intake, digestion, sleep, elimination and mental function.

These classical indicators do not replace CT, blood counts, kidney tests, liver tests or oncology assessment. They support monitoring of the patient’s functional and experiential recovery alongside modern investigations. (Charak Samhita)

How to Attribute Outcomes Honestly

Improvement During Combined Treatment Has More Than One Possible Cause

Most patients using Ayurveda for pleural mesothelioma are also receiving oncology treatment, pleural procedures, analgesia, nutritional support or palliative care.

When several treatments are used together, improvement cannot automatically be attributed to one component.

A scan response during chemotherapy or immunotherapy should first be interpreted in the context of the oncology treatment known to affect tumour response.

Improvement in breathlessness after pleural drainage should be attributed to drainage unless evidence suggests an additional effect.

Improved haemoglobin after transfusion should not be attributed to an Ayurvedic tonic.

Improved appetite after nausea control, constipation treatment and introduction of an Ayurvedic formulation should be documented as a combined clinical improvement unless the contribution of each intervention can be distinguished.

This does not reduce the value of supportive Ayurveda. It increases credibility by reporting outcomes accurately.

Every Intervention Should Have a Predefined Outcome

Before treatment begins, the clinician should state what the intervention is intended to do.

An appetite-support intervention should be evaluated through food intake and meal completion.

A bowel intervention should be evaluated through bowel frequency, ease and abdominal comfort.

A sleep intervention should be evaluated through sleep duration, awakenings and morning alertness.

A Balya intervention should be evaluated through a selected functional measure.

A treatment should not later be declared successful for a different outcome simply because the original objective was not achieved.

Negative Outcomes Must Also Be Documented

Transparent monitoring records both benefit and lack of benefit.

If appetite does not improve, that should be recorded. If a product causes nausea, the adverse effect should be documented. If a patient discontinues treatment, the reason should be stated.

A case report that includes only successful outcomes creates a misleading picture.

A trustworthy clinical service should be able to explain how many patients improved, how improvement was measured, what other treatments they were receiving, what adverse effects occurred and what limitations remain.

Gulf-Focused Monitoring and Cross-Border Records

Reports Should Be Complete and Portable

Patients receiving oncology care in a Gulf country and Ayurvedic support from India or another country should maintain a portable treatment file.

The file should include pathology, immunohistochemistry, complete scan reports, DICOM images, oncology prescriptions, pleural-procedure records, laboratory reports, allergy history and every medicine or supplement being used.

Each report should show the patient’s name, date, laboratory units and reference ranges.

A cropped image sent through a messaging application may omit clinically important information. Complete PDF reports and original imaging access should be provided when possible.

Date and Unit Differences Must Be Checked

Different countries may use different date formats.

A date written as 04/07/2026 may mean April 7 or July 4, depending on the system used. For cross-border records, the month should be written in words or the ISO format should be used.

Kidney, glucose and other laboratory values may also be reported in different units.

The clinician should never compare numbers from two reports without checking the unit and reference range.

Contrast Safety Must Be Coordinated Locally

When a contrast-enhanced scan is planned, recent kidney function, previous contrast reaction and local radiology requirements should be reviewed.

An Ayurvedic clinician should not instruct the patient to stop medically required hydration, prescribed medicines or radiology preparation without coordination with the local team.

The presence of pleural fluid does not mean that the patient should deliberately dehydrate before a scan.

Urdu Guidance for Patients and Families

اسکین، خون کے ٹیسٹ اور مریض کی روزمرہ حالت تین الگ چیزیں بتاتے ہیں۔ اسکین سے رسولی کی کیفیت دیکھی جاتی ہے، خون کے ٹیسٹ سے علاج کی حفاظت اور جسم کے اعضا کی حالت معلوم ہوتی ہے، جبکہ سانس، بھوک، نیند، وزن، پٹھوں کی طاقت اور چلنے پھرنے کی صلاحیت سے مریض کی عملی بہتری کا اندازہ ہوتا ہے۔

صرف بھوک بہتر ہونے یا سانس میں کچھ آرام آنے سے یہ ثابت نہیں ہوتا کہ رسولی کم ہو گئی ہے۔ اسی طرح صرف ایک خون کا ٹیسٹ کینسر کے کم یا زیادہ ہونے کا فیصلہ نہیں کر سکتا۔

ہر آیورویدک دوا شروع کرنے سے پہلے اس کا مقصد، آغاز کی تاریخ، خوراک، مکمل اجزا اور نگرانی کا طریقہ لکھا ہونا چاہیے۔ یرقان، پیشاب میں واضح کمی، شدید دست، مسلسل الٹی، خون آنا، الجھن یا سانس کی خرابی ہونے پر دوا روک کر فوری طبی مشورہ لینا چاہیے۔

Arabic Guidance for Patients and Families

تقدّم الصور الشعاعية، وتحاليل الدم، وحالة المريض اليومية ثلاثة أنواع مختلفة من المعلومات. تُستخدم الصور لتقييم وضع الورم، وتُستخدم تحاليل الدم لتقييم سلامة العلاج ووظائف الأعضاء، بينما تُستخدم أعراض ضيق النفس، والشهية، والنوم، والوزن، وقوة العضلات، والقدرة على الحركة لتقييم التحسن الوظيفي.

لا يثبت تحسن الشهية أو التنفس وحده أن الورم قد تقلص. كما لا يستطيع تحليل دم واحد تحديد ما إذا كان السرطان قد تحسن أو ازداد.

ينبغي قبل بدء أي دواء أيورفيدي توثيق هدفه، وتاريخ البدء، والجرعة، والمكونات الكاملة، وطريقة المتابعة. وإذا ظهر اليرقان، أو انخفاض واضح في البول، أو إسهال شديد، أو قيء مستمر، أو نزف، أو ارتباك، أو تدهور في التنفس، فينبغي إيقاف العلاج وطلب التقييم الطبي العاجل.

When Monitoring Should Lead to Immediate Action

Contact the Oncology or Pleural Team Promptly

Increasing breathlessness over hours or days, new oxygen requirements, fever, worsening cough, reduced pleural-catheter drainage, catheter-site redness, jaundice, persistent diarrhoea, repeated vomiting, markedly reduced food intake or rapidly increasing weakness should be reported promptly.

These symptoms may indicate pleural-fluid recurrence, infection, treatment toxicity, organ dysfunction or disease progression.

The patient should not wait for the next routine Ayurvedic follow-up.

Go Directly to Hospital for Emergency Warning Signs

Sudden severe breathlessness, chest pain, coughing blood, fainting, severe confusion, bluish lips, inability to speak because of respiratory distress, uncontrolled bleeding or rapidly declining consciousness requires emergency care.

The patient should not first request a medicine adjustment through an online consultation.

What a Written Monitoring Plan Should Contain

A complete monitoring plan should state the date and findings of the latest scan, the expected next oncology review, the laboratory investigations required, the symptoms and functions being followed, and the purpose of every Ayurvedic intervention.

It should explain who is responsible for interpreting scans, who is responsible for oncology-treatment safety, who manages pleural procedures and who reviews complementary medicines.

The plan should identify the baseline value for each selected outcome and the time at which it will be reassessed.

It should also state the laboratory and symptom criteria for continuing, adjusting, withholding or stopping treatment.

The patient and caregiver should receive understandable emergency instructions in the language they use at home.

Request a Scan, Laboratory and Treatment-Safety Review

A monitoring-focused review is appropriate when a patient is receiving Ayurveda alongside chemotherapy or immunotherapy, when several supplements are being taken, when laboratory values are changing or when the family is uncertain how to interpret a scan report.

The review should include the histopathology and immunohistochemistry report, complete latest and previous scan reports, original imaging access where possible, current oncology prescription, pleural-procedure history, recent complete blood count, kidney function, liver function, electrolytes, symptom record and complete list of medicines and supplements.

The purpose is not to reinterpret the scan independently of the oncology team.

The purpose is to create one coordinated monitoring plan that distinguishes disease status, treatment safety, symptom relief, nutritional recovery and functional change.

A treatment that cannot be monitored cannot be responsibly personalised.

What Outcomes May Realistically Be Evaluated?

When surgery is not possible, the success of treatment cannot be judged through one question alone.

A patient may experience less breathlessness without measurable tumour shrinkage. Another may have stable disease on imaging but continue to lose muscle and independence. A third may tolerate oncology treatment better even though appetite and fatigue remain difficult. A fourth may prioritise comfort, sleep and the ability to remain at home rather than pursuing an intensive treatment schedule.

For this reason, outcomes should be evaluated across several separate domains. These include disease control, pleural-fluid management, symptom relief, nutritional stability, muscle and functional preservation, treatment tolerance, laboratory safety, quality of life and achievement of the patient’s own care goals.

These outcomes must not be combined into one vague claim such as “the patient improved.”

Before treatment begins, the clinician should define what improvement is being sought, how it will be measured, when it will be reviewed and which member of the healthcare team is responsible for interpreting it.

Treatment Success Has More Than One Meaning

Disease-control success refers to the behaviour of the mesothelioma itself. It may include a partial radiological response, stable disease, delayed progression or prolonged survival. These outcomes are assessed by the oncology team using imaging, clinical examination and recognised response criteria.

Pleural-management success refers to control of recurrent pleural fluid and its consequences. It may include relief after drainage, a longer interval between drainage procedures, successful pleurodesis, manageable home catheter drainage or fewer hospital visits.

Symptom-control success refers to changes in breathlessness, pain, cough, fatigue, nausea, appetite, sleep, constipation, anxiety and other problems affecting daily life.

Functional-recovery success refers to the patient’s ability to eat, walk, rise from a chair, bathe, dress, attend appointments and remain as independent as possible.

Treatment-tolerance success refers to whether prescribed oncology treatment can be given with acceptable toxicity and whether complications are identified promptly.

Quality-of-life success refers to the patient’s sense of physical, emotional, social and practical well-being. The National Cancer Institute describes quality of life in terms of well-being and the ability to carry out activities of daily living. (Cancer.gov)

These outcomes may move in different directions. A responsible clinical report should show each one separately.

Disease-Control Outcomes

Complete Response, Partial Response, Stable Disease and Progressive Disease

Radiological disease outcomes are generally described as complete response, partial response, stable disease or progressive disease.

Pleural mesothelioma grows in an irregular pattern along pleural surfaces and is more difficult to measure than a single spherical tumour. Mesothelioma-specific modified RECIST criteria were developed to improve the consistency of tumour measurement and response classification [20]. (PubMed)

A complete response means that measurable disease has disappeared according to the applicable radiological criteria. It should never be declared on the basis of symptom relief, improved appetite, a normal blood test or reduction of pleural fluid after drainage.

A partial response means that measurable tumour burden has reduced sufficiently to meet the defined radiological threshold.

Stable disease means that tumour measurements have not changed enough to qualify as either a partial response or progression.

Progressive disease means that recognised evidence of tumour growth or new disease has developed.

These categories must be assigned by the oncology and radiology teams. RECIST terminology is based on whether measurable tumours shrink, remain sufficiently unchanged or become larger. (Cancer.gov)

An Ayurvedic practitioner should not reinterpret a radiology report independently or replace the oncologist’s response classification with promotional terms such as “near cure,” “biological reversal,” “detoxification response” or “healing progression.”

Stable Disease Can Be a Meaningful Outcome

Patients often assume that treatment has failed unless the tumour becomes smaller.

In an aggressive malignancy, stable disease may represent a meaningful period during which measurable progression has not occurred. Its value depends on how long stability continues, whether symptoms remain manageable, whether treatment toxicity is acceptable and whether the patient retains useful function.

Stable disease should not be represented as cure. It does not mean that malignant cells have disappeared.

At the same time, it should not be dismissed as “no benefit” when the intended oncology objective was disease control rather than complete eradication.

Duration of Response Matters

A scan showing improvement at one time point is not the complete outcome.

The oncology team may also consider how long the response continues, whether the response is confirmed on subsequent imaging and whether new disease appears elsewhere.

A short-lived reduction followed by rapid progression has a different clinical meaning from a sustained response accompanied by preserved function.

This is why isolated before-and-after scan images should not be used as proof of treatment success without the complete imaging timeline, concurrent oncology treatment and subsequent follow-up.

Progression-Free Survival

Progression-free survival refers to the length of time during and after treatment that a patient lives without the disease becoming worse. It is commonly used as a clinical-trial endpoint and is not the same as cure [5, 6]. (Cancer.gov)

Progression-free survival is generally evaluated across groups of patients in clinical studies. It cannot be promised to an individual patient before treatment begins.

A single clinic may record how long a particular patient remained without documented progression, but it cannot claim that an Ayurvedic intervention prolonged progression-free survival without an appropriately designed comparative study.

Overall Survival

Overall survival describes survival from a defined starting point, regardless of the cause of death. In clinical studies, it may be reported as median survival or the proportion of patients alive at a specified time. (Cancer.gov)

Overall survival is influenced by numerous factors, including disease stage, histological subtype, general health, oncology treatment, treatment response, complications and supportive care.

No responsible clinician should promise a specific survival period for an individual patient.

Similarly, a long-surviving individual case should not be used as proof that one complementary treatment extends survival. Exceptional outcomes may occur for several reasons and require cautious interpretation.

Oncology Treatment Must Be Considered When Interpreting Tumour Response

When a patient is receiving chemotherapy, immunotherapy or another tumour-directed treatment, any radiological response must first be interpreted in the context of that treatment.

Nivolumab plus ipilimumab and chemotherapy-based combinations have demonstrated disease-control and survival outcomes in clinical trials involving eligible patients with unresectable pleural mesothelioma [5, 6]. A response occurring during such treatment cannot automatically be attributed to an Ayurvedic medicine added at the same time. (ASCO Publications)

The accurate statement may be that the patient experienced a response while receiving oncology treatment together with supportive Ayurvedic care.

The inaccurate statement would be that Ayurveda caused the tumour to shrink merely because both treatments were being used when the scan changed.

Pleural-Effusion Outcomes

Relief After Drainage Is a Pleural Outcome

When pleural fluid is contributing significantly to breathlessness, drainage may provide noticeable relief.

The response can be evaluated through breathlessness before and after drainage, ability to lie down, walking tolerance, sleep, meal completion and oxygen requirements where relevant.

Improvement after thoracentesis or catheter drainage should be documented as a response to pleural-fluid management.

It should not be attributed to an Ayurvedic formulation simply because Ayurvedic treatment was being taken at the same time.

Frequency of Fluid Recurrence

The interval between drainage procedures may be clinically useful.

A longer interval may reduce procedural burden and hospital travel. However, the interval can be influenced by pleurodesis, drainage strategy, systemic cancer treatment, catheter function, disease behaviour and the patient’s overall fluid balance.

A change in drainage frequency should therefore be interpreted by the pleural team.

It should not be assumed that reduced drainage volume proves that a herbal medicine has permanently stopped fluid production.

Pleurodesis Outcome

The outcome of pleurodesis may be evaluated through recurrence of symptomatic fluid, need for repeat pleural procedures, imaging findings, symptom relief and the patient’s subsequent hospital burden.

Successful pleurodesis does not mean that the mesothelioma has been cured. Its purpose is to reduce recurrent accumulation of pleural fluid.

Indwelling Pleural Catheter Outcome

For a patient with an indwelling pleural catheter, meaningful outcomes may include manageable home drainage, reliable symptom relief, reduced need for hospital procedures and absence of catheter infection or blockage.

The patient’s drainage record may show volume, appearance, frequency, pain, breathlessness before and after drainage and catheter-site condition.

A gradual decline in output may occur with reduced fluid production or spontaneous pleural adhesion. It may also result from catheter blockage or loculation.

The pleural team must determine which explanation is correct.

Hospital Days and Procedure Burden

A treatment strategy may be valuable when it reduces hospital days, repeated invasive procedures or disruption to family life without increasing complications.

Randomised studies comparing indwelling pleural catheters with talc pleurodesis have evaluated outcomes such as breathlessness, repeat procedures, quality of life and hospitalisation [9, 10].

These are practical patient-centred outcomes even when neither strategy changes the underlying cancer directly.

What Pleural Outcomes Do Not Prove

Reduced pleural drainage does not automatically prove tumour shrinkage.

A normal chest examination does not establish complete response.

Improved breathing after drainage does not prove that a complementary medicine eliminated malignant cells.

Pleural and tumour outcomes must remain separate.

Breathlessness Outcomes

Breathlessness Should Be Measured in Real-Life Situations

Breathlessness should not be evaluated only while the patient is seated quietly in the consultation room.

The clinician should determine whether breathlessness occurs during speech, meals, bathing, dressing, walking, climbing steps, lying flat and sleep.

A consistent numerical or verbal scale may be used over time. The same scale and activity should be repeated whenever possible.

The record may also document the number of pillows required for sleep, walking distance, recovery time after activity and whether the patient can speak a complete sentence without interruption.

Breathlessness at Rest and During Activity Are Different Outcomes

A patient may have comfortable breathing at rest but severe breathlessness during minimal activity.

Another may remain breathless at rest despite pleural drainage.

These patients do not have the same functional outcome.

Improvement should therefore specify the setting. A statement such as “breathlessness improved from severe at rest to mild at rest but remained moderate during walking” is more useful than “breathing is better.”

Oxygen Saturation Is Not the Same as Breathlessness

A patient may feel significantly breathless despite having an oxygen saturation that is not severely reduced.

Conversely, oxygen saturation may fall during activity even when resting readings appear acceptable.

Oxygen measurements should be interpreted by the medical team together with symptoms, respiratory examination and the underlying cause.

An improvement in oxygen saturation should not be attributed to Ayurveda unless other causes and treatments have been considered.

Patient-Reported Breathlessness Is a Valid Outcome

The patient’s own report is essential because breathlessness is a subjective experience.

Patient-reported outcomes provide information directly from the patient about symptoms and the effect of disease and treatment on physical, mental, emotional, social and spiritual well-being. (Cancer.gov)

The NCI PRO-CTCAE system evaluates symptomatic toxicities through patient report and can describe dimensions such as frequency, severity and interference with activities [22]. (healthcaredelivery.cancer.gov)

A practical clinical record does not need to reproduce an entire research questionnaire, but it should use clear and consistent questions.

Pain and Cough Outcomes

Pain Should Be Evaluated Beyond Intensity

Pain assessment should include location, severity, duration, triggers, effect on breathing, effect on sleep, movement limitation and use of rescue medication.

A lower pain score may be clinically meaningful when it allows the patient to sleep, walk or breathe more comfortably.

However, sudden new chest, back or bone pain requires medical assessment. It should not be treated solely by increasing an Ayurvedic analgesic formulation.

Reduced Analgesic Use Is Not Always the Primary Goal

Patients sometimes regard taking fewer pain medicines as evidence of recovery.

The more important outcome is adequate pain control with acceptable safety and alertness.

Reducing prescribed analgesia is not a success when the patient becomes more distressed, immobile or unable to breathe deeply because of pain.

Any change in opioid or other prescribed pain medicine should be coordinated with the oncology or palliative-care team.

Cough Should Be Characterised

Cough may be dry, productive, painful, nocturnal, meal-related or associated with blood.

Outcome monitoring should record frequency, severity, sleep disturbance, sputum and relationship to activity or pleural drainage.

Coughing blood is not a routine outcome for Ayurvedic adjustment. It requires urgent medical evaluation.

Appetite and Digestive Outcomes

Appetite Improvement Must Lead to Actual Intake

An intervention should not be considered successful merely because the patient reports feeling hungry.

The clinically meaningful question is whether the patient can eat and retain adequate food.

Outcome monitoring may include the proportion of meals completed, number of meals or snacks, protein-containing foods, use of oral nutritional supplements, nausea, early satiety and breathlessness during eating.

A patient who feels hungry but manages only a few mouthfuls remains nutritionally vulnerable.

Agni Outcomes Should Be Defined Clinically

Ayurvedic treatment may aim to support Agni, but the term should be translated into measurable clinical changes.

These may include appetite appearing at appropriate meal times, improved meal completion, less nausea, less abdominal discomfort, more predictable digestion and absence of treatment-induced diarrhoea or burning.

An intervention should not be declared successful because the clinician believes Agni has improved while the patient continues to lose weight and eat very little.

Bowel Outcomes

Bowel function may be evaluated through frequency, consistency, ease of passage, abdominal distension, pain and need for rescue laxatives.

The desired outcome is comfortable, predictable bowel function without diarrhoea, dehydration or electrolyte disturbance.

Repeated purgation is not evidence of cleansing or Samprapti-Vighatana.

New severe diarrhoea during immunotherapy may represent an immune-related adverse effect and requires oncology assessment.

Nausea and Vomiting Outcomes

The record should distinguish nausea from vomiting and document frequency, triggers, relationship to treatment, effect on intake and ability to retain fluids and medicines.

Reduced nausea is meaningful when it allows better hydration, food intake and treatment adherence.

Persistent vomiting, inability to drink or signs of dehydration require medical review and should not be managed by repeatedly changing herbal preparations.

Weight and Nutritional Outcomes

Stopping Rapid Weight Loss May Be an Important Success

In a patient losing weight rapidly, the first realistic outcome may be stabilisation rather than immediate weight gain.

A stable weight over a defined period may be clinically valuable when food intake and function are also stable.

However, weight must be interpreted with pleural drainage, oedema and hydration.

An increase on the weighing scale may represent pleural fluid or swelling rather than nutritional recovery.

Weight Gain Is Not Automatically Muscle Gain

Body weight may increase through fluid, fat, gastrointestinal contents or muscle.

The treatment objective should therefore not be limited to kilograms.

Muscle strength, mobility, meal intake and body-composition information should be considered where available.

A patient who gains two kilograms while becoming weaker and more oedematous has not necessarily achieved successful Brimhana.

Food Intake Is an Outcome in Its Own Right

Meal completion can improve before visible weight or muscle changes occur.

A patient who increases from consuming approximately one quarter of meals to three quarters of meals may have achieved a meaningful early nutritional outcome.

The record should also show whether intake is nutritionally adequate and whether the change is maintained.

Laboratory Nutrition Markers Require Caution

Albumin may contribute to the overall clinical assessment but is influenced by inflammation, liver function, kidney loss and fluid distribution.

A rise in albumin does not prove that muscle has been rebuilt.

A normal albumin does not exclude sarcopenia.

Laboratory findings should be interpreted together with food intake, weight history, oedema, muscle function and systemic inflammation.

Muscle and Functional Outcomes

Strength Should Be Measured Through a Repeatable Activity

A treatment described as Balya should be linked to a specific functional outcome.

The patient may be assessed through handgrip strength, chair-rise ability, walking distance, transfer from bed to chair or ability to climb a small number of steps.

The same activity should be repeated under comparable conditions.

The goal should be selected according to the patient’s baseline capacity and safety.

Activities of Daily Living Are Clinically Meaningful

Functional outcomes may include the ability to bathe, dress, use the toilet, prepare food, eat independently, attend medical appointments or move safely within the home.

For a severely frail patient, reducing the assistance needed for one daily activity may represent a meaningful improvement.

For another patient, maintaining current independence may itself be a successful outcome.

Performance Status

The oncology team may use a recognised performance-status scale to describe how illness affects ordinary activity and self-care.

Performance status influences treatment selection, prognosis and interpretation of functional decline.

Ayurvedic practitioners may record changes in activity and Bala, but should avoid independently altering an oncology performance-status classification without adequate assessment.

Mobility Improvement Must Not Be Achieved Through Unsafe Exertion

Greater walking distance may be a useful outcome when it occurs without severe breathlessness, chest pain, dizziness or prolonged exhaustion.

Exercise should not be intensified solely to create a more impressive measurement.

The purpose is safe preservation of function, not performance testing beyond the patient’s cardiopulmonary reserve.

Treatment-Tolerance Outcomes

Completing Oncology Treatment Is Not the Only Measure

Treatment tolerance may be evaluated through the number of cycles completed, dose delays, dose reductions, hospital admissions, infections, severe adverse effects and the patient’s reported experience.

However, completing every planned cycle is not always the correct outcome. The oncology team may appropriately modify or stop treatment because of toxicity, progression or changing goals.

Ayurveda should not be promoted as a method that guarantees completion of chemotherapy or immunotherapy.

Fewer Symptoms Do Not Prove Prevention of Toxicity

A patient may experience less nausea, better bowel function or improved sleep during a later treatment cycle.

This may result from changes in antiemetic treatment, dose modification, natural variation, dietary support, Ayurvedic intervention or several factors together.

Without a controlled comparison, it is not scientifically valid to claim that Ayurveda prevented chemotherapy toxicity.

The accurate statement is that selected symptoms improved during coordinated supportive care.

Laboratory Tolerance

Stable blood counts, kidney function, liver function and electrolytes may allow treatment to continue safely.

These are important outcomes, but their meaning should be interpreted by the oncology team.

An Ayurvedic formulation should not be credited with protecting the liver or kidneys merely because laboratory values remained within range.

To support such a claim, appropriate clinical evidence would be required.

Hospitalisation and Emergency Visits

A reduction in avoidable hospital visits may be meaningful when the patient’s condition remains safe.

However, fewer hospital visits should never be achieved by discouraging the patient from seeking care when warning signs occur.

A patient who remains at home during severe infection or respiratory deterioration has not achieved a positive outcome.

Adverse Effects of Ayurvedic Treatment Must Also Be Counted

Safety reporting should include nausea, diarrhoea, rash, sedation, bleeding, allergic reactions, liver injury, renal deterioration and any other problem occurring after an Ayurvedic product is introduced.

Adverse effects should not be omitted from case reports or explained automatically as detoxification.

A treatment with modest benefit and significant toxicity may not be clinically worthwhile.

Quality-of-Life Outcomes

Quality of Life Is Broader Than Symptom Scores

Quality of life includes physical function, emotional well-being, social participation, independence, sleep, family relationships and the ability to engage in activities the patient values.

A patient may prioritise eating with family, praying comfortably, sleeping without panic, attending a family event or remaining at home.

These are legitimate treatment outcomes when they are defined before treatment and assessed honestly.

Mesothelioma-Specific Quality-of-Life Assessment

The EORTC QLQ-C30 and lung cancer symptom module have been evaluated as quality-of-life measures in patients receiving chemotherapy for pleural mesothelioma [21]. (PubMed)

A clinical service may use an appropriate validated questionnaire or a shorter consistent patient-reported record.

The purpose is not to generate a high score for marketing. It is to understand how disease and treatment affect the patient’s daily life.

Patient-Defined Goals Should Be Documented

The patient should be asked what meaningful improvement would look like.

For one person, the goal may be walking independently to the bathroom. For another, it may be completing an oncology cycle without uncontrolled constipation. Another may prioritise relief of night-time breathlessness or the ability to eat a full breakfast.

The goal should be specific enough to reassess.

The statement “I want to feel better” can be translated into a measurable objective through careful discussion.

Caregiver Outcomes May Also Matter

Caregiver burden can increase when the patient requires frequent night-time assistance, repeated travel, complex medicine schedules or help with every activity.

A simpler treatment schedule, improved sleep or safer mobility may reduce caregiver strain.

However, caregiver convenience should not override the patient’s own preferences, comfort or safety.

Palliative and Comfort-Focused Outcomes

Comfort Is a Legitimate Clinical Outcome

When tumour-directed treatment is unsuitable, no longer effective or not desired, care may focus primarily on comfort.

Meaningful outcomes may include less breathlessness, better pain control, peaceful sleep, reduced fear, manageable bowel function, fewer burdensome interventions and the ability to remain in the preferred place of care.

Early palliative care can be provided alongside active oncology treatment and may address physical, psychological, social and caregiver needs [14].

Comfort-focused care should not be described as “doing nothing.”

Reduced Treatment Burden May Be an Outcome

A complex schedule of medicines, diets and procedures may become burdensome for a frail patient.

Simplifying treatment while maintaining symptom control may improve quality of life.

Ayurvedic care should not add multiple decoctions, powders and procedures merely to make the plan appear comprehensive.

The minimum effective treatment burden may be the most personalised approach.

Dignity and Communication

The patient’s ability to understand choices, participate in decisions and express preferences is part of quality care.

An outcome plan should therefore consider not only physical symptoms but also fear, uncertainty, spiritual priorities and family communication.

For Gulf patients, important information should be available in the language understood by the patient and caregiver.

Ayurvedic Outcomes That May Be Evaluated

Agni

Agni-related outcomes may include improved appetite at mealtime, greater food intake, less nausea, reduced abdominal discomfort, better tolerance of nourishment and more predictable digestion.

Agni improvement should not be declared when the patient remains unable to meet nutritional needs.

Ahara Shakti

Ahara Shakti can be considered through the patient’s ability to take an adequate quantity of food and digest it without significant distress.

The outcome may be measured through meal completion, food variety, nausea, early satiety and maintenance of intake between oncology cycles.

Koshta and Mala Pravritti

Koshta-related assessment may help individualise bowel management.

A successful outcome is comfortable and regular elimination without straining, severe urgency, diarrhoea or dependence on increasingly strong purgatives.

Nidra

Sleep outcomes may include total sleep duration, number of awakenings, reason for awakening, ability to return to sleep and morning alertness.

A sedating medicine should not be judged successful when the patient sleeps longer but becomes confused, falls or remains excessively drowsy during the day.

Bala

Bala should be linked to functional capacity.

Relevant outcomes may include walking tolerance, ability to rise from a chair, meal completion, participation in self-care and recovery after activity.

Bala should not remain an undefined promotional term.

Mamsa and Pushti

Mamsa and Pushti outcomes may include stabilisation of muscle loss, improved grip, safer transfers, maintenance of posture and reduced dependence during daily activities.

Weight gain alone is insufficient because pleural fluid and oedema may alter the scale.

Sattva and Manas

Mental and emotional outcomes may include reduced panic, better engagement with treatment, improved sleep, clearer decision-making and reduced distress.

Severe confusion, new agitation or altered consciousness is not a routine Sattva disturbance. It requires medical assessment.

Pranavaha Comfort

Ayurvedic supportive care may aim to reduce the distress accompanying breathlessness through calm routines, positioning, bowel management, sleep support and gentle non-forceful breathing awareness.

The outcome should be expressed as symptom relief or improved function.

It should not be described as reopening the lung or removing malignant pleural fluid.

Samprapti-Vighatana Outcome

The outcome of Samprapti-Vighatana may be considered through reduction of the active cycle linking poor intake, constipation, sleep loss, anxiety, deconditioning and declining Bala.

It is not established by claiming that the tumour’s Samprapti has been destroyed.

A successful supportive plan should show what part of the functional cycle changed and how that change was measured.

Classical Ayurvedic Framework for Evaluating Outcomes

Dhatu-Samya Is the Therapeutic Direction

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Sūtra Sthāna, Chapter 1, Dīrghañjīvitīya Adhyāya, verse 53. Article classical reference [38].

Sanskrit

इत्युक्तं कारणं कार्यं धातुसाम्यमिहोच्यते ।
धातुसाम्यक्रिया चोक्ता तन्त्रस्यास्य प्रयोजनम् ॥५३॥

Roman Transliteration

ityuktaṃ kāraṇaṃ kāryaṃ dhātusāmyam ihocyate |
dhātusāmyakriyā coktā tantrasyāsya prayojanam || 53 ||

English Translation

The intended therapeutic result is Dhatu-Samya, a balanced state of the sustaining and nourishing constituents. The purpose of this medical compendium is directed toward establishing that balance.

Urdu Translation

علاج کا مطلوبہ نتیجہ دھاتو سامیہ، یعنی جسم کو برقرار رکھنے اور غذائیت دینے والے عناصر کا متوازن ہونا ہے۔ اس طبی علم کا مقصد اسی توازن کے قیام کی طرف علاج کو منظم کرنا ہے۔

Arabic Translation

النتيجة العلاجية المقصودة هي دهاتو ساميا، أي اتزان المكوّنات التي تحفظ الجسم وتغذّيه. ويتمثل مقصد هذا العلم الطبي في توجيه العلاج نحو استعادة ذلك الاتزان.

This verse identifies Dhatu-Samya as a therapeutic direction rather than a marketing claim of cure. (Charak Samhita)

In advanced pleural mesothelioma, absolute restoration of all physiological balance may not be achievable. A realistic application may involve reducing avoidable disturbance, preserving nourishment, supporting function and preventing treatment from further weakening the patient.

Dhatu-Samya should not be equated with a complete radiological response.

Health and Disease Are Distinguished by Balance and Suffering

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Sūtra Sthāna, Chapter 9, Khuḍḍākacatuṣpāda Adhyāya, verse 4. Article classical reference [39].

Sanskrit

विकारो धातुवैषम्यं साम्यं प्रकृतिरुच्यते ।
सुखसञ्ज्ञकमारोग्यं विकारो दुःखमेव च ॥४॥

Roman Transliteration

vikāro dhātuvaiṣamyaṃ sāmyaṃ prakṛtir ucyate |
sukhasañjñakam ārogyaṃ vikāro duḥkham eva ca || 4 ||

English Translation

Disequilibrium of the sustaining bodily constituents is described as disorder, while their balanced state is regarded as the natural state. Health is associated with well-being, whereas disorder is associated with suffering.

Urdu Translation

جسم کو برقرار رکھنے والے عناصر کا عدم توازن وِکار یعنی بیماری ہے، جبکہ ان کا توازن فطری حالت سمجھا جاتا ہے۔ آروگیہ یا صحت کا تعلق سکون اور خیر و عافیت سے ہے، جبکہ بیماری کا تعلق تکلیف سے ہے۔

Arabic Translation

يُوصَف اختلال توازن مكوّنات الجسم الحافظة بأنه اضطراب، بينما يُعَدّ اتزانها الحالة الطبيعية. وترتبط الصحة بالعافية والراحة، في حين يرتبط المرض بالمعاناة.

The verse supports evaluating whether treatment reduces suffering and restores a more stable state. (Charak Samhita)

It does not imply that subjective comfort alone is sufficient to establish control of a malignant tumour.

A patient may experience Sukha through relief of breathlessness or pain while the disease remains radiologically stable or progressive. Both outcomes should be reported truthfully.

Karyaphala Includes Satisfaction of Mind, Intellect, Senses and Body

Classical Source

Charaka Saṃhitā of Agniveśa, redacted by Charaka, Vimāna Sthāna, Chapter 8, Rogabhiṣagjitīya Vimāna Adhyāya, passage 90. Article classical reference [32].

Sanskrit

कार्यफलं सुखावाप्तिः, तस्य लक्षणं मनोबुद्धीन्द्रियशरीरतुष्टिः ॥९०॥

Roman Transliteration

kāryaphalaṃ sukhāvāptiḥ, tasya lakṣaṇaṃ manobuddhīndriyaśarīratuṣṭiḥ || 90 ||

English Translation

The outcome of therapeutic action is the attainment of well-being, recognised through satisfaction or comfort of the mind, intellect, senses and body.

Urdu Translation

علاجی عمل کا نتیجہ خیر و عافیت اور سکون کا حصول ہے، جس کی پہچان ذہن، عقل، حواس اور جسم کے اطمینان اور آرام سے ہوتی ہے۔

Arabic Translation

تتمثل ثمرة العمل العلاجي في بلوغ العافية والراحة، ويُستدل عليها براحة العقل والإدراك والحواس والجسد ورضاها.

This passage gives a patient-centred dimension to treatment outcome. (Charak Samhita)

In modern supportive oncology, it may correspond conceptually to symptom relief, quality of life, mental clarity, physical comfort and the ability to engage in meaningful daily activity.

It should not be used to replace tumour-response assessment or survival data.

Sushruta’s Multidimensional Description of Health

Classical Source

Suśruta Saṃhitā, Sūtra Sthāna, Chapter 15, Doṣa-Dhātu-Mala-Kṣaya-Vṛddhi-Vijñānīya Adhyāya, verse 41. Article classical reference [41].

Sanskrit

समदोषः समाग्निश्च समधातुमलक्रियः ।
प्रसन्नात्मेन्द्रियमनाः स्वस्थ इत्यभिधीयते ॥४१॥

Roman Transliteration

samadoṣaḥ samāgniś ca samadhātumalakriyaḥ |
prasannātmendriyamanāḥ svastha ity abhidhīyate || 41 ||

English Translation

A person is described as healthy when Dosha and Agni are balanced, the Dhatus and eliminative functions operate appropriately, and the inner self, senses and mind remain clear and content.

Urdu Translation

اس شخص کو صحت مند کہا جاتا ہے جس میں دوش اور اگنی متوازن ہوں، دھاتوں اور اخراجی افعال کی کارکردگی مناسب ہو، اور آتما، حواس اور ذہن مطمئن اور صاف حالت میں ہوں۔

Arabic Translation

يُوصَف الشخص بأنه سليم الصحة عندما تكون الدوشات والأغني في حالة اتزان، وتعمل الأنسجة ووظائف الإخراج بصورة مناسبة، ويكون الأتمان والحواس والعقل في صفاء وطمأنينة.

The verse describes health through several interdependent domains rather than through one symptom or laboratory value. (Easy Ayurveda Hospital)

In a patient with advanced cancer, the verse should not be used to demand an idealised state that may be impossible to achieve. Its practical value is that outcomes should include digestion, tissue status, elimination, mental well-being and physical comfort—not tumour measurements alone.

Early, Intermediate and Longer-Term Outcomes

Early Outcomes

Early supportive outcomes may become visible before the next oncology scan.

These may include improved bowel regularity, reduced nausea, better sleep, increased meal completion, less panic during breathlessness or improved tolerance of a medicine.

Early symptom improvement should be documented but should not be converted into a tumour-response claim.

Intermediate Outcomes

Over a longer period, the plan may assess weight trend, food intake, grip strength, chair-rise ability, walking tolerance, caregiver dependence and treatment interruptions.

The review period should be determined according to the patient’s condition, oncology schedule and the intervention being evaluated.

A severely unstable patient requires more frequent assessment than a medically stable patient receiving a simple supportive measure.

Disease Outcomes Follow the Oncology Imaging Schedule

Tumour response cannot be evaluated reliably after only a few days of supportive treatment.

Disease outcomes should follow the scan schedule and response interpretation determined by the oncology team.

An Ayurvedic clinic should not promise a scan response within a fixed number of weeks.

Goals May Change Over Time

A patient’s priorities may change when disease progresses, treatment toxicity develops or function declines.

An initial goal of completing systemic treatment may later become a goal of remaining comfortable at home.

The outcome plan should therefore be reviewed rather than treated as a permanent contract.

Defining a Meaningful Improvement

Statistical Change and Clinical Meaning Are Not the Same

A small change in a score may be statistically detectable in research but may not matter to the individual patient.

Conversely, a modest change may be highly meaningful when it allows the patient to eat, sleep or walk safely.

The patient should therefore be asked whether the change has made a practical difference.

The Same Outcome Has Different Meaning for Different Patients

Walking an additional 100 metres may be meaningful for one patient.

For a severely frail patient, standing safely for one minute or transferring from bed to chair may be equally important.

The outcome should be matched to the patient’s baseline and goals.

Maintenance Can Be a Success

Not all meaningful outcomes involve improvement.

Preserving current mobility, preventing further weight loss, maintaining food intake or avoiding additional caregiver dependence may be valuable when the disease would otherwise be expected to cause decline.

The treatment plan should state clearly when maintenance is the intended outcome.

Honest Attribution of Outcomes

Timing Alone Does Not Prove Causation

An improvement occurring after treatment begins does not prove that the treatment caused it.

The patient may also have received pleural drainage, antiemetics, antibiotics, transfusion, analgesia, oncology treatment, nutrition counselling or natural recovery from a temporary adverse effect.

The clinician should reconstruct the treatment timeline before assigning cause.

The Strongest Attribution Belongs to the Most Direct Intervention

Relief occurring immediately after pleural drainage should primarily be attributed to drainage.

Improved haemoglobin after transfusion should primarily be attributed to transfusion.

Tumour shrinkage during effective systemic oncology treatment should primarily be interpreted in the context of that treatment.

An Ayurvedic intervention may still have contributed to appetite, sleep, bowel function or another supportive outcome, but its role should be described accurately.

Combined Improvement Should Be Described as Combined Care

When several interventions change simultaneously, the most truthful conclusion may be that improvement occurred during coordinated integrative care.

This language is more credible than assigning all benefit to one component without evidence.

A Case Report Is Not Proof of General Effectiveness

A carefully documented case may show that a particular outcome occurred in one patient.

It does not establish that the same outcome will occur in other patients or that the intervention caused the change.

A case report should disclose the diagnosis, stage, concurrent oncology treatment, pleural procedures, baseline condition, intervention dates, measured outcomes, adverse effects and follow-up.

What May Be Responsibly Reported

A responsible case statement may say that the patient’s breathlessness score improved after pleural drainage and coordinated supportive care.

It may report that meal completion increased, weight stabilised after accounting for pleural fluid and walking ability was maintained during systemic treatment.

It may report that imaging showed stable disease while the patient was receiving oncology treatment and complementary Ayurvedic care.

It may report that constipation, sleep or nausea improved after a specific supportive intervention, provided the measurement and treatment timeline are documented.

Such statements are transparent and clinically understandable.

What Must Not Be Promised

Ayurveda should not be promoted as a guaranteed cure for pleural mesothelioma.

It should not be claimed to permanently remove malignant pleural fluid, reopen a trapped lung, make every unresectable tumour operable, eliminate the need for oncology treatment or guarantee longer survival.

It should not be promised that chemotherapy or immunotherapy will have no adverse effects when Ayurvedic treatment is used.

A stable scan should not be advertised as complete tumour reversal.

An increase in body weight should not be presented as muscle restoration without accounting for pleural fluid and oedema.

Improved appetite, sleep or bowel function should not be presented as proof of tumour regression.

A single exceptional patient should not be used to guarantee the same result for others.

When the Outcome Shows That the Plan Should Change

No Meaningful Benefit

An intervention should be reconsidered when its predefined objective is not being achieved within a clinically reasonable review period.

A medicine should not be continued indefinitely because it is traditionally regarded as beneficial.

Lack of benefit should be documented honestly.

New Adverse Effects

The plan should change when new nausea, diarrhoea, rash, bleeding, sedation, jaundice, reduced urine or laboratory deterioration appears after a product is started.

A suspected adverse effect should not be treated as a healing crisis.

Disease Progression

Progression on imaging may require the oncology team to reconsider tumour-directed treatment.

Supportive Ayurveda may continue only when it remains safe, useful and consistent with the revised plan.

The Ayurvedic treatment should not be intensified automatically in an attempt to compete with radiological progression.

Functional Decline

A stable scan does not justify continuing the same supportive plan when the patient is losing weight, muscle and independence.

New functional decline should trigger assessment for infection, anaemia, treatment toxicity, malnutrition, pleural complications, pain, depression or disease progression.

Changing Patient Priorities

The plan should be revised when the patient’s goals change.

A patient may decide that the burden of treatment is no longer acceptable. Another may become sufficiently stable to pursue more active rehabilitation.

Respecting changing goals is part of personalised care.

اردو میں مریض اور خاندان کے لیے اہم وضاحت

علاج کے نتیجے کو صرف اسکین سے نہیں ناپا جاتا۔ رسولی کی کیفیت، پھیپھڑے کے اردگرد پانی، سانس، درد، بھوک، وزن، پٹھوں کی طاقت، نیند، پاخانے کی کیفیت، علاج برداشت کرنے کی صلاحیت اور روزمرہ زندگی سب الگ الگ نتائج ہیں۔

اگر سانس پانی نکالنے کے بعد بہتر ہو تو یہ پلورل ڈرینیج کا نتیجہ سمجھا جائے گا۔ اگر کیموتھراپی یا امیونوتھراپی کے دوران اسکین میں رسولی کم ہو تو اس نتیجے کو کینسر کے طبی علاج کے ساتھ سمجھنا ضروری ہے۔

آیورویدک علاج سے بھوک، ہاضمہ، قبض، نیند، روزمرہ معمول اور قوت میں مدد مل سکتی ہے، لیکن ان بہتریوں سے یہ ثابت نہیں ہوتا کہ رسولی ختم ہو گئی ہے۔

مناسب رپورٹ میں یہ واضح ہونا چاہیے کہ کون سا نتیجہ بہتر ہوا، اسے کیسے ناپا گیا، مریض ساتھ میں کون سا کینسر علاج لے رہا تھا اور کوئی نقصان یا ضمنی اثر تو نہیں ہوا۔

شرح مهم للمريض والأسرة باللغة العربية

لا يُقاس نجاح العلاج من خلال الصورة الشعاعية وحدها. فحالة الورم، والسائل الجنبي، وضيق النفس، والألم، والشهية، والوزن، وقوة العضلات، والنوم، وحركة الأمعاء، والقدرة على تحمل العلاج، والقيام بالأنشطة اليومية كلها نتائج مختلفة ينبغي تقييمها بصورة منفصلة.

إذا تحسن التنفس بعد تصريف السائل، فينبغي اعتبار ذلك نتيجة لإجراء التصريف الجنبي. وإذا تقلص الورم أثناء العلاج الكيميائي أو المناعي، فيجب تفسير النتيجة في سياق علاج السرطان المستخدم.

قد يساعد العلاج الأيورفيدي في الشهية والهضم والإمساك والنوم والروتين اليومي والقوة الوظيفية، لكن تحسن هذه الجوانب لا يثبت أن الورم قد اختفى.

ينبغي أن يوضح التقرير المسؤول ما الذي تحسن، وكيف تم قياسه، وما علاج السرطان الذي كان المريض يتلقاه بالتزامن، وما إذا ظهرت أي آثار ضارة.

What a Written Outcome Plan Should Contain

A written outcome plan should begin with the patient’s current condition.

It should document the latest oncology assessment, scan status, pleural-fluid pattern, breathlessness, pain, food intake, bowel function, sleep, weight interpreted with fluid status, muscle strength, mobility and laboratory safety.

The plan should define the principal disease-control objective and the principal supportive objectives.

Each added Ayurvedic intervention should have a specific purpose. The record should state whether it is intended to support appetite, bowel regularity, sleep, symptom comfort or another measurable outcome.

The plan should explain how the outcome will be measured, who will assess it and when it will be reviewed.

It should also specify which outcomes belong to oncology, which belong to pleural management and which may reasonably be evaluated as supportive Ayurvedic outcomes.

The document should include criteria for continuing, changing or stopping treatment.

It should also contain emergency escalation instructions that are understood by the patient and caregiver.

Request a Realistic-Outcome and Treatment-Goal Review

A realistic-outcome review is appropriate when the patient and family are uncertain about what treatment can reasonably achieve after surgery has been excluded.

The review should include the histopathology and immunohistochemistry report, latest and previous imaging, current oncology treatment, pleural-procedure history, symptom record, weight and functional history, recent laboratory investigations and the complete list of medicines and supplements.

The purpose is to establish a transparent outcome framework before treatment begins.

The review should distinguish tumour response from pleural control, symptom relief, nutritional recovery, functional preservation and treatment safety.

A trustworthy treatment plan does not promise every possible improvement.

It defines which outcomes matter to this patient, measures them consistently and reports the results honestly.

Frequently Asked Question

References

[1] Kindler, H. L., Ismaila, N., Bazhenova, L., Chu, Q., Churpek, J. E., Dagogo-Jack, I., Bryan, D. S., Drazer, M. W., Forde, P., Husain, A. N., Sauter, J. L., Rusch, V., Bradbury, P. A., Cho, B. C., de Perrot, M., Ghafoor, A., Graham, D. L., Khorshid, O., Lebensohn, A., White, J., & Hassan, R. (2025). Treatment of pleural mesothelioma: ASCO guideline update. Journal of Clinical Oncology, 43(8), 1006–1038. https://pubmed.ncbi.nlm.nih.gov/39778125/

Used for: Contemporary recommendations on surgical selection, unresectable pleural mesothelioma, immunotherapy, chemotherapy, pathological classification, germline testing and multidisciplinary decision-making. (PubMed)

[2] Popat, S., Baas, P., Faivre-Finn, C., Girard, N., Nicholson, A. G., Nowak, A. K., Opitz, I., Scherpereel, A., & Reck, M. (2022). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 33(2), 129–142. https://www.annalsofoncology.org/article/S0923-7534(21)04820-1/fulltext

Used for: Diagnosis, staging, surgical assessment, systemic therapy, radiotherapy, follow-up and multidisciplinary management of pleural mesothelioma. (Annals of Oncology)

[3] PDQ Adult Treatment Editorial Board. (2025). Malignant mesothelioma treatment: Health professional version. National Cancer Institute. https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq

Used for: Mesothelioma staging, prognostic factors, technical unresectability, systemic treatment, pleural procedures, radiotherapy and symptom-directed care. (Cancer.gov)

[4] Lim, E., Waller, D., Lau, K., Steele, J., Pope, A., Ali, C., Bilancia, R., Keni, M., Popat, S., O’Brien, M., Tokaca, N., Maskell, N., Fennell, D., Edwards, J., Rintoul, R. C., & MARS 2 Investigators. (2024). Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma: A phase 3 randomised controlled trial. The Lancet Respiratory Medicine, 12(6), 457–466. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00119-X/fulltext

Used for: Benefits, risks and limitations of extended pleurectomy-decortication and the importance of specialist surgical selection. (The Lancet)

[5] Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., Oulkhouir, Y., Bautista, Y., Cornelissen, R., Greillier, L., Grossi, F., Kowalski, D., Rodríguez-Cid, J., Aanur, P., Baudelet, C., Zalcman, G., & CheckMate 743 Investigators. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma: A multicentre, randomised, open-label, phase 3 trial. The Lancet, 397(10272), 375–386. https://pubmed.ncbi.nlm.nih.gov/33485464/

Used for: Evidence supporting nivolumab plus ipilimumab as a first-line disease-control option for eligible patients with unresectable pleural mesothelioma.

[6] Chu, Q., Perrone, F., Greillier, L., Tu, W., Planchard, D., Jahan, T., Greco, M., Morabito, A., Curioni-Fontecedro, A., Leighl, N. B., et al. (2023). Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: A phase 3, open-label, randomised controlled trial. The Lancet, 402(10419), 2295–2306. https://pubmed.ncbi.nlm.nih.gov/37931632/

Used for: Evidence concerning pembrolizumab combined with platinum-pemetrexed chemotherapy in advanced pleural mesothelioma and interpretation of treatment response during combined care.

[7] Roberts, M. E., Rahman, N. M., Maskell, N. A., Bibby, A. C., Blyth, K. G., Corcoran, J. P., Edey, A., Evison, M., de Fonseka, D., Hallifax, R., et al. (2023). British Thoracic Society guideline for pleural disease. Thorax, 78(11), 1143–1156. https://pubmed.ncbi.nlm.nih.gov/37553157/

Used for: Investigation and management of pleural effusion, pleural malignancy, pleurodesis, indwelling pleural catheters and non-expandable lung.

[8] Feller-Kopman, D. J., Reddy, C. B., DeCamp, M. M., Diekemper, R. L., Gould, M. K., Henry, T., Iyer, N. P., Lee, Y. C. G., Lewis, S. Z., Maskell, N. A., Rahman, N. M., Sterman, D. H., Wahidi, M. M., & Balekian, A. A. (2018). Management of malignant pleural effusions: An official ATS/STS/STR clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 198(7), 839–849. https://pubmed.ncbi.nlm.nih.gov/30272503/

Used for: Thoracentesis, pleurodesis, indwelling pleural catheters, non-expandable lung and management of symptomatic malignant pleural effusion.

[9] Davies, H. E., Mishra, E. K., Kahan, B. C., Wrightson, J. M., Stanton, A. E., Guhan, A., Davies, C. W. H., Grayez, J., Harrison, R., Prasad, A., Crosthwaite, N., Lee, Y. C. G., Davies, R. J. O., Miller, R. F., & Rahman, N. M. (2012). Effect of an indwelling pleural catheter versus chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA, 307(22), 2383–2389. https://pubmed.ncbi.nlm.nih.gov/22610520/

Used for: Comparison of indwelling pleural catheters and talc pleurodesis for relief of malignant-effusion-related breathlessness.

[10] Thomas, R., Fysh, E. T. H., Smith, N. A., Lee, P., Kwan, B. C. H., Yap, E., Horwood, F. C., Piccolo, F., Lam, D. C. L., Garske, L. A., Shrestha, R., Kosky, C., Read, C. A., Murray, K., & Lee, Y. C. G. (2017). Effect of an indwelling pleural catheter versus talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial. JAMA, 318(19), 1903–1912. https://pubmed.ncbi.nlm.nih.gov/29164255/

Used for: Hospitalisation, repeat pleural procedures, breathlessness and quality-of-life outcomes after catheter placement or talc pleurodesis.

[11] Hui, D., Bohlke, K., Bao, T., Campbell, T. C., Coyne, P. J., Currow, D. C., Gupta, A., Leiser, A. L., Mori, M., Nava, S., Reinke, L. F., Roeland, E. J., Seigel, C., Walsh, D., & Campbell, M. L. (2021). Management of dyspnea in advanced cancer: ASCO guideline. Journal of Clinical Oncology, 39(12), 1389–1411. https://pubmed.ncbi.nlm.nih.gov/33617290/

Used for: Assessment of reversible causes of breathlessness, fan therapy, positioning, breathing strategies, oxygen when indicated and palliative symptom treatment.

[12] Hui, D., Maddocks, M., Johnson, M. J., Ekström, M., Simon, S. T., Ogliari, A. C., Booth, S., & Ripamonti, C. I. (2020). Management of breathlessness in patients with cancer: ESMO Clinical Practice Guidelines. ESMO Open, 5(6), Article e001038. https://pmc.ncbi.nlm.nih.gov/articles/PMC7733213/

Used for: Cancer-related breathlessness assessment, non-pharmacological interventions, oxygen selection and palliative management.

[13] PDQ Supportive and Palliative Care Editorial Board. (2025). Cardiopulmonary syndromes: Health professional version. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/side-effects/cardiopulmonary-hp-pdq

Used for: Malignant pleural effusion, dyspnoea, thoracentesis, pleurodesis and supportive management of cardiopulmonary symptoms. (Cancer.gov)

[14] Sanders, J. J., Temin, S., Ghoshal, A., Alesi, E. R., Ali, Z. V., Chauhan, C., Cleary, J. F., Epstein, A. S., Firn, J. I., Jones, J. A., Litzow, M. R., Lundquist, D., Mardones, M. A., Nipp, R. D., Rabow, M. W., Rosa, W. E., Zimmermann, C., & Ferrell, B. R. (2024). Palliative care for patients with cancer: ASCO guideline update. Journal of Clinical Oncology, 42(19), 2336–2357. https://pubmed.ncbi.nlm.nih.gov/38748941/

Used for: Early palliative-care referral, symptom management, quality of life, caregiver support and care alongside active anticancer treatment.

[15] Muscaritoli, M., Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Hütterer, E., Isenring, E., Kaasa, S., Krznaric, Z., Laird, B., Larsson, M., Laviano, A., Mühlebach, S., Oldervoll, L., Ravasco, P., Solheim, T. S., Strasser, F., de van der Schueren, M., & Bischoff, S. C. (2021). ESPEN practical guideline: Clinical nutrition in cancer. Clinical Nutrition, 40(5), 2898–2913. https://pubmed.ncbi.nlm.nih.gov/33946039/

Used for: Nutritional screening, protein and energy requirements, oral nutritional support, exercise and prevention of progressive nutritional deterioration.

[16] Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., & Ripamonti, C. I. (2021). Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open, 6(3), Article 100092. https://pmc.ncbi.nlm.nih.gov/articles/PMC8233663/

Used for: Diagnosis and multimodal management of cachexia through nutrition, exercise, symptom control and psychosocial support.

[17] Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., Rugo, H. S., Schnipper, H. H., Smith, T. J., Tan, W., & Loprinzi, C. L. (2020). Management of cancer cachexia: ASCO guideline. Journal of Clinical Oncology, 38(21), 2438–2453. https://pubmed.ncbi.nlm.nih.gov/32432946/

Used for: Appetite loss, weight loss, cachexia, nutrition counselling and assessment of reversible factors contributing to poor intake.

[18] Ligibel, J. A., Bohlke, K., May, A. M., Clinton, S. K., Demark-Wahnefried, W., Gilchrist, S. C., Irwin, M. L., Late, M., Mansfield, S., Marshall, T. F., Meyerhardt, J. A., Thomson, C. A., Wood, W. A., & Alfano, C. M. (2022). Exercise, diet, and weight management during cancer treatment: ASCO guideline. Journal of Clinical Oncology, 40(22), 2491–2507. https://pubmed.ncbi.nlm.nih.gov/35576506/

Used for: Safe aerobic and resistance exercise, physical-function preservation and nutrition during active cancer treatment.

[19] PDQ Supportive and Palliative Care Editorial Board. (2024). Nutrition in cancer care: Health professional version. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq

Used for: Cancer malnutrition, appetite loss, cachexia, nutrition assessment and the effect of fluid accumulation on body-weight interpretation.

[20] Armato, S. G., III, & Nowak, A. K. (2018). Revised modified Response Evaluation Criteria in Solid Tumors for assessment of response in malignant pleural mesothelioma: Version 1.1. Journal of Thoracic Oncology, 13(7), 1012–1021. https://pubmed.ncbi.nlm.nih.gov/29660507/

Used for: Mesothelioma-specific CT measurement, specialist radiological response assessment and differentiation of stable disease, response and progression.

[21] Nowak, A. K., Stockler, M. R., & Byrne, M. J. (2004). Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results of using the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172–3180. https://pubmed.ncbi.nlm.nih.gov/15284263/

Used for: Quality-of-life, symptom and functional-outcome assessment during pleural mesothelioma treatment.

[22] National Cancer Institute. (n.d.). Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. https://healthcaredelivery.cancer.gov/pro-ctcae/

Used for: Structured patient reporting of breathlessness, pain, fatigue, nausea, appetite changes and treatment-related adverse effects.

[23] National Cancer Institute. (2024). Complementary and alternative medicine. https://www.cancer.gov/about-cancer/treatment/cam

Used for: Differentiating complementary treatment used alongside standard care from alternative treatment used instead of conventional care.

[24] PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. (2024). Cancer therapy interactions with foods and dietary supplements: Health professional version. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/cam/hp/dietary-interactions-pdq

Used for: Herb–drug and supplement–drug interactions involving absorption, metabolism, transport and elimination of cancer medicines.

[25] Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., Greenlee, H., Leblanc, T., Lee, R. T., Lopez, A. M., Loprinzi, C. L., Lyman, G. H., MacLeod, J., Master, V. A., Ramchandran, K., Strasser, F., & Bruera, E. (2022). Integrative medicine for pain management in oncology: Society for Integrative Oncology–ASCO guideline. Journal of Clinical Oncology, 40(34), 3998–4024. https://pubmed.ncbi.nlm.nih.gov/36122322/

Used for: Evidence-based integrative interventions for cancer-related pain and the principle that complementary care should target defined symptoms.

[26] Carlson, L. E., Ismaila, N., Addington, E. L., Asher, G. N., Atreya, C., Balneaves, L. G., Bradt, J., Garland, S. N., Greenlee, H., Johnson, J. A., Larkey, L. K., Levine, M., Liou, K. T., Mao, J. J., Mehta, A., Paller, C. J., Seely, D., Siwik, C. J., Telles, S., & Zick, S. M. (2023). Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO guideline. Journal of Clinical Oncology, 41(28), 4562–4591. https://pubmed.ncbi.nlm.nih.gov/37582238/

Used for: Evidence-based complementary interventions for anxiety, depression and emotional distress in adults with cancer.

[27] Saper, R. B., Kales, S. N., Paquin, J., Burns, M. J., Eisenberg, D. M., Davis, R. B., & Phillips, R. S. (2004). Heavy metal content of Ayurvedic herbal medicine products. JAMA, 292(23), 2868–2873. https://pubmed.ncbi.nlm.nih.gov/15598918/

Used for: Lead, mercury and arsenic contamination risks and the need for authenticated sourcing, ingredient disclosure and laboratory quality testing.

[28] U.S. Food and Drug Administration. (2025, December 2). FDA warns about heavy metal poisoning associated with certain unapproved Ayurvedic drug products. https://www.fda.gov/drugs/fraudulent-products/fda-warns-about-heavy-metal-poisoning-associated-certain-unapproved-ayurvedic-drug-products

Used for: Heavy-metal safety, product-quality controls, transparent labelling and avoidance of unidentified or untested Ayurvedic products.

[29] World Health Organization. (2025). Global traditional medicine strategy 2025–2034. https://www.who.int/publications/i/item/9789240113176

Used for: Safe, evidence-based, regulated and people-centred integration of traditional and complementary medicine into healthcare.

[30] Agniveśa. (1949). Srotas-vimāna: Body channels. In The Caraka Saṃhitā (Vimāna Sthāna, Chapter 5; Shree Gulabkunverba Ayurvedic Society, Trans.). https://www.wisdomlib.org/hinduism/book/charaka-samhita-english/d/doc730012.html

Used for: Srotas, Srotodushti and assessment of disrupted physiological pathways, including Pranavaha, Rasavaha, Annavaha and Udakavaha Srotas.

[31] Agniveśa. (1949). Lightening and roborant therapies: Langhana and Bṛṃhaṇa. In The Caraka Saṃhitā (Sūtra Sthāna, Chapter 22; Shree Gulabkunverba Ayurvedic Society, Trans.). https://www.wisdomlib.org/hinduism/book/charaka-samhita-english/d/doc627532.html

Used for: Selection between Langhana and Brimhana and avoidance of excessive depletion in weak, dehydrated, undernourished or cachectic patients.

[32] Agniveśa. (1949). The treatment of disease: Roga-bhiṣag-jitīya-vimāna. In The Caraka Saṃhitā (Vimāna Sthāna, Chapter 8; Shree Gulabkunverba Ayurvedic Society, Trans.). https://www.wisdomlib.org/hinduism/book/charaka-samhita-english/d/doc730015.html

Used for: Rogi–Roga Pariksha, Prakriti, Bala, Satmya, age, psychological strength, disease stage and individualised treatment intensity.

[33] Agniveśa. (1949). The therapeutics of hiccup and dyspnoea: Hikkā-śvāsa-cikitsā. In The Caraka Saṃhitā (Cikitsā Sthāna, Chapter 17; Shree Gulabkunverba Ayurvedic Society, Trans.). https://www.wisdomlib.org/hinduism/book/charaka-samhita-english/d/doc1083046.html

Used for: Classical understanding of Shwasa, Pranavaha Srotas, Vata–Kapha involvement, Rogi Bala and precautions in depleted patients.

[34] National Cancer Institute. (2020, January 23). Infection and neutropenia during cancer treatment. https://www.cancer.gov/about-cancer/treatment/side-effects/infection

Used for: Fever, chills, cough, catheter-site changes and other infection warning signs requiring prompt oncology or hospital contact.

[35] National Health Service. (n.d.). Pulmonary embolism. https://www.nhs.uk/conditions/pulmonary-embolism/

Used for: Sudden breathlessness, chest pain, coughing blood, fainting, rapid heartbeat and associated leg pain or swelling requiring emergency care.

[36] Government of India. (1954). The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. India Code. https://www.indiacode.nic.in/bitstream/123456789/19159/1/drugs_and_magic_remedies_act_1954.pdf

Used for: Restrictions concerning misleading cancer advertisements, guaranteed outcomes, miraculous-treatment representations and disease-cure claims.